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Three (3) medicinal plants [Aframomum melegueta K. Schum., Xylopia aethiopica (Dunal.) A. Rich. and 
Capsicum annuum L.] were selected based on their traditional uses in the treatment of diabetes in Africa. 
Various crude extracts and fractions from different parts of the plants were screened using several anti-
oxidative and anti-diabetic tests in vitro. Most active fractions from each plant were used to examine in vivo 
anti-diabetic activity in type 2 diabetes (T2D) rat model. Additionally, possible bioactive compounds from 
most active extracts and fractions were analyzed by using GC-MS, TLC and NMR spectroscopy. The results 
showed that ethanolic extracts derived from the fruits of the plants demonstrated excellent anti-oxidative 
and anti-diabetic activities in vitro compared to other extracts from the same or different parts of these 
plants. After fractionation, ethyl acetate fraction from A. melegueta and acetone fractions from 
X. aethiopica and C. annuum exhibited strong radical scavenging (IC50: 1-120 µg/mL) activity, inhibition 
of hemoglobin glycation (IC50: 100-150 µg/mL), α-amylase (IC50: 50-170 µg/mL) and α-glucosidase (IC50: 
40-87 µg/mL) activities hence were used for the in vivo study. The GC-MS analysis of the three (3) most 
active fractions revealed the presence of mostly phenolic compounds of 4-hydroxy-3-methoxyphenyl 
derivatives. Furthermore, the data of the in vivo study showed that oral intervention of the fractions (150 
and 300 mg/kg bw) for 4 weeks demonstrated potent anti-diabetic actions via improving body weight gain, 
reducing feed and fluid intake and hyperglycemia, improving glucose tolerance ability, insulin sensitivity, 
amelioration of pancreatic β-cell histology and β-cell functions, improving dyslipidemia in a T2D rat model. 
Additionally, the pancreatic histopathological damages and other oxidative damages caused by the 
induction of diabetes were attenuated to near normal in the liver, kidney, heart and pancreas of the treated 
animals. The bioassay-guided fractionations lead to the isolation of 3 arylalkanes (6-paradol (1), 6-shagaol 
(2), and 6- gingerol (3)) and oleanolic acid (4) from A. melegueta fruits, when oleanolic acid (4) was the 
first to be isolated from A. melegueta. Moreover, 6-gingerol (3) and oleanolic acid (4) were similarly 
isolated for the first time from X. aethiopica fruits as well. These compounds have exhibited significant 
inhibitions against the α-amylase and α-glucosidase actions and thus are possible anti-diabetic agents and 
the anti-diabetic action of A. melegueta and X. aethiopica fruits is attributed to the presence of these 
compounds. This study also confirmed the use of these plants in African anti-diabetic traditional medicines 
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Introduction and Literature Review 
1.0 Introduction and background of the study 
Diabetes mellitus (DM) is a group of complex and chronic metabolic disorders with diverse 
multiple etiologies. It is characterized by high blood glucose (hyperglycemia) resulting from 
malfunction in insulin secretion and/or insulin action, both leading to impair metabolism of 
carbohydrates, lipids and proteins (ADA, 2015). The alterations in the utilization of complex 
biomolecules by the most affected tissues (liver, muscle and adipose tissue) due to hyperglycemia 
initiate a sequence of oxidative processes that cause dysfunction and failure of other organs in the body. 
Long-term complications may affect the organs such as kidneys, eyes, nerves, heart and blood vessels, 
and in absence of effective treatment result into death (ADA, 2015; Surampud et al. 2009; Maritim et 
al. 2003).  
At present, different approaches are used to control diabetes using modern synthetic anti-diabetic 
drugs, insulin injection and life style modification. The synthetic anti-diabetic drugs include 
sulphonylureas, glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and biguanide. 
However, these synthetic drugs have characteristic profiles of serious side effects, which include 
hypoglycemia, weight gain, gastrointestinal discomfort and nausea, liver and heart failure, and diarrhea 
(Hung et al. 2012; Michael et al. 2005). This is in addition to being rather costly and not affordable by 
the majority of people in developing countries especially for African populations. These limitations 
coupled with an exponential increase in the prevalence of diabetes motivate researchers to scientifically 
validate the folkloric use of a number of medicinal plants and/or their isolated bioactive compounds as 
possible alternative therapies for diabetes. The prime target for such research is to pave the way for the 
development of newer plant-derived anti-diabetic compounds that could be used to ameliorate the 
diabetes associated complications. This can subsequently be standardized and be used as drug for the 
treatment of the DM. 
Furthermore, in many continents such as Africa, herbs and natural products form an integral 
component of the health care delivery system (Cragg and Newman, 2013). This has been further 
supported by the World Health Organization (WHO) report that 80% of the population in Africa 
depends almost entirely on traditional medicines, herbal medicines in particular, for their primary health 
care needs (WHO, 2001). This is attributed to the proven effectiveness of the plant-based therapies as 
well as the availability of these medicinal plants. Because, the African continent accounts for about 
25% of the total number of higher plants in the world where more than 5400 medicinal plants were 
reported to have over 16300 medicinal uses (van Wyk et al. 2008). Fortunately, some plant products 
either in the form of crude extracts, fractions or isolated compounds have been screened or investigated 





and/or isolated bioactive compounds with potential anti-diabetic actions is very limited and many of 
their anti-diabetic effects have not yet been scientifically validated. 
 
1.1 Literature Review 
1.2 Diabetes Mellitus 
Diabetes mellitus (DM) is a disorder that causes elevation of blood glucose, otherwise known as 
hyperglycemia (fasting blood glucose level: ≥126 mg/dL or 7.0 mmol/L; or postprandial hyperglycemia: 
≥200 mg/dL or 11.1 mmol/L) due to either decrease in insulin secretion and/or insulin sensitivity of 
target tissues (Panini, 2013; ADA, 2015).  
 
1.2.1 Types of diabetes mellitus 
Originally, diabetes has been classified into two major classes: (1) type 1 or insulin dependent 
diabetes mellitus (IDDM) and (2) type 2 or non-insulin dependent diabetes mellitus (NIDDM) (WHO, 
1980). However, rapidly changing pathogenesis of diabetes has been taken into account for the new 
classification of DM. The recent classification by the American Diabetes Association (ADA), diabetes 
is categorized into four types: type 1 diabetes, type 2 diabetes, gestational diabetes and the secondary 
form of diabetes which encompasses all types of diabetes due to other causes, for instance, monogenic 
diabetes syndromes, diseases of the exocrine pancreas and drug- or chemical-associated diabetes (ADA, 
2015).  
 
1.2.2 Type 1 diabetes mellitus 
This form of diabetes is due to autoimmune-mediated destruction of the pancreatic β-cells as a 
result of production of humoral auto antibodies (ADA, 2015; Canivell and Gomis, 2014). Although the 
cause of type 1 diabetes (T1D) remains elusive, it is strongly linked to interplay between genetic 
predisposition and environmental factors that possibly triggers an autoimmune destruction of the 
pancreatic β-cells leading to absolute insulin deficiency (Patterson et al. 2014). The environmental 
factors include infectious agents such as viruses (coxsackie B virus, rubella virus) and food toxins. The 
destruction of pancreatic β-cells is gradual and variable, being rapid in infants and children and slower 
in adults (Joslin and Kahn, 2005). The mechanism involves on selective destruction of pancreatic β-cells 
in T1D is poorly understood due to the dissimilarities of pancreatic lesions (Ozougwu et al. 2013). The 
proposed mechanism involves the infiltration of lymphocytes (innate immune cells) or insulitis due to 
co-interaction of genetic and environmental factors. The infiltration of innate immune cells produces 
cytokines such as glutamic acid decarboxylase antibodies (GAD-65), islet cell antibodies 





infiltration of islet reactive T cells that ultimately attack and destroys pancreatic β-cells (Szablewski, 
2014). 
Similarly, other form of T1D categorized as ʺidiopathic diabetesʺ which includes all forms of 
T1D with no known etiology and is mostly found among individuals from Asian or African regions. 
Individuals with this type of diabetes demonstrate no evidence of autoimmunity and exhibit 
insulinopenia and are prone to ketoacidosis (ADA, 2015; Canivell and Gomis, 2014). Apart from above, 
a brief summary of the pathogenesis of T1D is presented in Figure 1.1.   
 
  
Figure 1.1: Pathogenesis of type 1 diabetes (copied without permission from Atkinson and Eisenbarth, 2001). FPIP, first phase 
of insulin response; GADA, glutamic acid decarboxylase antibodies; ICA512A/ICA, islet cell antibodies; IAA, insulin 
antibodies. 
 
1.2.3 Type 2 diabetes mellitus 
Type 2 diabetes (T2D) is a heterogeneous disorder characterized by insulin resistance and 
partially dysfunctional pancreatic β-cells which cannot properly secrete insulin in response to 
hyperglycemia (Hui et al. 2007). It is the most prevalent type of diabetes, accounting for more than 90% 
of all reported diabetes cases in the world (IDF, 2014). The insulin deficiency is relative rather than 
absolute and usually no insulin treatment (unless special cases) is required for T2D (ADA, 2015). The 
pathogenesis of insulin resistance in T2D is complex and involves genetic (defect on insulin and its 
receptor genes etc.) and environmental (obesity, sedentary life, age and physical inactivity) factors 
(Tuomilehto et al. 2001). Furthermore, inadequate insulin secretion by pancreatic β-cell in type 2 diabetic 
individuals disrupts the regulation of hepatic gluconeogesis, muscles glucose uptake and lipolysis in 
adipose tissues (Gastaldelli, 2011). The consequence is postprandial hyperglycemia which results in to 






                                 Figure 1.2: Pathogenesis of type 2 diabetes (copied without permission from Caballero, 2005). 
 
1.2.4 Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) have been defined as heterogeneous group of disorders 
associated with any glucose intolerance diagnosed usually in the third trimester of the pregnancy 
(Ashwal and Hod, 2015) when in many cases disorder may improve or disappear after the delivery of 
baby. Similarly, it has been reported that about 3% to 65% of women with a history of GDM are at high 
risk of developing T2D in the later part their lives (Lee et al. 2008). In genetic predisposed women 
(during pregnancy), the alterations in glucose metabolism may lead to mix insulin resistance and 
impaired insulin secretion (Whitelaw and Gayle, 2010). This condition usually exaggerates as the 
pregnancy period increases which ultimately result in to hyperglycemia. The pathogenesis of GDM is 






Figure 1.3: Pathogenesis of gestational diabetes mellitus (GDM) (prepaid based on Whitelaw and Gayle (2010) report). 
 
1.2.5 Specific types of diabetes due to other causes (secondary type) 
This is further sub-divided in to the following; 
a) Maturity-onset diabetes of the young (MODY) 
This form of diabetes is due to the defect on DNA methylation of genes for pancreatic β-cell 
development (Thomas and Philipson, 2015). It is mainly categorized into neonatal diabetes and maturity-
onset diabetes of the young (MODY). The onset of elevated blood glucose as a result of pancreatic β-
cell failure usually occurs at an early stage of life (within the first 6 months). Furthermore, in MODY, 
there is a defect in insulin secretion with less or no reported alterations in insulin function (ADA, 2015; 
Thomas and Philipson, 2015). 
 
b) Cystic fibrosis related diabetes 
The cystic fibrosis–related diabetes is frequently occurs in individuals with cystic fibrosis. The 
disorder is due to impair insulin secretion as a result of partial fibrotic reduction of the pancreatic β-cell 
mass (ADA, 2015). Insulin sensitivity is usually normal or may be partially impaired in this kind of 
diabetes (Ode and Moran, 2013). Other disorders associated with pancreas include chronic pancreatitis, 







c) Drug associated diabetes 
The medications of some diseases were reported to interfere with complex metabolic processes, 
thereby alters the secretion and/or function of insulin in physiological system (Thomas and Philipson, 
2015). This may likely triggers diabetes or insulin resistance in susceptible individuals. For instance, 
glucocorticoids were reported to cause insulin resistance, hyperglycemia, and do interfere with some 
stages in the insulin-signaling pathways via multiple mechanisms (Ferris and Kahn, 2012). Antiretroviral 
drugs (HIV protease inhibitors) were also reported to induce insulin resistance and impaired glucose 
tolerance by inhibiting glucose disposal via GLUT4 in cellular system (Koster et al. 2003). Hence, it is 
clear that the pathogenesis of diabetes changing rapidly to create newer type of diabetes which directly 
affecting the total prevalence of diabetes mellitus. 
  
1.2.6 Prevalence of diabetes mellitus 
The global prevalence of DM is increasing exponentially. Recent data from the International 
Diabetes Federation (IDF) indicates that DM affects over 387 million people globally and this figure is 
likely to rise to 592 million by 2035 (IDF, 2014; Guariguata et al. 2014). The disease affects nearly 8.3% 
of adult (20-79 years) which are mostly live in the low- and middle-income countries. In Africa, more 
than 22 million people have diabetes, accounting for about 5.1% of adults (mostly < 60 years) in the 
region (Peer et al. 2014; IDF, 2014). In addition, multiple factors contribute to this rising prevalence of 
diabetes including population growth, urbanization, dietary change, nutritional transition, physical 
inactivity and so on (Guariguata et al. 2014; Hirst et al. 2013). 
 
1.2.7 Diabetes associated complications 
Although the pathogenesis of T1D and T2D are different, the consequences of their resulting 
complications are almost similar (van Dijk and Berl, 2004). These complications are categorized as either 
acute or chronic, which partly or solely depend on the uncontrolled hyperglycemia (Monnier et al. 2006). 
Acute complications include ketoacidosis, hyperosmolar non-ketotic coma and hypoglycemia (Fishbein 
and Palumbo, 1995). The chronic crises comprise of microvascular (retinopathy, neuropathy and 
nephropathy) and macro vascular (myocardial infarction, atherosclerosis and peripheral vascular 
diseases) complications (Heydari et al. 2010; Rahman et al. 2007). The over production of reactive 
oxygen species (ROS) via metabolic processes and due to hyperglycemia have been considered as the 
major hallmarks of diabetes-associated complications (Pazdro and Burgess, 2010). In chronic 
uncontrolled hyperglycemia, there is an increased production of ROS and a declined of in vivo anti-
oxidant defense system, a term referred as oxidative stress. The ROS are derived from the normal 
physiological processes and become highly deleterious if the levels increases and not arrested by 
complex anti-oxidant systems in the body (Chang and Chuang, 2010). Furthermore, major contributors 





production of glycation end products and mitochondrial ROS, the polyol, hexosamine and affected 
protein kinase C pathways (Giacco and Brownlee, 2010; Chang and Chuang, 2010; Chung et al. 2003; 
Maritim et al. 2003). The schematic diagram indicating hyperglycemia-induced oxidative damages is 
presented in Figure 1.4. The mechanisms involve in micro-vascular and macro-vascular complications 
can be linked to hyperglycemia-induced oxidative stress. For instance, in diabetic retinopathy, the 
increased oxidative stress due to inability of the cells to convert glucose to sorbitol caused cellular injury 
and increased the accumulation of advanced glycated end products (Jiang, 2000). 
 
 
Figure 1.4: Hyperglycemia-induced oxidative damages in diabetes mellitus (copied without permission from Brownlee, 2005). 
 
1.2.8 Treatment and management of diabetes mellitus 
The importance of protecting or delaying hyperglycemia cannot be overemphasized. The acute 
as well as chronic complications of diabetes are the major causes of morbidity and mortality in all types 
of diabetes (Fowler, 2008). Fortunately, in the last 2 decades, concerted research efforts by diabetologists 
and other relevant research scientists highlighted two main strategies to control DM which can be used 
either alone or in combination of the two, depending on the type and severity of diabetic condition. These 







1.2.9 Non-pharmacological therapy 
The non-pharmacological option refers to the use of lifestyle intervention strategies in patients 
with established risk factors for T2D in order to delay the progression and development of DM. Lifestyle 
changes such as weight loss, increased physical exercise and some dietary manipulations are effective in 
preventing and controlling  diabetes (Tuomilehto, 2009) and this was demonstrated in a number of 
randomized controlled clinical trials such as Swedish Malmo feasibility study (Eriksson and Lindgarde, 
1991), Chinese Da Qing study (Pan et al. 1997), Finnish diabetes prevention study (Tuomilehto et al. 
2001), U.S diabetes prevention program (DPP, 2002), Japanese lifestyle intervention study (Kosaka et 
al. 2005) and the Indian diabetes prevention program (Ramachandran et al. 2006). It has been reported 
that lifestyle modification by diabetic patients significantly improved hepatic and muscle insulin 
sensitivity, muscle glucose uptake and utilization, and the overall glycemic control in addition to 
decrease lipids and blood pressure levels (Hayes, 2008). 
 
1.2.10 Pharmacological therapy 
Pharmacological intervention to prevent diabetes involves the use of drugs or any agents to treat 
patients with established risk factors. The basic risk factors are impaired glucose tolerance (IGT) or 
impaired fasting blood glucose (IFG) because approximately 50% of IGT and IFG individuals progress 
to diabetes (T2D) over their lifetime (De Fronzo and Abdul-Ghani, 2011). 
 
 Insulin  
It has been well established that insulin therapy reduce hyperglycemia and micro- and macro-
vascular complications associated with diabetes in several randomized clinical trials (Holman  et al. 
2008; UKPDS, 1998; Ohkubo et al. 1995). However, insulin therapy is associated with two major 
limitations; hypoglycemia and weight gain, arose due to intensive insulin treatment (Swinnen et al. 
2009).  
 Mode of insulin action  
Insulin is a polypeptide hormone produced by the pancreatic β-cells of the islets of Langerhans 
in response to hyperglycemia (Harvey and Ferrier, 2011).The β-cells are freely permeable to glucose via 
type 2 glucose transporter (GLUT 2) which are immediately phosphorylated to glucose 6-phosphate by 
glucokinase enzyme. This stimulates the rise in metabolic flux through glycolysis, the citric acid cycle, 
and the generation of ATP (Murray et al. 2003).  Elevation of ATP concentration down regulates the 
ATP-sensitive K+ channel, leading to depolarization of the pancreatic β-cell membrane. This may 
eventually increases Ca2+ influx via voltage-sensitive Ca2+ channels and stimulates the exocytosis of 
insulin (Kieffer et al. 1997). Hence, the level of insulin in the blood is proportionate to that of the blood 





4 glucose transporter (GLUT 4) which are utilized as metabolic fuel and stored as well (Kieffer et al. 
1997).  
 
 Conventional oral hypoglycemic drugs 
Several classes of pharmacological agents have shown to reduce the risk of developing DM in 
double blind randomized controlled clinical trials (Phung et al. 2011). These include biguanides 
(phenformin), α-glycosidase inhibitors (acarbose), sulfonylureas glibenclamide), thiazolidinediones 
(rosiglitazone) and dipeptidyl peptidase-4 inhibitors (vildagliptin) (Phung et al. 2011; Padwal et al. 
2005).  
Moreover, these classes of drugs demonstrate their anti-diabetic actions via diverse mechanisms 
(Figure 1.5). Sulfonylureas, also called insulin secretogogues, improve insulin release from the 
pancreatic β-cells (Aguilar-Bryan et al. 1995). Biguanides improve sensitivity of insulin to the liver and 
muscle cells and inhibit hepatic glucose production (De Fronzo, 1999). Some enzyme inhibitors also 
reduce blood glucose by inhibiting the activities of carbohydrates digestive enzymes (α-amylase and α-
glucosidase) located at the intestinal brush border (Krentz et al. 1994). Furthermore, thiozolidinediones 
also referred as peroxisome proliferator activated receptor (PPAR)-γ agonist which improves insulin 
sensitivity in the liver, muscle and adipose tissues. They do achieve such effects by binding to PPARγ 
receptor, which eventually increase the expression of glucose transporters (Kintscher and Law, 2005; 
Lehrke and Lazar, 2005). Dipeptidyl peptidase-4 (DPP-4) inhibitors cause reduction on blood glucose 
levels via inhibiting an enzyme involve in the breakdown of incretin like peptides such as glucagon-like 
peptide (GLP)-1 and glucose-dependent insulinotropic peptide (GIP) (Hung et al. 2012).  
However, these conventional oral drugs stated above have many unwanted adverse effects 
(hypoglycemia, weight gain, gastrointestinal discomfort, nausea, hypersensitivity, liver and heart failure, 
and diarrhea) and are not cost effective for the majority of the people, particularly for those who are from 
the developing countries (Michael et al. 2005). Therefore, safer and more effective treatment options 
with fewer side effects are required in order to control the progression DM. Thus, with the increasing 
interest in alternatives to the present conventional oral drugs in the treatment of diabetes, the use of plant-











Figure 1.5: Target organs/tissues and mode of actions of orally anti-diabetic drugs (copied without permission from Koutnik, 
2013). (DPP4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide). 
 
1.3 Medicinal plants  
Medicinal plants are a plants of which one or more parts contain substances that can be used for 
therapeutic purposes or which are precursors of the useful drugs (Ebadi, 2006; Lewis, 1981). Medicinal 
plants have formed the basis of health care system worldwide for several years and are still widely used 
as good sources for the present modern drugs. Recognition of their therapeutic and economic value is 
emerging and receiving much attention. Plants are important for pharmacological research and drug 
discovery, not only when bioactive compounds are used directly for treatment of ailments, but also as 
template for the synthesis of modern conventional drugs (Mendonça-Filho, 2006; Geldenhuys and 
Mitchell, 2006). 
 
1.3.1 Medicinal plants in future drug discovery 
Medicinal plants are natural products endowed with tremendous capacities to treat wide arrays of 
diseases. The use of plant-based formulation to treat diseases also known as herbal medicine is the oldest 
form of medicine since around 2600 BCE (Cragg and Newman, 2013; Soladoye et al. 2012). Fortunately, 
this area has documented the traditional uses of more than 1000 plant-derived formulations which are 
still being used to treat both communicable and non-communicable diseases. Studies conducted 
previously have demonstrated that about 80% of isolated compounds, which are used in the modern 
medicines, are derived from medicinal plants and traditionally these medicinal plants were used for the 
same or similar purposes (Cragg and Newman, 2013; Farnsworth et al. 1985). For instance, the anti-
diabetic agent galegine (a template for synthesis of metformin) was isolated from Galega officinalis L., 
which plant was used to treat diabetes traditionally (Heinrich, 2010). Similarly, the anti-malarial drug, 
artemisinin and anti-HIV drug, calanolide A were derived from the plant Artemisia annua L. and 





also been widely used in the traditional medicines for the treatment of fevers and some microbial 
infections (Gurib-Fakim, 2006).  
Moreover, search for plant-derived drugs is a multidisciplinary work incorporating research, 
financial and technical supports, and hence needs carefully planned strategy (Rates, 2001) and has been 
a difficult and expensive task (Borris, 1996; Turner, 1996). For instance, a huge amount of money (US$ 
100-360 million) is estimated for the development of newer drug with a minimum of 10 years of work, 
with about 0.01% probability of getting promising one (Williamson et al. 1996). The schematic flow 




                     Figure 1.6: Flow chart for plant-derived drug discovery (modified from Balunas and Kinghorn, 2005). 
 
1.3.2 Selection of medicinal plant for drug discovery 
In order to select medicinal plant for target drug discovery, various approaches were map out by 
scientists to evaluate plant materials for their pharmacological properties (Heinrich et al. 2004; Fabricant 
and Farnsworth, 2001). Ethnobotanical uses play a significant role in selecting plant as a candidate for 
drug discovery. In this approach, information on the local usage of plant is the key-driven factor which 
is normally obtained through ethnobotanical studies (Shizen and Xiwen, 2004). The phytochemistry-
based selection mainly focused on the isolated ingredients responsible for the pharmacological uses of 





approaches include random and/or target selection of plants followed by some biological studies and 
follow-up bioactivity reports (Heinrich et al. 2004; Harborne, 1998).  
 
1.3.3 Collection, authentication and preparation of plant material 
Collection of individual plant materials and/or whole plant samples depends on the parts with 
rich bioactive constituents and is greatly affected by some environmental factors such as nature of the 
soil, rainfall, weather and temperature (Harborne, 1998). The collected plant parts need to be 
scientifically and correctly authenticated by either taxonomist or a botanist (Satyajit et al. 2006). The 
voucher specimen number is usually deposited in the herbarium for subsequent reference purposes for 
an unlimited period of time (Harborne, 1998). 
Furthermore, extraction of the plant samples is an integral part on the way of plant-derived drug 
discovery (Brusotti et al. 2014). Several methods are employed to achieve successful extraction of the 
bioactive compounds from the plant materials. The conventional solid-liquid solvent extraction 
procedure depends mainly on the polarity and solubility of the target bioactive compounds in the 
extracting solvent (Hostettmann et al. 1991). Such conventional methods include but not limited to 
maceration, infusion, decoction, percolation, steam distillation, sequential solvent extraction and soxhlet 
extraction (Harborne, 1998). This is in addition to some modern techniques currently employed for 
sample extraction which include the microwave-assisted extraction, ultrasound assisted extraction, 
supercritical fluid extraction and pressurized liquid extraction (Brusotti et al. 2014). Before subjecting 
the sample to extraction procedure, the plant materials must be dried, usually under shade in a well 
ventilated space to avoid microbial contamination and loss of target compounds. After drying, the 
samples are grounded into a fine powder for proper extraction of the bioactive metabolites. Then the 
extracts can be used either for in vitro, ex-vivo or in vivo study. 
 
1.3.4 Preliminary in vitro studies 
Once the extracts are obtained, the next step is to subject the extracts to some in vitro bioassay 
protocols in order to examine whether the extracts are active or not. In vitro assays are usually faster, 
specific and not much amount of the extracts are used (mostly in micro or milligram amount) (Cos et al. 
2006). Furthermore, some of the in vitro methods employed include chemical and enzymatic procedures, 
which depend on spectrophotometric analysis (Beretta and Facino, 2010). For instance in evaluating 
plants as possible anti-diabetic drugs, several in vitro models are used to assess the anti-diabetic effects 
and mode of actions as well. These models include enzyme inhibition-based assays (e.g. α-amylase, α-
glucosidase and glucose 6-phosphatase inhibitions), glucose uptake bioassays (using cell lines such as 





which is usually conducted in perfused pancreas, isolated pancreatic islets cells or clonal pancreatic β-
cell-lines (van de Venter et al. 2008; Bhandari et al. 2008; Hannan et al. 2007).  
 
1.3.5 Bioassay-guided fractionation of the active principles 
Bioassay-guided fractionation is an important method employed to identify the plant derived 
bioactive compounds. It involves repetitive fractionation (column chromatography and thin layer 
chromatography) and evaluation of bioactivity of the fractions up to the isolation of pure target principles 
with the selected biological activity (Gurib-Fakim, 2006). As soon as the isolation of a pure compound 
is achieved, the next step is the structural elucidation of the compound isolated which requires the use 
of Nuclear Magnetic Resonance Spectroscopy (NMR) and Mass Spectroscopy (MS) (Verpoorte, 1989). 
 
1.3.6 In vivo, clinical and toxicological studies 
In in vivo approach, animals are used to investigate the efficacy, mode of action and side effects 
of the plant extracts, fractions and their active principles (Eddouks et al. 2012). In vivo screening is 
usually conducted based on the results of the in vitro study and its require a large scale production and/or 
extraction of the target compound from the extract. In some cases structural modification is employed to 
ascertain or improve the bioactivity of the target substance (Rates, 2001). This approach otherwise called 
pre-clinical investigation can take longer time and demand a lot of resources.  
Furthermore, in some diseases such as DM, several models are employed in order to establish 
the potency of the target compounds, due to the complex heterogeneity of human body system in disease 
conditions. These include chemically induced animal models such as alloxan and streptozotocin-induced 
diabetic animals that are mostly used for the induction of T1D (Wang et al. 2009). The animal models 
of T2D include genetically induced or spontaneous (e.g. Zucker diabetic fatty model) and experimentally 
induced or nonspontaneous (e.g. high-fats diet-fed and fructose-fed/streptozotocin) models (Eddouks et 
al. 2012; Islam and Loots, 2009). Due to the easy induction of diabetes, lower maintenance cost and 
wider availability the experimentally induced model has been recommended as a better option over 
genetically induced spontaneous model, particularly for the researchers and scientists from the 
developing countries (Eddouks et al. 2012; Islam and Loots, 2009). Additionally, if the target drug 
candidate was observed to cause some adverse effects in the animal model, structural modification of 
the compound is carried out to reduce the severity of the consequences (Lin and Lu, 1997). Preliminary 
toxicological effects of the plant derived compounds are conducted both in vitro (cell line) and at in vivo 
level to ascertain their safety for clinical use.  
Clinical trials are usually carried out to confirm the safety of potential bioactive compounds in 
human subjects. Before the commencement of such investigation, a careful protocol has to be prepared 





in USA or Europe, an investigational new drug application is usually applied to the relevant authorities 
such as Food and Drug Administration (FDA) or European Medicines Agency (EMA) (Mishra and 
Tiwari, 2011). Once the investigation is successful, the candidate drug is now ready for marketing and 
will subsequently be available to the general people.  
 
1.3.7 Medicinal plants for the treatment of diabetes  
The practice of using plants to treat DM by humans has been employed by different cultural 
settings worldwide since immemorial time (Gurib-Fakim, 2006; Bnouham et al. 2006; Samuelsson, 
2004). With the recent escalation of the prevalence of DM, high cost and inaccessibility to modern drugs, 
the popularity of using medicinal plants derived medicines to treat DM has been increased especially in 
the developing countries (Rachid et al. 2012). On the other side, reports available have also showed a 
dramatic increase on the use of plant-derived formulations to manage DM in developed countries 
(Achaya and Shrivastava, 2008; Gilani, 2005; Cordell and Colvard, 2005). This increase has been 
attributed due to the undesirable adverse effects of synthetic anti-diabetic drugs (Shu, 1998).  
Recently, Hung et al. (2012) highlighted that during 2005 to 2010; about 100 plant-derived 
preparations have been investigated for possible anti-diabetic actions. Interestingly, some of these 
preparations are now formulated and available in the market as anti-diabetic remedy. Additionally, 85 
bioactive compounds have demonstrated anti-diabetic potentials within the same periods of time. In a 
similar study reported earlier, about 106 plant-derived compounds were reported to show possible anti-
diabetic effects in various studies published within the period of 2000-2005 (Jung et al. 2006). However, 
the exert mode of actions of plant-derived formulations and/or compounds used in diabetes treatment is 
still remain elusive and speculative. Some of the mechanisms proposed include insulin-like action 
(Broadhurst et al. 2000), inhibition of carbohydrate digestive enzymes (Bhandari et al. 2008), decreasing 
the absorption of glucose at the gut (Gallagher et al. 2003), stimulation of hepatic and muscle glucose 
uptake (Eid et al. 2010), anti-oxidative effects in preventing β-cell damage (Sef et al. 2011), complement 
the action of insulin (Donga et al. 2011). 
 
1.3.8 African medicinal plants with anti-diabetic potentials 
African region is among the regions endowed with the richest biodiversity in the world, with an 
abundance of plants used for therapeutic purposes. According to the World Health Organization (WHO) 
report, more than 80% of the population in Africa depends almost entirely on plant-derived preparations 
to treat various types of diseases (Zhang, 2001). However, many of these plants still await proper 
scientific investigation. 
Similarly, the undesirable adverse effects and high cost of conventional oral synthetic drugs 





validate the folkloric use of a number of African medicinal plants as possible alternative therapies. The 
anti-diabetic potentials of a number of these medicinal plants have been reported and some bioactive 
compounds were isolated and screened as well. In review, we have reported that a total number of 185 
plants species from 75 families were reported to be investigated for anti-diabetic effects in Africa during 
2000 to 2013 (Mohammed et al. 2014). Plants such as Anacardium occidentale L. (Anacardiaceae), 
Gongronema latifolium Benth (Asclepiadaceae), Sclerocarya birrea (A. Rich) Hochst. (Anacardiaceae), 
Sutherlandia frutescens (L.) R.Br. (Fabaceae), Trigonellafoenum graecum L. (Leguminosae) Vernonia 
amygdalina Del. (Asteraceae) and Zizyphus spina-christi (L.) Desf (Rhamnaceae) are some of the 
African medicinal plants that received much attention due to the content of possible anti-diabetic agents 
(Table 1.1). 
  
Table 1.1: Most studied anti-diabetic medicinal plants in the African continent. 
Scientific name Part (s) 
used 





Stem bark Polyphenols  Stimulated muscles 
glucose uptake 
Tedong et al. 
2010  
 Antihyperglycemic in 
















 Mimic insulin action Adebajo et al. 
2013 
 Decreased blood 
glucose level in 
diabetic animals/ 
Anti-oxidative 
Akah et al. 2011 





 Stimulated insulin 
release 
Galvez et al. 1992 
 Enhanced glucose-
stimulated insulin 
secretion in INS-1E 
cells 
Ndifossap et al. 
2005 
Sutherlandia frutescens 
(L.) R.Br. (Fabaceae) 
Leaf/ Shoot/ 
Whole plant 
Flavonoid   Decreased blood 
glucose level in 
diabetic animals 
Ojewole, 2004 
Aerial part  Improved insulin 
sensitivity in vivo 





Seed  Diosgenin  Inhibited α-
glucosidase action  















utilization in human 
subjects 
Okolie et al. 2008 
 Decreased blood 
glucose level in 
diabetic animals 
Atangwo et al. 
2007 
Ziziphus spina-christi 
(L.) Desf (Rhamnaceae) 





1.3.9 Bioactive compounds from African medicinal plants with anti-diabetic potentials 
The major target of screening medicinal plants as anti-diabetic agent is to isolate pure bioactive 
compounds that could be responsible for the observed activities of the plant under study. Such 
compounds can be further standardized and used as alternative anti-diabetic drugs. In Africa, just like 
other continents, some bioactive compounds were isolated and screened as possible anti-diabetic agents. 
In our current search, a total of 53 compounds isolated from African medicinal plants which were 
reported to be investigated as possible anti-diabetic agents include 3 phenolic compounds from marine 
algae Ecklonia maxima (Osbeck) Papenfuss. Interestingly, 45 compounds were found to be active in the 
models used in the reported studies (Table 1.2). However, numerous other plants and plant-based natural 
products from the African continent are still need to be evaluated scientifically to identify better 
alternative of existing anti-diabetic medicines or natural products. Some of these plants are included in 














Table 1.2: Bioactive compounds from African medicinal plants with reported activities 





Akuammicine Picralima nitida 
(Stapf) T. 
Durand & H. 
Durand 
Apocynaceae Seed (10 μg/ml) Stimulate glucose uptake 
in fully differentiated 
3T3-L1 adipocytes (200% 
basal) 





Rutaceae Stem bark 
Dichloromethane 
extract (0.1 mg/ml) 
Inactive to stimulate 
insulin secretion in INS-1 
cell  












extract (0.1 mg/ml) 
Insulin secretion in INS-1 
cell  
 
















































Caryatin-3'methyl ether  Anti-hyperglycemic, 






















Increase glucose uptake in 
C2C12 skeletal muscle 
cells and 3T3-L1 
adipocyte 
Abdel Motaal 



















































Seed (100 mg/kg 
bw) (p.o) 
Inhibited rat lens aldose 
reductase activity (IC50: 
5.4 µM) 





Ayepola et al. 
2014 
Epicatechin  Euclea undulata 
Thunb. var. 
myrtina 




glucosidase (IC50: 5.86 ± 
4.28 μg/ml) 
Deutschländer 































glucosidase (IC50: 33.693 
± 0.61 µM); DPPH (EC50: 










nzo [1,4] dioxine  
Inhibition of α-
glucosidase (IC50: 11.163 
± 0.29 µM); DPPH (EC50: 





glucosidase (IC50: 1991 ± 
111.90 µM); DPPH (EC50: 
0.128 ± 0.001 µM) 
Vanillic acid  Fagara 
tessmannii 
Rutaceae Stem bark (800 μM) Inhibition of α-
glucosidase (IC50: 69.4 ± 
0.8 μM) 
Mbaze et al. 
2007 



























Brevipsidone B  Inhibition of α-















Brevipsidone D  Inhibition of α-
glucosidase (IC50: 7.04 ± 
0.26 μM) 







Stem bark (800 μM) Inhibition of α-
glucosidase (IC50: 5.2 ± 
0.2 μM) 





Methyl gallate  Inhibition of α-









































glucosidase (IC50: 194.1 ± 
0.2 μM) 






Ellagic acid 3,3'-dimethyl 
ether  
Inhibition of α-




dimethyl ether  
Inhibition of α-






glucosidase (IC50: 7.95 ± 
0.33 μM) 








































































(L.) Merr. & 
L.M. Perry 
Anti-hyperglycemic, 





















Somova et al. 
2003b 
Christinin-A  Zizyphus spina-
christi (L.) 
Desf. 





et al. 2005 
Foetidin  Momordica 
foetida 
Schumach. 
Cucurbitaceae Fruit (1 mg/kg bw) Anti-hyperglycemic  Marquis et al. 
1977 
α-Amyrin-3-O-β-(5-















glucosidase (IC50: 4.79 ± 
2.54 μg/ml) 
Deutschländer 





Lupeol  Inhibition of α-
glucosidase (IC50: 6.27 ± 
4.75 μg/ml) 
Betulin   Inhibition of α-
glucosidase (IC50: 32.04 ± 
2.79 μg/ml) 
3β-Acetoxy-16β-hydroxy 
betulinic acid  
Fagara 
tessmannii 
Rutaceae Stem bark (800 μM) Inhibition of α-
glucosidase (IC50: 7.6 ± 
0.6 μM) 






















Increase glucose uptake in 
C2C12 skeletal muscle 





















   
 
 






Rutaceae Stem bark (800 μM) Inhibition of α-
glucosidase (IC50: 900.0 ± 
3.5 μM) 








Fabaceae Stem bark (2-8 












1.4 Aframomum melegueta K. Schum. 
 
Figure 1.7: Aframomum melegueta plant, whole plant (A), fruits (B).  
 
1.4.1 Description 
Aframomum melegueta K. Schum. commonly known as alligator pepper, grains of paradise or 
guinea pepper belongs to Zingiberaceae family (Iwu, 2014). It is a perennial herbaceous plant with 
aromatic spicy fruits and grows up to 4 m height. The fruits are indehiscent with many tiny seeds 
integrated in tasting axils. The seeds are strongly aromatic and pungent, usually golden or red-brown in 
color when fresh but darken on drying. The flowers are pinkish-orange and develop separately from the 
leafy stem. The leaves are large, parallel pinnate nerves and appear with open or closed sheath. It has 
short, branched and leafy stem with adventitious root located at the lower end. It also possessed tuberous 
rhizome with scaly leaves and occasional buds in axils (Figure 1.7) (Iwu, 2014; Irvine, 1961). 
 
1.4.2 Distribution 
A. melegueta is an indigenous spice widely available throughout the tropical Africa, but mostly 
cultivated in West and Central African regions (Iwu, 2014). 
 
1.4.3 Phytochemistry 
Many of the phytochemical investigations reported on A. melegueta were carried out on the 
seed part, with very scanty or no information on the other parts (fruit, leaf and stem) of this plant. 
Available studies indicated that, A. melegueta seed aqueous extract is rich in phenolic compounds and 
minerals (Adefegha and Oboh, 2012a; Gbadamosi et al. 2011; Okwu, 2005). It was also reported that 
gingerols, shogaols and paradols as are the active constituents of A. melegueta seed (Tackie et al. 1975; 
Connelland McLachlan, 1972; Connell, 1970). Other compounds isolated from this plant include 
gingerdione, 5-oxo-l-(4-hydroxy-3-methoxyphenyl) decan-3-one, [6]-paradol, 1-(4-hydroxy-3-





and [6]-shogaol, 1-(4-hydroxy-3-methoxyphenyl) dec-5-en-3-one (Ilic et al. 2014; El-Halawany et al. 
2014; Escoubas et al. 1995). The oil derived from the seed was reported to contain volatile compounds 
such as α-humulene, β-caryophyllene, δ-cadinene and dibutyl phthalate (Markson et al. 2011; Ukeh et 
al. 2009; Ajaiyeoba and Ekundayo, 1999; Menut et al. 1991). Similarly, labdane dieterpenoids was 
recently isolated from the organic extracts of A. melegueta rhizome (Ngwoke et al. 2014). In our most 
recent study, the fruit and leaf ethanolic extracts were found to have eugenol, gingerol, capsaicin, 3-
decanone, 1-(4-hydroxy-3-methoxyphenyl), ethyl homovallinate, oleic acid and other fatty acid 
derivatives (Mohammed et. al. 2015).  
 
1.4.4 Ethnobotanical uses 
A. melegueta has been widely used in food preparation as a spice and also locally in the 
treatment of various ailments. Various seed decoctions are used traditionally against bacterial 
infections, diarrhea, abdominal pain, snakebite and wounds healing in most parts of Africa 
(Akendengue and Louis, 1994; Kokwaro, 1993). Similarly, fruit, seed and leaf were also reported to be 
used in the treatment of DM and other metabolic diseases in Nigeria (Soladoye et al. 2012; Gbolade, 
2012; 2009). It was also reported that leaf and stem of A. melegueta are used for wounds and bacterial 
infections (Akendengue and Louis, 1994). Additionally, the root has been a good remedy against 
snakebite and dysentery (Kokwaro, 1993). 
 
1.4.5 Pharmacological importance 
The A. melegueta seed extracts have been reported to demonstrate broad anti-microbial 
activities (Nneka and Jude, 2013; Doherty et al. 2010). Doherty et al. (2010) reported that seed ethanolic 
extract (5-50 mg/mL) exhibited higher anti-microbial (Salmonella spp, Escherichia coli, Shigella spp 
and klebsiella spp) action compared to the aqueous extract. In another study, the seed methanolic extract 
(5%-30%) has also shown anti-fungal activity against Helminthosporium solani, Aspergillus niger, 
Penicillium digitatum and Mucor piriformis (Nneka and Jude, 2013). In a more recent study, the 
dieterpenoids isolated from the organic extracts (0.97-250 mg/mL) of A. melegueta rhizome showed 
bactericidal activity in vitro against Escherichia coli, Listeria moncyogenes and Staphylococcus aureus 
strains (Ngwoke et al. 2014). The seed diethyl ether extracts (0.6 mg/mL) was reported to exhibit potent 
insect repellant activity against the maize weevil, Sitophilus zeamais (Ukeh et al. 2009).  
Furthermore, the various extracts from A. melegueta seed showed anti-oxidative and potent 
inhibitory effects against α-glucosidase activity in vitro (Adefegha and Oboh, 2012a; Kazeem et al. 
2012; Adefegha and Oboh, 2011; Etoundi et al. 2010). In another study by Adefegha and Oboh (2012a), 
the seed aqueous extract (0-3 mg/mL) demonstrated moderate radical scavenging ability (IC50: 17.38 





mg/mL; α-amylase: 4.83 mg/mL). The same extract at the concentration of 0.2 g/mL was also reported 
to inhibit the α-amylase (30.61%) and lipase (8.91%) activities in vitro (Etoundi et al. 2010). It was also 
reported previously that the seed aqueous extract (0-3 mg/mL) attenuated the Fe2+-induced lipid 
peroxidation in normal rat’s brain (Adefegha and Oboh, 2011). Kazeem et al. (2012) have reported that 
seed polyphenolic-rich extract (0.1-1 mg/ml) exhibited good anti-oxidant action (IC50 values: DPPH: 
0.11 mg/mL; anti-glycation: 0.125 mg/mL; Superoxide anion: 0.105 mg/mL). In a more recent study, 
treatment of seed ethanolic extract (100-400 mg/kg bw) daily for 4 weeks was reported to improve in 
vivo anti-oxidative status in normal rats (Onoja et al. 2014).  
Similarly, the seed aqueous extract (4.8 g/kg bw/day) demonstrated hepato-protective effect in 
ethanol-induced toxic animals after 16 days oral intervention (Nwozo and Oyinloye, 2011). The seed 
ethanolic extract (0.5-1 g/kg bw) including paradol, gingerol, and shogaol isolated from the seed (0.15 
g/kg bw) have showed anti-inflammatory activities in a rats paw edema model after 3 hour post-
administration period (Ilic et al. 2014). Umukoro and Ashorobi (2008) had earlier reported that 
treatment of aqueous extract (50-200 mg/kg bw) daily for 4 days exhibited anti-inflammatory action in 
rats. Some previous findings have showed the potential of the seed extracts in ameliorating problems 
associated with reproductive function.  Kamtchouing et al. (2002) have shown that treatment of aqueous 
extract (115 mg/kg bw/day) improved penile erection in rats. Subsequently, after 55 days treatment, the 
extract at the same dose increased the secretions of epididymis and seminal vesicle in animals (Mbongue 
et al. 2012). In another study, seed aqueous extract (25-200 mg/kg bw) showed anti-stress as well as 
anti-nociceptive potentials in mice after 30 minutes post-treatment period (Umukoro and Ashorobi, 
2007; 2005).  
Sugita et al. (2013) have recently reported that daily administration of A. melegueta capsule (10 
mg) for 4 weeks activates brown adipose tissue and increases whole-body energy expenditure in healthy 
human subjects. In a preliminary study, Adesokan et al. (2010) reported that daily treatment of A. 
melegueta seed aqueous extract (200, 400 mg/kg bw) demonstrated blood glucose lowering ability in 
alloxan-induced diabetic rats. Similarly, the leaf extract (50-200 mg/kg bw) was also reported to cause 
reduction of blood glucose level in alloxanized animals after 5 day post-treatment period (Mojekwu et 
al. 2011). Additionally, the seed ethanolic extract was reported safe up to a dose of 300 mg/kg bw 
(Akpanabiatu et al. 2013; Ilic et al. 2010). In another study, paradol, gingerol, and shogaol isolated from 
the seed have showed anti-inflammatory activity in a rats paw edema model (Ilic et al. 2014). El-
Halawany et al. (2014) have also reported that diarylheptanoid, 8-dehydrogingerdione, 6-
dehydroparadol, dihydrogingerenone, 6-gingerol, dihydroparadol, paradol and 6-shogaol demonstrated 









1.5 Xylopia aethiopica (Dunal) A. Rich 
  
Figure 1.8: Xylopia aethiopica whole plant (A), fruits (B). 
 
1.5.1 Description 
Xylopia ethiopica (Dunal) A. Rich (Annonaceae) also known as Ethiopian pepper or African 
pepper is an evergreen plant, 20 m height, the peppery fruits are in carpels, forming dense cluster, 
twisted bean-like pods, dark brown, cylindrical, 1.5-6 cm long and 4-7 mm thick. It has short roots and 
smooth grey bark and usually scented when fresh. The leaves are broad (5-15 cm long and 2.5-6 cm 
wide), while flowers are greenish-white, usually in clusters of about 3-5 (Iwu, 2014; Orwa et al. 2009; 
Burkill, 1985). 
 
1.5.2 Distribution  
Xylopia aethiopica is an African indigenous spices located in savannah rain forest and widely 
distributed in West, Central and Southern parts of Africa (Iwu, 2014). 
 
1.5.3 Phytochemistry 
Active principles of X. aethiopica fruit include xylopic acid (a kaurene diterpene) (Biney et al. 
2014; Woode et al. 2012), kaurenoic, 15-oxo-kaurenoic acid, and kauran-16-α-ol (Iwu, 2014; Ekong 
and Ogan, 1968). The oils derived from the fruit were reported to contain α- and β-pipenes, careen, 
cymene, α-phellandrene, limonene, terpinoline, cineole, bisabolone, linolool, terpinen-4-ol, terpineal, 
cuminyl alcohol, and cumminicaldyhyde (Harrigan et al. 1994). 
 
1.5.4 Ethnobotanical uses  
The fruit is popularly used as condiment in many local dishes by different traditions in Africa 






ailments and also as an excipient to many other medicines as well (Freiesleben et al. 2015; Fall et al. 
2003). In Nigerian, Guinean, Togolese and Senegalese traditional medicines, the fruit decoction is 
widely used in the treatment of diabetes (Soladoye et al. 2012; Diallo et al. 2012; Karou et al. 2011; 
Diéye et al. 2008). The fruit and/or stembark are also used as pain reliever and in the treatment of 
stomach aches, dysentery, ulceration, skin infections and coughs (Ezeikwesili et al. 2010). The seed is 
employed by women after childbirth to promote healing, lactation and/or promote fertility (Iwu, 2014). 
The leaf or root decoction is used as tonic and in the treatment of constipation (Ndukwu and Ben-
Nwadibia, 2005). 
 
1.5.5 Pharmacological importance 
The X. aethiopica fruit methanolic extract (20 µg/mL) was reported to inhibit more than 50% 
of the proliferation of the tested cancer cells; human pancreatic cancer cell line MiaPaCa-2, leukemia 
CCRF-CEM cells and their multidrug resistant (MDR) subline CEM/ADR5000, and the normal human 
umbilical vein endothelial cells (HUVECs) (Kuete et al. 2013; 2011). Additionally, Choumessi et al. 
(2012) have reported that the fruit ethanolic extract (100 mg/mL) demonstrated anti-proliferative 
activity against HCT116 colon cancer cells, U937 and KG1a leukemia cells.  
In another study, fruit aqueous extract (100 mg/mL) exhibited moderate anti-microbial activity 
against Escherichia coli and Staphylococcus aureus (Esekhiagbe et al. 2009). Tekwu et al. (2012) have 
reported that the fruit methanolic extract (0.002-2 mg/mL) showed anti-mycobacterial activity against 
Mycobacterium tuberculosis strains (H37Rv (ATCC27294) and H37Ra (ATCC25177)).  
Furthermore, various extracts from X. aethiopica fruit have shown good anti-oxidative action 
in vitro in a number of previously reported studies.  The fruit aqueous and methanolic extracts (0-3 
mg/mL) have demonstrated excellent radical scavenging ability (Adefegha and Oboh, 2012a,b; 2011; 
George and Osiama, 2011; Etoundi et al. 2010; Odukoya et al. 2005). In addition, dietary inclusion of 
X. aethiopica fruit (2% and 4%) for 2 weeks improved the in vivo anti-oxidant status of normal rats 
(Adefegha and Oboh, 2012b). Moreover, fruit aqueous extract (0-3 mg/mL) demonstrated moderate 
inhibition of the carbohydrate hydrolyzing enzymes (IC50 values: α-glucosidase: 2.57 mg/mL; α-
amylase: 2.81 mg/mL) (Adefegha and Oboh, 2012a; Etoundi et al. 2010). In another study, fruit 
ethanolic extract (30-300 mg/kg bw/day) showed anti-anaphylactic and anti-inflammatory actions in 
mice after 7 days treatment period (Obiri and Osafo, 2013). Furthermore, oral treatment of fruit 
ethanolic extract (100-400 mg/kg bw) for 2 weeks did not cause any toxicological effect in the treated 
animals (Johnkennedy et al. 2011; Taiwo et al. 2009).  
More recently, Etoundi et al. (2013) have reported that the blood glucose tolerance ability after 
2 hour post-administration period was improved in high-sucrose fed rats treated with 400 mg/kg bw of 
fruit ethanolic extract. Additionally, no significant anti-hyperlipidemic action was observed after 2-day 





study, administration of X. aethiopica aqueous extract (250 mg/kg bw) for 8 weeks demonstrated potent 
anti-hyperlipidemic effect in hypercholesterolemic rats (Nwozo et al. 2011). Nwangwa (2012) has 
reported that the fruit ethanolic extract (750 mg/kg bw/day) treatment for 4 weeks demonstrated 
decrease in the semen count and motility, indicating anti-fertility action. Furthermore, the aqueous, 
ethanol and methanol extracts of fruit (10-100 mg/kg bw) exhibited anti-helminthic potential after 30 
minute post-treatment period (Ekeanyanwu and Etienajirhevwe, 2012).  
 









Figure 1.9: Capsicum annuum whole plant (A), fruits (B). 
 
1.6.1 Description 
Capsicum annuum L. (Solanaceae) popularly known as red pepper is a spice that is readily 
available worldwide. The fruit is widely consumed in vast quantities as flavoring agent in various 
traditional foods. The plant is an annual or biennial of about 1 m in height. The green leaves are oval in 
shape while flowers are greenish-white and borne on axillary bunches. Fruit are usually globular, ovoid, 
or oblong in shape; green colored and yellow to red when ripe (Griffiths, 1959). 
 
1.6.2 Distribution  
The plant is widely distributed in almost all part of the world, from tropical Africa to Europe, 
Asia, South America and Middle East, with over 30 different varieties (Iwu, 2014).  
 
1.6.3 Phytochemistry 
C. annuum fruit has been consistently reported to be the rich source of phenolics, vitamins and 
carotenoids (Hernández-Ortega et al. 2012; Hervert-Hernández et al. 2010; Zimmer et al. 2012; Park et 
al. 2010).The active phytochemicals isolated from the fruit extracts include capsaicin, 






pentosyldihexosides, dihydroxyflavone O-hexoses and quercetin-3-O-L-rhamnoside (Santos et al. 
2012; Hervert-Hernández et al. 2010; Materska and Perucka, 2005). In another study, capsiate, 
dihydrocapsiate and vanillyl alcohol were also isolated from C. annuum fruit (Kobata et al. 1998). 
Furthermore, some amide derivative compounds were also isolated from the stem of C. annuum (Chen 
et al. 2011). These compounds include N-p-trans-coumaroyl-tyramine, N-trans-caffeoyltyramine, β-
sitostenone, ferulic acid, hydroferulic acid, 5-hydroxy-3,4-dimethoxycinnamic acid, vatic acid, vanillic 
acid, isovanillic acid, syringic acid, (+)-syringaresinol, pheophorbide, 7'-(4'-hydroxyphenyl)-N-[(4-
methoxyphenyl) ethyl] propenamide, 7'-(3',4'-dihydroxyphenyl)-N-[(4-methoxyphenyl) ethyl] 
propenamide (Chen et al. 2011). 
 
1.6.4 Ethnobotanical uses  
The fruit is locally used as a blood tonic, stimulant and in the treatment of nerve weakness due 
to diabetes in Africa and Asia (Iwu, 2014; Jayakumar et al. 2010). In most part of Africa, the fruit is 
used in the treatment of skin infections and other bacterial infections (Iwu, 2014). Additionally, the fruit 
and seed are also used in the remedy of cold, fever, dysentery, malaria and gonorrhea (Ndukwu and 
Ben-Nwadibia, 2005). 
 
1.6.5 Pharmacological importance 
The radical scavenging ability of C. annuum fruit has been well documented (Tundis et al. 
2013; Tundis et al. 2012; Chen et al. 2012; Ghasemnezhad et al. 2011; Kim et al. 2011; Kumar et al. 
2010; Deepa et al. 2007; Kwon et al. 2007; Perucka and Materska, 2001). In these studies, the aqueous 
and ethanolic extracts (0.01-1 mg/mL) have demonstrated excellent electron quenching ability (IC50: 
0.1-0.5 mg/mL). Kim et al. (2011) have also reported the potent anti-oxidative actions (DPPH: IC50: 
0.2-3 mg/mL; ABTS: 0.05-0.3 mg/mL) of C. annuum fruit and leaf ethanolic extracts (0.01 mg/mL) in 
vitro. Additionally, the fruit aqueous extract (3.3-16.7 mg/mL) was reported to prevent Fe2+-induced 
lipid peroxidation in rat’s brain homogenate in vitro (Oboh et al. 2007).  
In some other studies, C. annuum fruit ethanolic extract (0.005-1 mg/mL) was reported to 
inhibit the activities of α-amylase (IC50: 0.05-0.5 mg/mL) and α-glucosidase (IC50: 0.1-1 mg/mL) in 
vitro in addition to its anti-oxidative actions (Tundis et al. 2013; Kwon et al. 2007). Capsaicin and 
dihydrocapsaicin (0.005-1 mg/mL) have also demonstrated α-amylase (IC50: capsaicin: 0.083 mg/mL; 
dihydrocapsaicin: 0.092 mg/mL) and α-glucosidase (IC50: capsaicin > 0.5 mg/mL; dihydrocapsaicin > 
0.5 mg/mL) inhibitory action (Tundis et al. 2013). Moreover, the volatile oil (0.3-7.8%) derived from 
C. annuum fruit has shown anti-parasitic effect against Anopheles gambiae. (Dadji et al. 2011). In 
another study, fruit ethanolic extract (0.004-0.3%) was also exhibited potent larvicidal efficacy against 





Furthermore, fruit ethanolic extract (0.1 mg/mL) showed anti-nociceptive and anti-
inflammatory actions in mice (Hernández-Ortega et al. 2012). Cichewicz and Thorpe (1996) have 
earlier reported that the fruit juice extract (100 µL) showed anti-microbial action against Bacillus spp., 
Clostridium spp., Enterobacter aerogenes, Salmonella typhimurium and Staphylococcus aureus. In 
another study, the fruit ethyl acetate extracts (5-40 mg/mL) and the capsaicinoids (2.5-10 µg/mL) 
demonstrated excellent anti-microbial activity against Streptococcus mutans (Santos et al. 2012). 
Careaga et al. (2003) have also reported that the fruit juice (0.02-5 mL/100g) showed anti-bacterial 
activity against Salmonella typhimurium and Pseudomonas aeruginosa inoculated in raw beef meat. In 
a preliminary study, Monsereenusorn (1980) has reported that the intraperitoneal injection of fruit 
extract (500-700 mg/kg bw) showed a significant hypoglycemic action after 30 minutes post-treatment 
period in normal rats.  
Conversely, Babu and Srinivasan (1997) have reported that diabetic animals maintained on 
capsaicin (0.015%) in diet, for 8 weeks have shown no any significant reduction on blood glucose levels. 
In another study, consumption dietary C. annuum (0.9 g/day) for 2 days increases energy expenditure, 
decreases appetite and food intake in human subjects (Westerterp-Plantenga et al. 2004). Similarly, C. 
annuum and its pungent principle capsaicin has been reported to play a beneficial role on lipid 
metabolism in a number of studies reported previously. Capsaicin (0.015%) included in diet for 8 weeks 
was reported to ameliorate dyslipidemia in diabetic and high-fat diet-fed animals (Kempaiah and 
Srinivasan, 2006; Babu and Srinivasan, 1997). Additionally, oral treatment of capsaicin (50 mg/kg bw) 
or whole fruit extract (500 mg/kg bw) for 2 months demonstrated hypolipidemic actions in normal rats 
(Monsereenusorn, 1983). 
 
1.7 Statement of the problem 
The epidemic of DM is among the major cause of morbidity and mortality worldwide and has 
been on the rise particularly in developing countries such as Africa. It has been estimated that about 
80% of diabetic patients live in low- and middle- income countries (ADA, 2015). In Africa, more than 
22 million people have diabetes, accounting for about 5.1% of adults and it is responsible for about 
8.6% deaths in the region (IDF, 2014). Furthermore, the high cost and unwanted adverse effect of most 
of the modern synthetic drugs for the treatment of DM is also an issue of concern. Similarly, treatment 
and control of DM is still a major challenge to medical community and requires safer and cheaper 
alternative to effectively curb the problem of this disease. However, the use of natural products for the 
treatment of DM is getting more popular due to the lower side effects, availability and cost effectiveness 
compared to conventional synthetic drugs. However, the number of plants with potential anti-diabetic 
actions is very limited and many of their anti-diabetic effects have not yet been scientifically validated. 







1.8 Justification and significance of the research work 
With rapid advancement in medicine, novel treatment options with fewer side effects have 
become feasible for the long-term control of diabetic complications. Recent scientific investigations 
have confirmed the efficacy of many plant-derived formulations (extracts and fractions) and their 
isolated bioactive compounds in the treatment and control of diabetes (Hung et al. 2012; Ponnusamy et 
al. 2010). The recommendation of the WHO committee on DM encouraged research on hypoglycemic 
agents from natural products such as plant (WHO, 1980). Therefore, there is a need to investigate and 
establish the anti-diabetic effects of natural products. This will prove and display their anti-diabetic 
potentials for the treatment of DM. Subsequently, a chemical lead for the development of newer classes 
of drugs that can be used in the treatment of DM could be derived from this research work as well. 
Moreover, previous ethnobotanical studies have shown that the fruits and leaves from the selected plants 
(Aframomum melegueta, Xylopia aethiopica, and Capsicum annuum) are used locally in the treatment 
of diabetes. This is in addition to some preliminary studies that demonstrated the blood glcose lowering 
potentials of A. melegueta (Adesokan et al., 2010), X. aethiopica (Adefegha and Oboh, 2012a,b; 
Etoundi et al. (2013) and C. annuum (Monsereenusorn, 1980). Thus, this study will prove and establish 
the detail scientific evidences to support the anti-diabetic potentials of these plants. 
 
1.9 Objective of the study 
1.9.1 General Objective 
This research work is aimed at screening and isolation of some potent anti-diabetic compounds 
from some African medicinal plants [Aframomum melegueta K. Schum., Xylopia aethiopica (Dunal.) 
A. Rich. and Capsicum annuum L.] by using several in vitro and in vivo models.  
 
1.9.2 Specific Objectives 
The research work specifically focused on: 
(i) Screening the various solvent extracts from different parts of the selected medicinal plants 
for in vitro anti-oxidative and anti-diabetic activities using several in vitro models.  
(ii) Screening the in vitro anti-oxidant and anti-diabetic activities of various solvent fractions 
from the most active extracts from the selected parts of the medicinal plants.  
(iii) Preliminary phytochemical studies of the most active extracts and fractions from the 






(iv) Investigating the in vivo anti-diabetic and anti-oxidative effects of the most active fractions 
(from the in vitro studies in (ii) above) from the selected natural in an experimentally-
induced type 2 diabetes model of rats. 
(v) Based on the results of above in vitro and in vivo studies, isolation and structural elucidation 
of possible bioactive components from the most active fractions of the selected medicinal 
plant parts by thin layer chromatography (TLC), column chromatography and Nuclear 
Magnetic Resonance (NMR) spectroscopy. 
























Materials and methods 
2.1 Chemicals and reagents 
Ascorbic acid, quercetin, hemoglobin (human lyophilized powder), gallic acid, aluminium 
chloride, citric acid, sodium citrate, sodium phosphate dibasic (Na2HPO4), sodium phosphate 
monobasic (NaH2PO4), dimethyl sulfoxide (DMSO), potassium hydroxide, Streptozotocin (STZ), 
metformin, formalin, α-amylase from porcine pancreas, α-glucosidase from Saccharomyces cerevisiae 
and 1,1-diphenyl-2-picrylhydrazyl radical (DPPH), xylene, hematoxylin dye, absolute ethanol, hexane, 
ethyl acetate, dichloromethane and methanol were purchased from Sigma-Aldrich through Capital Lab 
Supplies, New Germany, South Africa. Folin Ciocalteau reagent was purchased from Merck Chemical 
Company, South Africa. Gentamycin was purchased from EMD Chemicals, San Diego, CA, USA. 
Ultrasensitive rat insulin ELISA kit was purchased from Mercodia, Uppsala, Sweden.  
 
2.2 Equipment  
Glucometer (Glucoplus Inc., Saint-Laurent, Quebec, Canada), rotary evaporator (Buchi 
Rotavapor II, Buchi, Germany), Whatmann filter paper (No. 1), multiplate reader (MR-96A, Vacutec 
Pvt. Ltd., Durban, South Africa), Automated Chemistry Analyzer (Labmax Plenno, Labtest Co. Ltd., 
Lagoa Santa, Brazil), Leica slide scanner (SCN 4000, Leica Biosystems, Wetzlar, Germany), Nuclear 
Magnetic Resonance (NMR) spectroscopy (Bruker BioSpin, Rheinstetten, Germany), 
spectrophotometer (Shimadzu Corporation, Kyoto, Japan).  
 
2.3 Plant materials 
The various parts of Aframomum melegueta (Rosc.) K. Schum. and Xylopia aethiopica (Dunal) 
A. Rich. were freshly collected in December, 2012 from Ibadan, Oyo State, Nigeria. Capsicum annuum 
L. parts were collected in December, 2012 from Zaria, Kaduna State, Nigeria. They were identified and 
authenticated at the herbarium unit of the Biological Science Department, Ahmadu Bello University, 
Zaria, Nigeria by Mr. Umar Gallah and a voucher specimen number for each plant was deposited 
accordingly [A. melegueta (1511), X. aethiopica (1025) and C. annuum (1755)]. The various plants 
samples (fruits, leaves, stems and roots) were immediately washed and shade-dried for two weeks to 
constant weights. The dried samples were ground to a fine powder, and then stored individually in 
airtight containers for transport to the University of KwaZulu-Natal, Westville campus, Durban, South 






2.3.1 Preparation of the plant extracts 
Three (3) kilograms of each of the finely powdered plant parts were separately defatted with 10 
L of hexane. The defatted material was sequentially extracted with ethyl acetate, ethanol and water by 
soaking for 48 hour in 200 mL of the relevant solvent followed by a 2 hour orbital shaking at 200 rpm. 
After filtration through Whatmann filter paper (No. 1), respective solvents were evaporated under 
vacuum, using a rotary evaporator (Buchi Rotavapor II, Buchi, Germany) at 40°C under reduced 
pressure to obtain the different solvent extracts with the exception of the aqueous extracts which were 
dried on a water bath at 45°C. The extracts in each case were weighed, transferred to 50 mL falcon 
tubes and stored in a refrigerator at 4-8°C until further analysis. 
 
2.3.2 Fractionation of the crude extracts 
Forty (40) grams of the crude extracts of the selected plant parts were dissolved in 500 mL of 
distilled water: methanol (9:1) and successively partitioned with hexane (2 x 500 mL), dichloromethane 
(2 x 500 mL), ethyl acetate (2 x 500 mL) and acetone (2 x 500 mL). The fractions were evaporated to 
dryness in vacuum at 40°C under reduced pressure by using afore-mentioned rotary evaporator. The 
dried fractions were transferred to tubes and stored at 4°C until further analysis. 
 
2.4 In vitro studies  
2.4.1 Estimation of total polyphenol content 
The total polyphenol content of each extracts and/or fraction was determined (as gallic acid 
equivalent) according to the method described by McDonald et al. (2001) with slight modifications. 
Briefly, a 200 µL of the extract (240 µg/mL) was incubated with 1 mL of 10 times diluted Folin 
Ciocalteau reagent and 800 µL of 0.7 M Na2CO3 for 30 minutes at room temperature. The absorbance 
values were then determined at 765 nm in a Shimadzu UV mini 1240 spectrophotometer (Shimadzu 
Corporation, Kyoto, Japan). All measurements were done in triplicate. 
Quantification was done on the basis of a standard curve of gallic acid. Results were expressed 
mg/g (GAE) and calculated using following formula,  
Total polyphenol content (mg/g GAE) = [GAE (mg/mL) × V (mL)]/W (g)  
Where GAE (mg/mL) = (y-c)/m 
GAE: Gallic acid equivalent (mg/mL), V: Total volume of sample (mL), W: Sample weight 









2.4.2 Determination of total flavonoid content 
The total flavonoid content of the plant extracts and/or fractions was determined using a method 
reported by Chang et al. (2002) with slight modification. Briefly, a 500 µL (240 µg/mL) of each sample 
was mixed with 500 µL methanol, 50 µL of 10% AlCl3, 50 µL of 1 mol/L potassium acetate and 1.4 
mL water, and allowed to incubate at room temperature for 30 minutes. The absorbance of the reaction 
mixture was subsequently measured at 415 nm using the spectrophotometer mentioned above. The total 
flavonoid content was calculated as quercetin equivalent (QE) in mg per g of dry extract. 
Quantification was done on the basis of a standard curve of quercetin. Results were expressed 
mg/g (QE) and calculated using following formula,  
Total polyphenol content (mg/g QE) = [QE (mg/mL) × V (mL)]/W (g)  
Where QE (mg/mL) = (y-c)/m 
QE: quercetin equivalent (mg/mL), V: Total volume of sample (mL), W: Sample weight (g), y: 
absorbance of the sample, c: intercept at the y-axis, m: slope of the standard curve. 
 
2.4.3 DPPH radical scavenging activity 
The total free radical scavenging activity of the extracts and/or fractions was determined and 
compared to that of ascorbic and gallic acids by using a slightly modified method described by Tuba 
and Gulcin (2008). An aliquot of 500 µL of a 0.3 mM solution of 1,1-diphenyl-2-picryl-hydrazyl 
(DPPH) in methanol was added to 1 mL of the extracts and/or fractions at different concentrations (30, 
60, 120 and 240 µg/mL). These solutions were mixed and incubated in the dark for 30 minutes at room 
temperature. The absorbance was measured at 517 nm against blank samples lacking the free radical 
scavengers. 
The results of the DPPH were expressed as a percentage of the control (blank) according to the 
following formula: 
% Inhibition = [(Abs of control-Abs of sample)/Abs of control] x 100 
 
2.4.4 Ferric (Fe3+) reducing anti-oxidant power assay 
The ferric reducing anti-oxidant power method of Oyaizu (1986) was used with slight 
modifications to measure the reducing capacity of the samples. To perform this assay, 1 mL of each 
extract and/or fractions (30, 60, 120 and 240 µg/mL) were incubated with 1 mL of 0.2 M sodium 
phosphate buffer (pH 6.6) and 1% potassium ferricyanide at 50°C for 30 minutes. After 30 minutes 
incubation, the reaction mixtures were acidified with 1 mL of 10% trichloroacetic acid. Thereafter, 1 
mL of the acidified sample of this solution was mixed with 1 mL of distilled water and 200 μL of FeCl3 





Increased absorbance of the reaction mixture indicated the greater reductive capability of the extracts 
(Gulcin et al. 2004). 
The results of the ferric reducing anti-oxidant power assay was expressed as a gallic acid 
equivalent according to the following formula: 
% Inhibition = (Abs of sample/Abs of Gallic acid) x 100 
 
2.4.5 Inhibition of hemoglobin glycation  
Inhibition of non-enzymatic glycosylation of hemoglobin by various extracts and/or fractions 
was measured by the modified method of Pal and Dutta (2006). Glucose (2%), hemoglobin (0.06%) 
and gentamycin (0.02%) solutions were prepared in phosphate buffer 0.01 M, pH 7.4. An aliquot of 1 
mL of each of the solution above was mixed with 1 mL of extracts with different concentrations (30, 
60, 120 and 240 µg/mL) in dimethyl sulfoxide (DMSO). These mixtures were incubated in the dark at 
room temperature for 72 hour. The percentage inhibition of glycosylation of hemoglobin was calculated 
from the absorbance measured at 520 nm. Gallic acid was used as a standard. 
The results of the inhibition of hemoglobin glycation were expressed as a percentage of the 
control (blank) according to the following formula: 
% Inhibition = [(Abs of control-Abs of sample)/Abs of control] x 100 
 
2.4.6 α-Amylase (E.C. 3.2.1.1) inhibitory effect 
The α-amylase inhibitory effect of the extracts and/or fractions was carried out using a modified 
method of McCue and Shetty (2004). Briefly, a 250 µL aliquot of extracts, fractions and/or compounds 
at different concentrations (30, 60, 120 and 240 µg/mL) was placed in a tube and 250 µL of 0.02 M 
sodium phosphate buffer (pH 6.9) containing α-amylase (2.0 U/mL) solution was added. This solution 
was pre-incubated at 25°C for 10 minutes, after which 250 µL of 1% starch solution in 0.02 M sodium 
phosphate buffer (pH 6.9) was added at a time interval of 10 seconds and then further incubated at 25°C 
for 10 minutes. The reaction was terminated after incubation by adding 1 mL of dinitrosalicylic acid 
(DNS) reagent. The tube was then boiled for 10 minutes and cooled to room temperature. The reaction 
mixture was diluted with 5 mL distilled water and the absorbance was measured at 540 nm using a 
Shimadzu UV mini 1240 spectrophotometer. A control was prepared using the same procedure, 
replacing the extract with distilled water.  
The results of the α-amylase assay were expressed as a percentage of the control (blank) 
according to the following formula: 







2.4.7 α-Glucosidase (E.C. 3.2.1.20) inhibitory effect 
The inhibitory effect of the plant extracts and/or fractions on α-glucosidase activity was 
determined according to the method described by Kim et al. (2005) using α-glucosidase from 
Saccharomyces cerevisiae. The substrate solution 5.0 mM p-nitrophenylglucopyranoside (pNPG) was 
prepared in 20 mM phosphate buffer, pH 6.9. An aliquot of 500 µL of α-glucosidase (1.0 U/mL) was 
then pre-incubated with 250 µL of the different concentrations of the extracts, fractions and/or 
compounds (30, 60, 120 and 240 µg/mL) for 10 minutes. Thereafter, a 250 µL of 5.0 mM pNPG was 
dissolved in 20 mM phosphate buffer (pH 6.9) as a substrate to start the reaction. The reaction mixture 
was incubated at 37°C for 30 minutes. The α-glucosidase activity was determined by measuring the 
yellow coloured p-nitrophenol released from pNPG at 405 nm.  
The results of the α-glucosidase assay were expressed as a percentage of the control (blank) 
according to the following formula: 
% Inhibition = [(Abs of control-Abs of sample)/Abs of control] x 100 
 
2.4.8 Calculation of IC50 values 
Concentrations of extracts, fractions or compounds resulting in 50% inhibition of radical or 
enzyme activities (IC50) were calculated from the plot of percentage inhibition against log(concentration 
of the samples). 
IC50= 10x  
Where x (mg/mL) = (y-c)/m  
y: 50%, c: intercept at the y-axis, m: slope of the graph of log(concentration of sample used) 
against the percentage inhibitions. 
 
2.4.9 Mechanism of α-glucosidase and α-amylase inhibitions 
The most active fractions or compounds were subjected to kinetic experiments to determine the 
type of inhibition exerted on α-glucosidase and α-amylase. The experiment was conducted according 
to the protocols as described above at a constant concentration of the fractions or compounds (30 
µg/mL) with a variable concentration of substrate. For the α-glucosidase inhibition assay, 0.313-5.0 
mmol/L of pNPG was used and 0.063-1.0% of starch was used for the α-amylase inhibition assay. The 
initial rates of reactions were determined from calibration curves constructed using varying 
concentrations of p-nitrophenol (0.313-5.0 mmol/L) and maltose (0.063-1.0%) for the α-glucosidase 
and α-amylase inhibition assays, respectively. The initial velocity data obtained were used to construct 
Lineweaver-Burke’s plot to determine the KM (Michaelis constant) and vmax (maximum velocity) of the 
enzyme as well as the Ki (inhibition binding constant as a measure of affinity of the inhibitor to the 





2.4.10 Gas Chromatography-Mass Spectroscopic (GC-MS) analysis 
Based on the results of in vitro anti-oxidative and anti-diabetic studies, the most active extracts 
and/or fractions were subjected to GC-MS analysis. The GC-MS analysis was conducted with an 
Agilent technology 6890 GC coupled with an Agilent 5973 Mass Selective Detector and driven by 
Agilent Chemstation software. Compounds were identified by direct comparison of the retention times 
and mass spectral data with those in the National Institute of Standards and Technology (NIST) library. 
 
2.5 In vivo studies 
2.5.1 Experimental animals 
Six-week-old male Sprague-Dawley (SD) rats were obtained from the Biomedical Resource 
Unit (BRU) located at the University of KwaZulu-Natal (Westville Campus), South Africa with initial 
mean body weight (bw) 163.25 ± 13.67 g. Animals were housed as two in one medium size poly-
carbonated cage in a temperature and humidity controlled room with a 12 hour light-dark cycle. A 
standard rat pellet diet was supplied ad libitum to all animals during the entire experimental period. 
Animals were maintained according to the rules and regulations of the Experimental Animal Research 
Ethics Committee of the University of KwaZulu-Natal, South Africa (Ethical approval number: 
018/14/Animal).  
 
2.5.2 Animal grouping 
Animals were randomly divided into twelve groups of 5 (non-diabetic groups) or 8 (diabetic 
groups) animals namely; NC: Normal Control, DBC: Diabetic Control, DAML: Diabetic + low dose 
(150 mg/kg bw) of AMEF, DAMH: Diabetic + high dose (300 mg/kg bw) of AMEF, DCAL: Diabetic 
+ low dose (150 mg/kg bw) of CAAF, DCAH: Diabetic + high dose (300 mg/kg bw) of CAAF, DXAL: 
Diabetic + low dose (150 mg/kg bw) of XAAF, DXAH: Diabetic + high dose (300 mg/kg bw) of XAAF, 
DMF: Diabetic + metformin (300 mg/kg bw), NAMH: Non-diabetic + high dose (300 mg/kg bw) of 
AMEF. NCAH: Non-diabetic + high dose (300 mg/kg bw) of CAAF, NXAH: Non-diabetic + high dose 
(300 mg/kg bw) of XAAF. The animals were allowed to acclimatize for two weeks before starting the 









Figure 2.1: Animal grouping in vivo study. 
Key: NC: Normal control; DBC: Diabetic control; DMF: Diabetic treated with metformin AMEF: A. melegueta ethyl acetate 
fraction; DAML & DAMH: Diabetic treated with lower & higher dose of AMEF; NAMH: Normal treated with higher dose of 
AMEF; CAAF: C. annuum acetone fraction; DCAL & DCAH: Diabetic treated with lower & higher dose of CAAF; NCAH: 
Normal treated with higher dose of CAAF; XAAF: X. aethiopica acetone fraction; DXAL & DXAH: Diabetic treated with 
lower & higher dose of XAAF; NXAH: Normal treated with higher dose of XAAF; SD: Sprague-Dawley. 
 
2.5.3 Induction of Type 2 diabetes (T2D)  
In order to induce the two major pathogeneses of T2D, insulin resistance and partial pancreatic 
β-cell dysfunction, during the first two weeks of the experiment, the animals in the DBC, DAML, 
DAMH, DCAL, DCAH, DXAL, DXAH and DMF groups were supplied with a 10% fructose solution 
ad libitum for the induction of insulin resistance when the animals in the NC, NAMH, NCAH and 
NXAH groups were supplied with normal drinking water. After this period, a low dose of STZ (40 
mg/kg bw) dissolved in citrate buffer (pH 4.5) were intraperitoneally injected to the animals in the DBC, 
DAML, DAMH, DCAL, DCAH, DXAL, DXAH and DMF groups to induce partial pancreatic β-cell 
dysfunction, whereas the animals in the NC and NAMH, NCAH and NXAH groups were injected with 
a similar volume of vehicle buffer only (Wilson and Islam, 2012). One week after the STZ injection, 
the non-fasting blood glucose (NFBG) of all animals were measured in the blood collected from the tail 
vein by using a portable glucometer (Glucoplus Inc., Saint-Laurent, Quebec, Canada). Animals with a 
NFBG level ≥ 200 mg/dL were considered as diabetic (Davidson et al. 2011) while animals with a 






2.5.4 Intervention period 
After the confirmation of diabetes, a respective dose of the various fractions were orally 
administered once daily for four weeks using a gastric gavage needle to the animals in DAML, DAMH, 
DCAL, DCAH, DXAL, DXAH, NAMH, NCAH and NXAH groups while the animals in controls (NC 
and DBC) and DMF groups were treated with similar volume of the vehicle and metformin, 
respectively. Throughout the experimental period, feed and fluid intake were measured every morning 
by subtracting the remaining amount of feed and fluid respectively from the amount given on the 
previous morning. Moreover, the weekly bw and NFBG levels were measured in all animal groups 
during the entire intervention period. 
 
2.5.5 Oral glucose tolerance test (OGTT)  
To determine the glucose tolerance ability of each animal, the OGTT was performed in the last 
week of the four-week intervention period. To perform this test, a single dose of glucose solution (2 
g/kg bw) was orally administered to each animal and the subsequent levels of blood glucose were 
measured at 0 (just before glucose ingestion), 30, 60, 90 and 120 minutes after the ingestion of glucose.  
 
2.5.6 Collection and preparation of blood and organs  
At the end of the experimental period, animals were euthanized with halothane anesthesia and 
blood and organ samples were collected. The whole blood of each animal was collected via cardiac 
puncture and immediately preserved in a refrigerator until further processing. The blood samples were 
centrifuged at 3000 rpm for 15 minutes and serum from each blood sample was separated and preserved 
at -30°C for further analysis. The liver, kidney, heart and pancreas were collected from each animal, 
washed with normal saline, wiped with filter paper, weighed and preserved at -30°C until subsequent 
analysis. A small piece of pancreatic tissue from each animal was cut and placed in a 10% neutral 
buffered formalin solution and preserved at room temperature for histopathological study. The neutral 
buffered formalin of each pancreatic tissue sample was replaced weekly during the entire preservation 
period.  
For the organs, about 0.5 g each organ (liver, pancreas, heart and kidney) was homogenized in 
4 mL of homogenization buffer (50 mM sodium phosphate buffer with triton X-100, pH 7.5) using a 
portable tissue homogenizer. Thereafter, the mixtures were transferred to micro tubes and spinned for 
15 minutes at 15000 rpm in a microcentrifuge at 4°C. The supernatants were then collected in other 








2.5.7 Analytical methods 
The serum insulin concentrations were measured by an enzyme-linked immunosorbent assay 
(ELISA) method using an ultrasensitive rat insulin ELISA kit (Mercodia, Uppsala, Sweden) in a 
multiplate reader (MR-96A, Vacutec Pvt. Ltd., Durban, South Africa). The serum lipid profile, 
fructosamine, urea, uric acid, total protein, lactate dehydrogenase (LDH), creatine kinase (CK-MB) and 
creatinine concentrations as well as liver function enzymes; aspartate and alanine aminotransferases 
(AST and ALT) and alkaline phosphatase (ALP) were measured using an Automated Chemistry 
Analyzer (Labmax Plenno, Labtest Co. Ltd., Lagoa Santa, Brazil) with commercial assay kits from the 
same company. Homeostatic model assessment (HOMA-IR and HOMA-β) scores were calculated at 
the end of the intervention according to the following formula: 
HOMA-IR = [(Fasting serum insulin in U/l x Fasting blood glucose in mmol/L) / 22.5]  
HOMA-β = (Fasting serum insulin in U/l x 20 / Fasting blood glucose in mmol/L -3.5) 
Conversion factor: insulin (1 U/l = 7.174 pmol/L).  
LDL-cholesterol was calculated according to Friedewald et al. (1972) equation as shown below:                   
LDL-Cholesterol (mg/dL) = TC- (HDL+ (TG/5) 
Where, TG/5 is equivalent to the concentration of VLDL-cholesterol. 
Atherogenic index (AI) was calculated according to the method described by Liu et al. (1999) and 
expressed as:  
AI = (TC - HDL-cholesterol)/HDL-cholesterol.  
Coronary artery risk index (CRI) was also calculated using the following formula (Boers et al., 2003). 
Coronary artery risk index (CRI): TC / HDL-cholesterol  
Liver glycogen concentrations were measured by phenol-sulfuric acid method as described by Lo et al. 
(1970). 
 
2.5.8 Histopathological examination of pancreatic tissue  
A standard laboratory protocol for paraffin embedding was used to treat the formalin preserved 
pancreatic tissues. Tissue sections were cut into a size of 4 mm before fixing on the slides. Then, the 
slides were deparaffinized in p-xylene and rehydrated in ethanol gradient (100, 80, 70 and 50%) and 





counter stained in eosin, mounted in DPX, cover-slipped and viewed with Leica slide scanner (SCN 
4000, Leica Biosystems, Wetzlar, Germany).  
 
2.5.9 Determination of reduced glutathione (GSH) 
The reduced glutathione levels were determined using the procedure described by Ellman 
(1959) with slight modifications. A 0.5 mL of the serum or tissue homogenate was added to 0.5 ml of 
10% TCA and centrifuged at 5000 rpm for 10 minutes. Thereafter, 0.5 mL of the supernatant was mixed 
with 0.5 mL of Ellman’s reagent (19.80 mg of DTNB dissolved in 100 mL of 0.1% NaNO3) and 3 mL 
of phosphate buffer (200 mM, pH 8.0). The mixture was incubated for 30 minutes at room temperature 
and the absorbance was measured at 412 nm. The concentration of the reduced glutathione in the 
samples was calculated from a standard glutathione curve.  
 
2.5.10 Determination of thiobarbituric acid reactive substance (TBARS) concentration as 
malondialdehyde (MDA) equivalent  
Thiobarbituric acid reactive substances, expressed as MDA equivalent, were measured to 
determine the extent of lipid peroxidation using the protocol described by Fraga et al. (1988). A 200 μL 
of the sample or MDA standards were thoroughly mixed with 200 μL of 8.1% sodium dodesylsulphate 
(SDS) solution, 750 μL of 20% acetic acid, 2 mL of 0.25% TBA and 850 μL of distilled water. 
Subsequently, the resulting mixture was heated in a water bath at 95°C for 1 hour and allowed to cool 
to room temperature. The absorbance of the resulting solution was then read at 532 nm and the 
concentration of TBARS in the samples was calculated from the MDA standard curve.  
 
2.5.11 Determination of catalase activity  
This assay was carried out as described by Aebi (1984). A 340 μL of 50 mM sodium phosphate 
buffer (pH 7.0) was mixed with 150 μL of 2 M H2O2. Thereafter, a 10 μL of the sample was added and 
the decrease in absorbance at 240 nm was monitored for 3 min at 1 minute interval.  
Activity (µmol/min/µg protein)= [(Abs1-Abs2)/ε] x 0.5/µmol/min/µg protein. Where ε= 
0.00394 mM-1cm-1; Abs1= Initial absorbance; Abs2= Final absorbance 
 
2.5.12 Determination of superoxide dismutase (SOD) activity  
This assay was carried out by transferring 1 ml of 0.1 mM diethylenetriaminepentaacetic acid 
(DETAPAC) and 90 μl of the sample into a quartz cuvette. Then a 90 μl of 1.6 mM 6-hydroxydopamine 
(6-HD) was added and the mixture was quickly mixed. Absorbance of the resulting mixture was 





Activity (µmol/min/µg protein)= [(Abs1-Abs2)/ε] x 0.5/µg protein. Where ε= 1.742 mM-1cm-1; 
Abs1= Initial absorbance; Abs2= Final absorbance 
 
2.5.13 Determination of glutathione peroxidase (GPx) activity  
GPx was assayed by the method of Paglia and Valentine (1967). The reaction mixture contained 
0.1 M phosphate buffer (pH 7.0), 1 mM EDTA, 10 mM glutathione, 1 mM NaN3, 1 unit of glutathione 
reductase, 1.5 mM NADPH and 0.1 ml of sample. After incubating for 10 minutes at 37ºC, H2O2 was 
added to each sample to a final concentration of 1 mM. GPx activity was measured as the rate of 
NADPH oxidation at 340 nm in a spectrophotometer for 3 minutes at 1 minute intervals. 
Activity (µmol/min/µg protein)= [(Abs1-Abs2)/ε] x 0.5/µg protein. Where ε= 6.22 mM-1cm-1; 
Abs1= Initial absorbance; Abs2= Final absorbance 
 
2.5.14 Determination of glutathione reductase (GR) 
Glutathione reductase (GR) activity was determined according to the method described by 
Foyer and Halliwell (1976). About 800 μL of 25 mM sodium phosphate buffer (pH 7.8) was added to 
the sample and blank tubes respectively. This was followed by the addition of 100 μL of each oxidized 
glutathione (GSSG) and NADPH in both blank and the sample tubes. A 100 μL of the sample is finally 
added into the sample tube. The oxidation of NADPH was recorded by reading the absorbance at 340 
nm continuously for 180 seconds.  
Activity (µmol/min/µg protein)= [(Abs1-Abs2)/ε] x 0.5/µg protein. Where ε= 6.22 mM-1cm-1; 
Abs1= Initial absorbance; Abs2= Final absorbance 
 
2.6 Isolation of the bioactive anti-diabetic compounds from the fractions  
All NMR data, 1H, 13C and 2D experiments were recorded on a Bruker Avance III 400 MHz 
spectrometer. Samples were acquired with deuterated chloroform (CDCl3). The spectra were referenced 
according to the deuteriochloroform signal at δH 7.24 (for 1H NMR spectra) and δC 77.0 (for 13C NMR 
spectra) for CDCl3. The HRESIMS spectra were obtained from a Bruker Micro TOF-QII instrument. 
A bioassay guided isolation protocol was used to isolate the pure bioactive anti-diabetic 
agent(s) from each of the most active fraction (from in vitro studies described in sub chapter 2.4) but 









2.6.1 Isolation of the bioactive compounds from the ethyl acetate fraction of ethanolic 
extract of Aframomum melegueta fruit  
15.5 g of the ethyl acetate (EtOAc) crude extract of A. melegueta was subjected to column 
chromatography on a silica gel column using gradient solvent systems of hex: EtOAc and EtOAc: 
MeOH with increments of 10% in each step to afford 84 fractions. After monitoring with TLC, similar 
fractions were pooled together to afford seven major fractions (A: 11-13; B: 14-17; C: 20-25; D: 26-32; 
E: 33-34; F: 35-47 and G: 48-55). Compound 1 (210.0 mg), was obtained as an oil from fraction C (2.51 
g) after further purification on a 2.0 cm diameter column using hex: EtOAc (17:3) as eluent.  Fraction 
D (990. 3 mg) was further purified on a column (1.5 cm in diameter) by elution with hex: EtOAc (8:2) 
to obtain compound 2 (490.0 mg) as an oil. Compound 3 (990.9 mg) was obtained as an oil by 
purification of fraction F (4.13 g) on a silica column and eluted with hex: EtOAc (3:2). Fraction E 
(100.9 mg) was further purified with a hex: EtOAc (7:3) solvent system, which yielded compound 4 
(60.0 mg). All the isolated bioactive compounds demonstrated considerable α-amylase and α-
glucosidase inhibitory actions. 
 
2.6.2 Isolation of the bioactive compound from the acetone fraction of ethanolic extract 
of Xylopia aethiopica fruit  
A part of the acetone crude extract of X. aethiopica (16 g) was fractionated on a 3.5 cm diameter 
column over silica gel (0.040-0.063 mm) using a gradient elution of n-hexane:EtOAc (with 10% 
increments of EtOAc) and then  MeOH (100%) resulting in 64 fractions. The fractions were pooled 
together on the basis of TLC to afford six main fractions (A: 6-8; B: 9-13; C: 14-16; D: 18-22; E: 27-
32 and F: 33-54). Compound 4 (440.7 mg) was purified with hex: EtOAc (7:3) from fraction C (1.55 
g) by CC (2 cm column) where 4 eluted again in fractions 16-43. Fraction E (1.92 g) was separated by 
CC on a 2.0 cm column using Hex: EtOAc (1:1) which yielded 3 (350.6 mg) again as a brownish oil in 
fractions 16-44. Additionally, these compounds showed considerable α-amylase and α-glucosidase 
inhibitory actions. 
 
2.6.3 Isolation of the bioactive compound from the acetone fraction of ethanolic extract 
of Capsicum annuum fruit  
A 15.13 g sample of the acetone crude extract of C. annuum was fractionated by column 
chromatography using Hex: EtOAc and then EtOAc: MeOH in a stepwise gradient elution by 10% 
increments using a 3.5 cm diameter column. After TLC, the 4 main fractions were combined as follows: 





fraction C (3.03g) yielded a mixture of compounds 5, which could not be separated despite several 
attempts and exhibited considerable α-amylase and α-glucosidase inhibitory actions.  
 
2.7 Statistical analysis 
For all the in vitro studies, data were presented as the mean ± SD of triplicates determination 
while in the in vivo studies, the data were presented as the mean ± SD of 5 to 7 animals. Data were 
analyzed by using a statistical software package (SPSS for Windows, version 23, IBM Corporation, 
NY, USA) using Tukey's-HSD multiple range post-hoc test. Values were considered significantly 
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3.1.1 Abstract 
Objective: Aframomum melegueta K. Schum. (Zingiberaceae) fruits, leaf or seeds are used for 
treatment of different diseases such as diabetes, microbial infections, stomach ache, snakebite and 
diarrhea in Africa. This study investigated and compared the anti-oxidative, anti-diabetic effects and 
possible compounds present in various solvent extracts of fruit, leaf and stem of A. melegueta.  
Methods: Samples were sequentially extracted using solvents of increasing polarity. They were 
subjected and investigated for 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging activity, 
ferric reducing power, inhibition of hemoglobin glycosylation, α-amylase and α-glucosidase activities 
as markers of in vitro anti-diabetic effects at various doses (30-240 µg/mL). Possible compounds were 
analyzed using Gas Chromatography-Mass Spectrometry (GC-MS) analysis.  
Results: Fruit ethanolic (EtOH) extract showed higher total polyphenol (12.52 ± 0.13 mg/gGAE) and 
flavonoid (4.92 ± 0.12 mg/gQE) contents compared to other extracts. Similarly for all the in vitro 
models used in this study, fruit EtOH extract exhibited lower IC50 values compared to other extracts and 
comparable to standards used accordingly (DPPH 0.04 ± 0.01 mg/mL; Ascorbic acid: 0.03 ± 0.02 
mg/mL; Gallic acid: 0.05 ± 0.01 mg/mL; Hemoglobin glycosylation: 0.72 ± 0.03 mg/mL; Gallic acid: 





± 0.01 mg/mL; Acarbose: 0.21 ± 0.01 mg/mL).  The GC-MS analysis of the most active extracts (EtOH 
fruit and leaf) revealed the presence of some phenolics and other fatty acids derivatives as possible 
compounds present.  
Conclusion: Fruit EtOH extract exhibited higher anti-oxidative and anti-diabetic effects compared to 
other solvent extracts in vitro and thus require further work to fully validate these effects in vivo. 
 
Keywords: Aframomum melegueta, Anti-oxidative, α-amylase, α-glucosidase, Type 2 diabetes 
 
3.1.2 Introduction 
Globally, the prevalence of diabetes mellitus (DM) is increasing exponentially. Presently, over 
387 million people are diabetic and this figure is likely to rise to 592 million by 2035 (IDF, 2014). 
Among the major types of diabetes (type 1 and type 2), type 2 is the most prevalent one and about 90-
95% of diabetics suffer from type 2 diabetes (T2D) (van-Dam et al. 2002). T2D is a heterogeneous 
disorder characterized by insulin resistance and partially dysfunctional pancreatic β-cell to properly 
secrete insulin in response to hyperglycemia (Hui et al. 2007). The hyperglycemia increases the 
generation of reactive oxygen species (ROS) that bind to carbohydrates, proteins, lipids or DNA, 
thereby cause cellular and tissue damages, leading to oxidative stress in T2D (Devasagayam et al. 2007; 
Rosen et al. 2001). Hence, oxidative stress is considered as the major causal factor of T2D associated 
complications. Moreover, anti-oxidants are molecules that can inhibit or terminate the initiation or 
propagation of oxidative chain reactions, and can therefore prevent or repair the damage caused by ROS 
(Halliwell et al. 1995). However, the increasing risk associated with the use of existing synthetic anti-
oxidants has been an issue of concern. Therefore, focus has been shifted to the use of natural anti-
oxidants in preventing oxidative damage either in disease condition or food preservation.  
Furthermore, the major treatment options for T2D include the use oral hypoglycemic drugs in 
addition to lifestyle modification. However due to the number of short- and long-term side effects 
associated with the use of the synthetic drugs, their popularity are decreasing gradually (Stephen, 2006; 
Suba et al. 2004). This has paves way for a search of newer alternative agents such as plant-derived 
products to control T2D that are known to pose fewer side effects. Furthermore, the inhibition of 
carbohydrate digesting enzymes such as α-glucosidase is now regarded as another alternative approach 
to control T2D. This caused a reduction of postprandial hyperglycemia via decrease in the intestinal 
glucose absorption (Imam, 2015). Additionally, in a number of recently published data, plant-derived 
extracts or fractions have shown potent anti-oxidant and demonstrated abilities to inhibit α-glucosidase 
activities (Ibrahim et al. 2014; Kong et al. 2014; Gulati et al. 2012; Adefegha and Oboh, 2012a).  
Aframomum melegueta K. Schum. (Zingiberaceae) commonly known as guinea or alligator 
pepper is abundantly found in central and western part of Africa (Iwu, 2014). The seeds, leaf or fruit 





as diabetes, microbial infections, diarrhea, abdominal pain, snakebite and wounds healing in Nigeria, 
Cameroon, Kenya and Gabon (Iwu, 2014; Soladoye et al. 2012; Gbolade, 2009; Akendengue and Louis, 
1994; Kokwaro, 1993). Recently, the dieterpenoids isolated from the organic seed extract of A. 
melegueta has showed bactericidal activity in vitro against Escherichia coli, Listeria moncyogenes and 
Staphylococcus aureus strains (Ngwoke et al. 2014). In another study, Sugita et al. (2013) have reported 
that A. melegueta alcohol extract activates brown adipose tissue and increases whole-body energy 
expenditure in human subjects which is directly linked to the pathogenesis of T2D. Moreover, in a 
number of studies reported earlier, various extracts from A. melegueta seed possessed anti-oxidative as 
well as anti-diabetic effects in vitro (Kazeem et al. 2012; Adefegha and Oboh, 2012a; Adefegha and 
Oboh, 2011; Etoundi et al. 2010) and in vivo (Onoja et al. 2014; Adesokan et al. 2010) when the anti-
oxidative or anti-diabetic effects of fruit, leaf and stem are still unknown. Additionally, to our 
knowledge, no study is available that investigated and compared anti-oxidative and anti-diabetic effects 
of A. melegueta fruit, leaf and stem in a single study either in vitro or in vivo. 
Therefore, this study was designed to investigate and compare the anti-oxidative and inhibition 
of key enzymes linked to T2D by various extracts from fruit, leaf and stem of A. melegueta using several 
in vitro models. Additionally, possible bioactive compounds on most active extracts were analyzed 
using GC-MS. 
 
3.1.3 Materials and methods 
For sample collection, identification and preparation of the extracts, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.4.  
 
3.1.4 Results  
The yields recovered, total polyphenols and flavonoids contents from different solvent extracts 
of various parts are presented in Table 3.1. The aqueous leaf extract showed higher yield compared to 
other solvent extracts, while stem ethyl acetate (EtOAc) extract was the least recovered. Moreover, 
significantly (p < 0.05) higher total polyphenols and flavonoids contents were observed in the fruit 
ethanolic (EtOH) extract compared to other solvent extracts of the same or different parts of A. 
melegueta (Table 3.1). Interestingly, the contents of leaf EtOH extract were also higher compared to 
the EtOAc and aqueous extracts of this part. However, in the stem part, the EtOAc extract showed 








Table 3.1: Percentage yield, total polyphenol and flavonoid contents of various solvent extracts of A. 
melegueta parts 
Samples Yield (%) Total polyphenols content 
(mg/g GAE) 
Total flavonoids content 
(mg/g QE) 
Fruit    
Ethyl acetate 0.73 9.03 ± 0.21d 1.53 ± 0.18b 
Ethanol 0.53 12.52 ± 0.13e 4.92 ± 0.12d 
Aqueous 1.63 2.97 ± 0.03b 0.17 ± 0.06a 
Leaf    
Ethyl acetate 1.05 5.49 ± 0.51c 0.69 ± 0.12a 
Ethanol 2.63 9.43 ± 0.03d 3.50 ± 0.18c 
Aqueous 3.00 1.84 ± 0.44b 0.42 ± 0.29a 
Stem    
Ethyl acetate 0.25 1.58 ± 0.54a,b ND 
Ethanol 1.13 0.66 ± 0.09a 0.31 ± 0.06a 
Aqueous 2.38 0.18 ± 0.01a 0.11 ± 0.06a 
Data are presented as mean ± SD values of triplicate determinations. a-e Different superscripted letters for a given value within 
a column are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). ND, Not 
determined.  
 
The results of ferric (Fe3+) reducing anti-oxidant power (expressed as gallic acid equivalents) 
of various extracts are presented in Figure 3.1. According to the data, various solvent extracts from 
fruit and leaf parts of A. melegueta showed considerable reducing abilities, irrespective of the solvent 
used. The EtOH extracts had demonstrated significantly (p < 0.05) higher activities compared to other 
solvent extracts. In addition, fruit EtOH extract showed higher reducing power compared to other 
solvent extracts of the same or different parts and was comparable to ascorbic acid used as a standard 











Figure 3.1. Ferric reducing power (relative to gallic acid) of fruit (A) and leaf (B) extracts of A. melegueta. Data are presented 
as mean ± SD of triplicate determinations. a-c Different letters presented over the bars for a given concentration of each extract 
are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
The data of DPPH radical scavenging activities and the calculated IC50 values of various 
extracts from different parts of A. melegueta are presented in Figure 3.2 and Table 3.2, respectively. 
The IC50 values recorded for various solvent extracts from fruit ranges from 0.04 to 0.16 mg/mL (Table 
3.2). The EtOH extract has demonstrated significantly (p < 0.05) lower IC50 value (0.04 ± 0.01 mg/mL) 
compared to other extracts and is comparable to the standards used in this study (ascorbic acid: 0.03 ± 
0.02 mg/mL; gallic acid: 0.05 ± 0.01 mg/mL). Similarly, leaf EtOH extract exhibited lower IC50 value 







those of the standards. Various extracts from stem showed weak scavenging effect as the calculated 
IC50 values were significantly higher compared to other solvent extracts from the other parts and the 
standards as well (Table 3.2). In addition, EtOH extracts from different parts exhibited the least IC50 
values for DPPH scavenging activity compared to other extracts from the respective parts of A. 
melegueta. 
 














Fruit     
Ethyl acetate 0.16 ± 0.01a 1.55 ± 0.32a 3.59 ± 0.12c 2.73 ± 0.08e 
Ethanol 0.04 ± 0.01a 0.72 ± 0.03a 0.13 ± 0.01a 0.06 ± 0.01a 
Aqueous 0.06 ± 0.01a 3.34 ± 0.32b 3.62 ± 0.03c 0.32 ± 0.01b 
Leaf     
Ethyl acetate 0.17 ± 0.01a 16.75 ± 0.39d 25.99 ± 0.26f 1.05 ± 0.01c 
Ethanol 0.07 ± 0.02a 5.12 ± 1.21c 8.79 ± 0.44d 0.06 ± 0.01a 
Aqueous 1.78 ± 0.10b 57.57 ± 0.82e 15.10 ± 0.35e 2.65 ± 0.40e 
Stem     
Ethyl acetate 4.45 ± 0.16d ND ND 2.31 ± 0.18d,e 
Ethanol 2.46 ± 0.01c ND ND 1.93 ± 0.02d 
Aqueous 4.70 ± 0.21e ND ND 81.29 ± 0.90f 
Ascorbic acid 0.03 ± 0.02a ND ND ND 
Gallic acid 0.05 ± 0.01a 0.20 ± 0.01a ND ND 
Acarbose ND ND 0.37 ± 0.03b 0.21 ± 0.01b 
Data are presented as mean ± SD values of triplicate determinations. a-f Different superscript letters presented within a column 









Figure 3.2. DPPH Radical scavenging activity (%) of fruit (A), leaf (B) and stem (C) extracts of A. melegueta. Data are 
presented as mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of 





The results of the inhibition of hemoglobin glycation by the extracts are presented in Figure 
3.3 and Table 3.2. Fruit EtOH extract has exhibited a significantly (p < 0.05) lower IC50 value (0.72 ± 
0.03 mg/mL) compared to other solvent extracts from the same or different parts, which again was 
comparable to the gallic acid (0.20 ± 0.01 mg/mL) used as a standard (Table 3.2). Moreover, leaf EtOH 
extract exhibited lower IC50 value (5.12 ± 1.21 mg/mL) compared to the EtOAc and aqueous extracts. 





Figure 3.3. Inhibition of hemoglobin glycosylation (%) of fruit (A) and leaf (B) extracts of A. melegueta. Data are presented 
as mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract 





The results of inhibition of α-amylase action by various extracts from A. melegueta are 
presented in Figure 3.4 and Table 3.2. It was observed from the data that, fruit EtOH extract exhibited 
significantly (p < 0.05) lower IC50 value (0.13 ± 0.01 mg/mL) compared to other solvent extracts of 
this part (EtOAc: 3.59 ± 0.12 mg/mL; aqueous: 3.62 ± 0.03 mg/mL) and comparable to acarbose (0.37 
± 0.03 mg/mL). The degree of inhibitions was in the increasing order: aqueous < EtOAc< EtOH (Table 
3.2). On the other hand, the calculated IC50 value of leaf EtOH extract (8.79 ± 0.44 mg/mL) was 
significantly (p < 0.05) higher compared to acarbose (0.37 ± 0.03 mg/mL). Furthermore, none of the 




Figure 3.4. α-Amylase inhibition (%) of fruit (A) and leaf (B) extracts of A. melegueta. Data are presented as mean ± SD of 
triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract are significantly 





The data of the α-glucosidase inhibitory action by various solvent extracts from A. melegueta 
are presented in Figure 3.5 and Table 3.2. According to the data, fruit and leaf EtOH extracts have 
demonstrated potent α-glucosidase inhibitory effects with the same IC50 value (0.06 ± 0.01 mg/mL) 
which is significantly lower compared to that of acarbose (0.21 ± 0.01 mg/mL). Stem EtOH extract 
which shows no α-amylase inhibitory effect exhibited moderate α-glucosidase (IC50= 1.93 ± 0.02 




Figure 3.5. α-Glucosidase inhibition (%) of fruit (A), leaf (B) and stem (C) extracts of A. melegueta. Data are presented as 
mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract 





Figures 3.6 and 3.7 as well as Table 3.3 present the data of the phytochemical analysis of the 
most active extracts (EtOH fruit and leaf) from A. melegueta. Several peaks appeared in the 
chromatogram of the fruit EtOH extract and were identified and compared with standards from the 
NIST library (Figure 3.6A). The available constituents (1-5 and 8-10) in fruit EtOH extract were 
phenolics and other long chain fatty derivatives (Figure 3.7 and Table 3.3).  The phenolics include 
eugenol (1), gingerol (8) and capsaicin (9), whereas the fatty derivatives detected were oliec acid (4), 
hexadecanoic derivatives (2, 3, 5) and 13-docosenoic acid, methyl ester (10) (Figure 3.7 and Table 
3.3). Furthermore peaks visible from the chromatogram of leaf EtOH extract (Figure 3.6B) lead to 
identification of some phenolics; gingerol (8), 3-decanone, 1-(4-hydroxy-3-methoxyphenyl) (10), ethyl 
homovallinate (6), with other fatty acid derivatives as oleic acid (4) and 13-docosenoic acid, methyl 
ester (10) (Figure 3.7 and Table 3.3). It is also evident from the result that all the aromatic compounds 
(1, 6, 8, 9) identified in both extracts are of 4-hydroxy-3-methoxyphenyl derivatives.  
 
 






                       






Table 3.3: Identified compounds from the EtOH fruit and leaf extracts of A. melegueta by GC-MS 
Extracts Compounds Retention time (min) Mass/amu 
EtOH fruit    
1 Eugenol 6.68 164 [M]+ 
2 n-Hexadecanoic acid 10.22 256 [M]+ 
3 Hexadecanoic acid, ethyl ester 10.39 284 [M]+ 
4 Oleic acid 11.11a 282 [M]+ 
5 Z-9-Hexadecen-1-ol acetate 11.24a 282 [M]+ 
6 Gingerol 12.20 294 [M]+ 
7 Capsaicin 12.49 239 [M]+ 
10 13-Docosenoic acid, methyl 
ester, (Z) 
13.37 352 [M]+ 
EtOH leaf    
4 Oleic acid 11.11 282 [M]+ 
6 3-Decanone, 1-(4-hydroxy-3-
methoxyphenyl) 
11.63 278 [M]+ 
8 Ethyl homovanillate 12.15 210 [M]+ 
6 Gingerol 12.20 294 [M]+ 
10 13-Docosenoic acid, methyl 
ester, (Z) 
13.37 352 [M]+ 
a isomers with same mass/amu at the different retention time 
 
3.1.5 Discussion 
Natural products in the form of crude or plant preparations have been used in the treatment and 
control of wide array of diseases. In many of such plants, some parts usually receive much attention 
compared to others. For instance A. melegueta, where most of the studies previously reported focused 
on seed alone, rendering the other parts to almost wastage.  In this regard, we intend to explore the anti-
oxidative and inhibition of key enzymes linked to T2D by various solvent extracts from fruit, leaf and 
stem of A. melegueta. This is of great importance as this will shade more light on the medicinal 
potentials of other parts of A. melegueta.  
In previous studies, Adefegha and Oboh (2012a; 2011) have reported that, the seed aqueous 
extract of A. melegueta possessed higher polyphenolic and flavonoid contents, which was further 
supported in another study by Etoundi et al. (2010). Our data is partly in line with above-mentioned 
studies (Table 3.1). The higher polyphenolic and flavonoid contents of fruit EtOH extract compared to 





study the polyphenolic and flavonoid contents of the aqueous extract were relatively similar with that 
of the seed aqueous extract reported earlier (Adefegha and Oboh, 2012a; 2011). Interestingly, leaf EtOH 
extract was also found to be rich in polyphenols and flavonoids contents. This is the first study that 
highlighted the contents of these phytochemicals from either the leaf or the stem parts. Furthermore, it 
is important to notice that, the amount and distribution of plants products such as polyphenols varies 
greatly from one species of plants to another or among the parts of the same plants. The production and 
accumulation of polyphenols are influenced by many factors, such as genetic and environmental factors 
(nature of the soil, high temperature and rain fall) in addition to growth or maturation stages for most 
of the parts of the plants (Mamphiswana et al. 2010; Pandey and Rizvi, 2009). Hence, the higher 
polyphenols and flavonoids contents of fruits compared to other parts could be attributed to one or 
combination of the above-mentioned factors, which were linked to most of the anti-oxidant ability of 
various plant-derived extracts.  
In this study, a number of in vitro models were used to investigate the anti-oxidative potentials 
of various solvent extracts from different parts of A. melegueta. Among such model is the reduction of 
Fe3+ to Fe2+ by plant extracts or compounds is another reliable index and a good indicator of their 
electron-quenching abilities (Chung et al. 2002). This reaction is monitored by the formation of Perl’s 
Prussian blue color at 700 nm. In an attempt to further support the anti-oxidative nature of A. melegueta, 
Adefegha and Oboh, (2012b) have earlier reported higher reducing potential of A. melegueta aqueous 
seed extract, which correlate well with the results of our present study (Figure 3.1). Moreover, although 
no previous study is available on the A. melegueta leaf, our data have shown that leaf could be a good 
source of anti-oxidant in addition to seed and fruit that are popularly utilized. The higher ferric iron 
(Fe3+) reducing anti-oxidant power of various extracts from A. melegueta scavenging activity of EtOH 
extracts than other extracts from different parts of A. melegueta could be attributed to their rich 
polyphenols and flavonoids contents of these extracts, which has been further supported by the DPPH 
radical scavenging activity (Table 3.2). 
The DPPH radical scavenging activity is a quick and reliable method for determining the anti-
oxidative nature of plant-derived products. DPPH is a stable radical that usually delocalized by 
accepting electrons from the referenced anti-oxidant, thereby becoming a stable molecule (Lobo et al. 
2010). The anti-oxidative effectiveness of various solvent extracts was assessed base on the calculated 
IC50 values. The lower the IC50 value, the higher the anti-oxidative potential of the extract. In some 
previous studies various extracts from the A. melegueta seed have shown good radical scavenging 
capacities. Kazeem et al. (2012) have reported an IC50 value of 0.110 ± 0.010 mg/mL for seed acetone 
extract, whereas 17.38 ± 2.00 mg/mL was earlier reported for seed aqueous extract (Adefegha and 
Oboh, 2012a). However, these are by far higher compared to that of fruit EtOH and aqueous extracts 
(EtOH: 0.04 ± 0.01mg/mL; aqueous: 0.04 ± 0.01 mg/mL) as well observed in our present study (Table 





Additionally, this is the lowest IC50 value reported for DPPH scavenging of any extracts derived from 
A. melegueta.  
Hemoglobin glycation is a non-enzymatic reaction occurs when proteins are exposed to excess 
reducing sugars and contributes immensely to the formation of advanced glycation end products that 
lead to oxidative stress (Yamagishi et al. 2008; Rahbar and Figarola, 2003; Brownlee et al. 1984). 
Kazeem et al. (2012) have earlier reported an IC50 value of 0.125 ± 0.02 mg/mL for acetone extract 
(0.25-1 mg/mL), which is obviously lower compared to that of fruit EtOH extract and other solvent 
extracts (Table 3.2). This could be due to the lower concentrations (30-240 µg/mL) used in our present 
study. The results were further supported by the α-amylase and α-glucosidase inhibitory actions of 
various extracts from A. melegueta (Table 3.2). 
On the other hand, the control of postprandial hyperglycemia is crucial for the management of 
DM and prevention of its complications at early stage (Ali et al. 2006). This is achieved by delaying 
the absorption of glucose from the small intestine through the inhibition of carbohydrates metabolizing 
enzymes such as α-amylase and α-glucosidase, located at the intestinal tract. The α-amylase catalyzes 
the endo-hydrolysis of α-1, 4-glucosidic linkage releasing disaccharides and oligosaccharides which are 
further hydrolyzed at the small intestinal brush border by α-glucosidases to release glucose (Hua-Quang 
et al. 2012; Hanhineva et al. 2010). In a previous study, Adefegha and Oboh (2012a) have reported an 
IC50 value of 4.83 ± 0.56 mg/mL for α-amylase inhibition by seed aqueous extract. However, according 
to our results all the extracts derived from fruit part have demonstrated lower IC50 values compared to 
that of seed aqueous extract reported earlier, indicating better activity of the fruit than the seed part 
(Table 3.2). Similarly, the calculated IC50 value of the seed aqueous extract (2.14 ± 1.08 mg/mL) for 
α-glucosidase inhibition reported earlier was again far higher compared to that of fruit EtOH extract 
(0.06 ± 0.01 mg/mL) observed in our present study (Adefegha and Oboh, 2012a). Also observed in our 
data is that the IC50 value of the fruit aqueous extract was about 6-fold lower compared to that reported 
by Adefegha and Oboh (2012a) for seed aqueous extract. Furthermore, the relatively similar α-
glucosidase inhibitory action of the leaf and fruit EtOH extracts has shown that leaf could be another 
potential source for α-glucosidase inhibitors (Table 3.2). 
Based on the results of this study, fruit and leaf EtOH extracts that exhibited higher activities 
were subjected to GC-MS analysis to find the possible bioactive compounds that could be responsible 
for their activities. The study reported by Ilic et al. (2010) has indicated that, seed EtOH extract contains 
mainly the phenolic compounds such as gingerol, shogaol and paradol, which supports our present 
finding. It is also evident that eugenol (1), gingerol (6), capsaicin (7) 3-decanone, 1-(4-hydroxy-3-
methoxyphenyl) (10) and ethyl homovallinate (11), detected in fruit and leaf EtOH extracts were of 4-
hydroxy-3-methoxyphenyl derivatives. Therefore, it is propose that the presence of phenolics is 
regarded as the key feature that could be responsible for the higher anti-oxidative and anti-diabetic 
effects of the fruit and leaf EtOH extracts observed in this study in addition to the contribution of other 





due to their low reduction potential compared to highly reactive species such as hydroxyl (•OH), 
superoxide (O2•-), nitric oxide (NO•) radicals. Their ability to donate electron or proton from hydroxyl 
moieties result in stabilizing lipid peroxidation, neutralizing ROS and ultimately inhibit the initiation 
and propagation of chain reaction associated with oxidative damage (Brewer, 2011). Likewise, it has 
been proposed that phenolics interact with one or multiple sites of the α-glucosidase or α-amylase 
surface proteins and thus form a hydrophobic layer. This leads to aggregation and precipitation which 
changes the conformation of the enzyme structure and hence decrease in activity (Toda et al. 2001; 
Spencer et al. 1988). 
 
3.1.6 Conclusions 
In conclusion, various solvent extracts from fruit and leaf of A. melegueta have demonstrated 
anti-oxidative as well as anti-diabetic effects in vitro when stem extracts showed very low or no 
significant activities in these regards. The fruit EtOH extract exhibited higher actions compared to other 
extracts of the same or different parts. Thus, it is recommended for further bioassay-guided fractionation 


























According to the in vitro anti-oxidative and anti-diabetic studies of the various solvent extracts derived 
from different parts of A. melegueta stated above, fruit ethanolic extract demonstrated higher activities 
compared to other extracts. Therefore it was selected for further studies. 
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3.2.1 Abstract 
Objectives: This study was aimed to investigate the anti-oxidative potentials and α-glucosidase and α-
amylase inhibitory effects of various fractions derived from crude ethanolic (EtOH) extract of A. 
melegueta fruit. Additionally, possible bioactive compounds from the fraction with higher activity were 
analyzed using GC-MS.    
Methods: Fruit EtOH extract was fractionated using solvents of increasing polarity. They were 
subjected and investigated for 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging activity, 
ferric reducing power, inhibition of hemoglobin glycosylation, α-amylase and α-glucosidase activities 
as markers of in vitro anti-diabetic effects at various doses (30-240 µg/mL). Possible compounds were 
analyzed using Gas Chromatography-Mass Spectroscopic (GC-MS) analysis. 
Results: Our findings revealed that the ethyl acetate (EtOAc) fraction had the highest anti-oxidative 
activities (IC50 values, DPPH: 15.49 ± 4.38 µg/mL; Hemoglobin glycosylation: 111.33 ± 6.46 µg/mL) 
and inhibition of α-amylase (IC50 values: 68.69 ± 6.05 µg/mL) and α-glucosidase (IC50 values: 40.44 ± 
5.77 µg/mL) actions compared to other fractions and the respective standards used in this study. GC-
MS analysis revealed that the EtOAc fraction contained some compounds aromatic in nature.  
Conclusion: Data obtained from the study suggest that the EtOAc fraction derived from the EtOH 
extract of A. melegueta fruit possessed potent anti-oxidative as well as α-glucosidase and α-amylase 
inhibitory activities than other solvent fractions. 
Keywords: Aframomum melegueta, Anti-oxidative, Ethyl acetate fraction, Type 2 diabetes 






Type 2 diabetes (T2D) is a heterogeneous disorder characterized by insulin resistance and 
partially dysfunctional pancreatic β-cell to properly secrete insulin in response to elevation of blood 
glucose levels (Hui et al. 2007). The inability of pancreatic β-cell to secret insulin disrupts the regulation 
of hepatic gluconeogesis, muscles glucose uptake and lipolysis in adipose tissues. The consequence is 
postprandial hyperglycemia which results into T2D (Gastaldelli, 2011). Moreover, in chronic 
uncontrolled hyperglycemia, there is an increased production of reactive oxygen species (ROS) and a 
declined of in vivo anti-oxidant defense system, a term referred as oxidative stress (Maritim et al. 2003). 
The ROS are derived from the normal physiological processes and become highly deleterious if the 
levels increases and not arrested by complex anti-oxidant systems in the body (Chang and Chuang, 
2010). The most common ROS include superoxide (O2·-), hydrogen peroxide (H2O2), peroxyl (ROO·) 
and reactive hydroxyl (OH·) radicals (Niki, 2010). Furthermore, increase intake of anti-oxidants has 
good correlation in amelioration of complication caused by ROS. However, people are now aware of 
the high risk caused by the synthetic anti-oxidants due to their chemical instability and hence depend 
on plant-derived anti-oxidants for food preservations and disease controls such as T2D.  
On the other hand, inhibition of the activities of carbohydrate hydrolysing enzymes such as α-
glucosidase has been used as one of the recent alternatives for the treatment and control of T2D 
(Adefegha and Oboh, 2012). This reduces the rate of intestinal glucose absorption which apparently 
decreases the postprandial hyperglycemia (Bhadari et al. 2008). Currently, some synthetic α-
glucosidase inhibitors such as acarbose and miglitol are available for the control of T2D. But the 
undesirable adverse effects with the use of these drugs cause a shift to look for options from natural 
sources such as plants that are to cause fewer or no adverse side effects.  
Interestingly, in most of the recent studies, plant-derived extracts and/or fractions have shown 
potent anti-oxidant as well as inhibition of α-glucosidase activities and therefore could possibly be a 
potential candidates for the treatment and control of T2D (Ibrahim et al. 2014; Kong et al. 2014; 
Adamson and Oboh, 2012; Adefegha and Oboh, 2012a).  
Aframomum melegueta K. Schum. (Zingiberaceae) commonly known as guinea or alligator 
pepper is a native to west and central parts of Africa (Iwu, 2014). The seeds, leaf or fruit are consumed 
as flavoring agent in various traditional foods and are used locally to treat diseases such as diabetes, 
microbial infections, diarrhea, abdominal pain, snakebite and wounds healing in Nigeria, Kenya and 
Gabon (Iwu, 2014; Soladoye et al. 2012; Gbolade, 2009; Akendengue and Louis, 1994; Kokwaro, 
1993). Previously, Sugita et al. (2013) have reported that A. melegueta seed alcoholic extract stimulates 
brown adipose tissue and increases whole-body energy expenditure in human subjects which is directly 
linked with the pathogenesis of T2D. Additionally, in a number of recent studies reported that various 
solvent extracts from A. melegueta seed have demonstrated potent anti-oxidant as well as anti-diabetic 





al. 2010) and in vivo (Onoja et al. 2014). Furthermore, in our recent study, we have reported that fruit 
ethanolic (EtOH) extract demonstrated higher anti-oxidant and anti-diabetic actions in vitro compared 
to other solvent extracts from the various parts of A. melegueta (Mohammed et al. 2015a). Therefore, 
in our effort to find potent anti-diabetic plant-derived formulations, we further partitioned and 
fractionated the crude EtOH extract from A. melegueta fruit with the hope to obtain the best fraction 
with highest anti-diabetic activities.  
Therefore, our present study was aimed to investigate the anti-oxidative potentials and 
inhibitory effects of various fractions derived from crude EtOH extract of A. melegueta fruit on the 
activities of α-glucosidase and α-amylase enzymes. Additionally, possible bioactive compounds from 
the fraction with highest activities was also analysed using GC-MS.    
 
3.2.3 Materials and methods 
For sample collection, identification and preparation of the fractions, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.4.  
 
3.2.4 Results  
The results of the percentage yield recovered, total polyphenols and flavonoids contents of 
various fractions from the fruit EtOH extract are presented in Table 3.4. It was observed from the data 
that the least polar solvent (hexane) recovered higher yield whereas the acetone, which is the most polar 
recovered the least amount. Similarly, the most polar fractions (ethyl acetate (EtOAc) and acetone) have 
demonstrated higher polyphenols and flavonoids contents compared to the less polar solvent fractions 
(hexane and dichloromethane). Furthermore, within the most polar, the polyphenols and flavonoids 
contents of the EtOAc fraction were relatively higher compared to that of acetone fraction (Table 3.4). 
The total polyphenols content was in the order; EtOAc > acetone > dichloromethane > hexane. 
 
Table 3.4. Percentage yield, total polyphenol and flavonoid contents of various fractions from ethanolic 
fruit extract of A. melegueta  




Hexane 17.80 1.46 ± 0.16a 0.53 ± 0.41a 
Dichloromethane 10.54 3.64 ± 0.41b 0.52 ± 0.14a 
Ethyl acetate 5.60 18.98 ± 0.06c 6.06 ± 0.06b 
Acetone 1.70 16.21 ± 0.70c 5.02 ± 0.34b 
Data are presented as mean±SD values of triplicate determinations. a-cDifferent superscripted letters for a given value within 





The results of ferric (Fe3+) reducing total anti-oxidant power (expressed as gallic acid 
equivalents) of the various fractions are presented in Figure 3.8. It was observed that EtOAc fraction 
showed a significantly (p < 0.05) higher and concentration dependent reducing power compared to other 
solvent fractions as well as the standard ascorbic acid (Figure 3.8). Hexane and acetone fractions 
demonstrated similar Fe3+ to Fe2+ reducing abilities while dichloromethane fraction was the least active 
among the fractions tested (Figure 3.8). 
 
 
Figure 3.8. Total reducing power (relative to gallic acid) of various fractions from fruit ethanolic extract of A. melegueta. Data 
are presented as mean±SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of 
each extract are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05).  
 
The data of DPPH radical scavenging activities and the calculated IC50 values of various 
fractions from the fruit EtOH extract are presented in Figure 3.9 and Table 3.5, respectively. All the 
solvent fractions have shown variable scavenging abilities. The EtOAc fraction exhibited significantly 
(p < 0.05) lower IC50 value (15.49 ± 4.38 µg/mL) for DPPH scavenging activities compared to other 
solvent fractions and comparable to standards used in this study (Ascorbic acid: 25.34 ± 6.19 µg/mL; 






Figure 3.9: DPPH Radical scavenging activity (%) of various fractions from fruit ethanolic extract of A. melegueta. Data are 
presented as mean±SD of triplicate determinations. a-e Values with different letters presented for a given concentration for each 
extract are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05).  
 
Table 3.5: IC50 values of various solvent fractions from ethanolic fruit extract of A. melegueta in 











inhibitory  effect 
α-glucosidase 
inhibitory  effect 
Hexane 356.63 ± 28.02d 1728.72 ± 714.10c 1567.63 ± 71.46e 6351.8 ± 606.74d 
Dichloromethane 262.60 ± 12.11c 4054.78 ± 387.76d 268.56 ± 2.79b 133.99 ± 1.85b 
Ethyl acetate 15.49 ± 4.38a 111.33 ± 6.46a 68.69 ± 6.05a 40.44 ± 5.77a 
Acetone 69.88 ± 3.34b 398.80 ± 44.24c 678.14 ± 49.09d 356.23 ± 4.50c 
Ascorbic acid 25.34 ± 6.19a ND ND ND 
Gallic acid 20.01 ± 4.42a 199.09 ± 2.85b ND ND 
Acarbose ND ND 374.95 ± 26.81c 211.59 ± 3.39b 
Data are presented as mean ± SD values of triplicate determinations. a-e Different superscripted letters for a given value within 
a column are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). ND, Not 
determined. 
The results of inhibition of hemoglobin glycation and the calculated IC50 values of various 
fractions are presented in Figure 3.10 and Table 3.5, respectively. The EtOAc fraction demonstrated 
significantly (p < 0.05) lower IC50 (111.33 ± 6.46 µg/mL) compared to hexane (1728.72 ± 714.10 
µg/mL) and dichloromethane (4054.78 ± 387.76 µg/mL) fractions. Similarly, the IC50 value for  EtOAc 





standard gallic acid (199.09 ± 2.85 µg/mL), although did not differ significantly among the fractions 
(Table 3.5).  
 
Figure 3.10: Inhibition of hemoglobin glycation (%) of various fractions from fruit ethanolic extract of A. melegueta. Data 
are presented as mean±SD of triplicate determinations. a-d Values with different letters presented for a given concentration for 
each extract are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
The data of α-amylase inhibition by the various fractions and the calculated IC50 values are 
presented in Figure 3.11 and Table 3.5, respectively. EtOAc fraction had exhibited a significantly (p < 
0.05) lower calculated IC50 value (68.69 ± 6.05 µg/mL) towards α-amylase inhibition compared to other 
solvent fractions and acarbose as well (Table 3.5). The activity of the acetone fraction did not differ 
significantly (p < 0.05) compared to the standard acarbose.  
 
Figure 3.11: α-Amylase inhibition (%) of various fractions from fruit ethanolic extract of A. melegueta. Data are presented as 
mean±SD of triplicate determinations. a-e Values with different letters presented for a given concentration for each extract are 





Furthermore, results of α-glucosidase inhibition by the various fractions and the calculated IC50 
values are presented in Figure 3.12 and Table 3.5, respectively. The EtOAc fraction had showed a 
significantly (p < 0.05) lower IC50 value (40.44 ± 5.77 µg/mL) for α-glucosidase inhibition compared 
to other solvent fractions and acarbose (211.59 ± 3.32 µg/mL) (Table 3.5). The inhibitory action 
exhibited by the EtOAc was almost 5-fold higher compared to the standard acarbose. Additionally, the 
order of inhibition by the various fractions was in the order; EtOAc > dichloromethane > acarbose 
>acetone > hexane. 
 
Figure 3.12: α-Glucosidase inhibition (%) of various fractions from fruit ethanolic extract of A. melegueta. Data are presented 
as mean ± SD of triplicate determinations. a-c Values with different letters presented for a given concentration for each extract 
are significantly different from each other(Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
The data of the kinetics of the inhibitory mode of the α-glucosidase and α-amylase by the most 
active fraction are presented in Figure 3.13. According to the results, EtOAc fraction has exhibited a 
non-competitive inhibition towards α-glucosidase action. The KM value remains unchanged (1.10 
mmol/L), whereas the Vmax was found to decreases from 471.56 µmol/min to 114.45 µmol/min and the 
equilibrium constant for inhibitor binding (Ki) was calculated as 9.68 µg/mL (Figure 3.13A). On the 
other hand, the mode of inhibition of α-amylase action by the EtOAc fraction was observed to be a 
mixed inhibition type. That is upon addition of the fraction, the KM value (control: 0.06%; with EtOAc: 
0.16%) was found to increase, when the value of Vmax (control: 35.67 µmol/min; with EtOAc: 22.99 
µmol/min) was observed to decrease and the Ki value for inhibiting α-amylase was 54.34 µg/mL 







Figure 3.13: Lineweaver-Burke’s plot of (A) α-glucosidase and (B) α-amylase catalyzed reactions in the presence and in the 
absence of the ethyl acetate (EtOAc) fraction derived from the A. melegueta fruit ethanolic extract. 
 
In Figure 3.14 and Table 3.6, possible bioactive compounds detected from the most active 
fraction (EtOAc) including the chromatogram and their chemical structures are presented. Several peaks 
appeared in the chromatogram of the EtOAc fraction (Figure 3.14A) and were identified by their 
fragmentation pattern and in conjunction with the NIST library. The major peaks correspond to 4-
methylphenol (1), 2,6-dimethylphenol (2), isobornyl propionate (3), eugenol (4), 5-ethyl-2-methyl 
thiazole (5), 4-hydroxy-3-methoxyphenyl butan-2-one (6), benzyl benzoate (7), 1,2-
benzenedicarboxylic acid, butyl 2-methylpropyl ester (8), 4-hydroxy-3-methoxyphenyl decan-3-one (9) 
and 1,2-benzenedicarboxylic acid, mono(2-ethylhexyl) ester (10) (Table 3.6). Additionally, with the 
exception of compounds 3 and 5, the remaining compounds are aromatic in nature when compounds 1, 























































Table 3.6: Identified compounds from the ethyl acetate fraction from fruit ethanolic extract of A. 
melegueta by GC-MS 
Solvent Compounds Retention time (min) Mass/amu 
Ethyl acetate    
1 4-Methylphenol 4.44 107 [M]+ 
2 2,6-Dimethylphenol 5.07 122 [M]+ 
3 Isobornyl propionate 6.22 210 [M]+ 
4 Eugenol 6.67 164 [M]+ 
5 5-Ethyl-2-methyl thiazole 7.65 127 [M]+ 
6 4-Hydroxy-3-methoxyphenyl butan-
2-one 
8.58, 12.43 194 [M]+ 
7 Benzyl benzoate 9.36 212 [M]+ 
8 1,2-Benzenedicarboxylic acid, butyl 
2-methylpropyl ester 
10.26 278 [M]+ 
9 4-Hydroxy-3-methoxyphenyl decan-
3-one 
11.63 278 [M]+ 
10 1,2-Benzenedicarboxylic acid, 
mono(2-ethylhexyl) ester 























T2D has been associated with a number of complications such as retinopathy, neuropathy, 
nephropathy, myocardial infarction, atherosclerosis and peripheral vascular diseases, which partly or 
completely depend on uncontrolled hyperglycemia (Heydari et al. 2010; Rahman et al. 2007; Monnier 
et al. 2006). The hyperglycemia initiate a sequence of oxidative processes that cause dysfunction and 
failure of organs such as liver, kidney, eyes and other peripheral tissues in type 2 diabetic patients. 
Several synthetic drugs were developed to control the hypeglycemia. But the associated adverse effects 
with the use of these drugs cause a shift to look for options from plant-derived products. This is because 
fewer side effects were associated with the use of plant-derived formulations (Singh, 2001). Therefore, 
our current study investigated the anti-oxidative potentials and inhibitory effects of various fractions 
derived from fruit EtOH extract of A. melegueta fruit on the activities of α-glucosidase and α-amylase 
actions in vitro. 
In our recent study, we have reported higher polyphenols and flavonoids contents in the fruit 
EtOH extract compared to other extracts of the same or different parts of A. melegueta (Mohammed et 
al. 2015). In another studies, Adefegha and Oboh (2012; 2011) have reported higher polyphenols in the 
seed aqueous extract. These are in line with our present results, when higher contents were observed in 
the most polar fractions (EtOAc and acetone) (Table 3.4). This has signified that polarity of the solvent 
play a role in the availability of the polyphenols in the fractions. Polyphenols are anti-oxidants that can 
prevent the deleterious actions of reactive oxygen species (ROS) to cellular biomolecules thereby 
modulating the initiation and propagation of oxidative chain reactions, and thus attenuate oxidative 
stress (Alia et al. 2003). Furthermore, the higher polyphenolic content of the EtOAc fraction was further 
supported by the greater radical scavenging activities of the fraction than other solvent fractions (Figure 
3.8). 
The reduction of Fe3+ to Fe2+ is a reliable method of assessing the anti-oxidant nature of various 
plant-derived extracts, fractions and/or bioactive compounds (Chung et al. 2002). The higher reducing 
power of EtOAc fraction observed in our present study suggest that most of the anti-oxidant 
biomolecules in crude extract are available in this fraction (Figure 3.8). This might be attributed to the 
rich polyphenols of the EtOAc fraction and was further supported by the greater DPPH scavenging 
ability (Table 3.5). 
According to the studies reported earlier, the fruit or seed extracts have demonstrated better 
radical scavenging ability compared to other extracts (Mohammed et al. 2015; Kazeem et al. 2012; 
Adefegha and Oboh, 2012: 2011). For instance, in our recent study, fruit EtOH extract has exhibited 
potent electron quenching ability and depicted the least IC50 value for DPPH scavenging ability (0.04 ± 
0.01 mg/mL) (Mohammed et al. 2015). However, based on our present data the IC50 value for EtOAc 





for any extract or fraction derived from A. melegueta Table 3.5). This was again supported by its 
capacity to inhibit hemoglobin glycosylation (Table 3.5). 
Kazeem et al. (2012) have previously indicated that seed acetone extract possessed strong anti-
glycosylation property. However, in our present study, such higher anti-glycosylation property was 
depicted by the EtOAc fraction derived from the fruit EtOH extract (Table 3.5). The higher inhibition 
of hemoglobin glycosylation by EtOAc fraction indicated the ability of this fraction to attenuate the 
hyperglycemia-induced oxidative stress, which may also be attributed the rich polyphenols of the 
EtOAc fraction compared to other fractions.  
On the other hand, among the recent approach to control postprandial hyperglycemia involves 
the inhibition of α-amylase and α-glucosidase actions, which are key relevant enzymes linked to T2D 
located at the enterocyte brush border (Imam, 2015).  They are known to be involved in the breakdown 
and absorption of complex carbohydrates biomolecules at intestinal tract (Hua-Quang et al. 2012; 
Hanhineva et al. 2010). Inhibitors of the activities of these enzymes such as acarbose and miglitol are 
currently utilized as potential anti-T2D agent. But the associated adverse effects such as diarrhea, 
bloating, flatulence, cramping and abdominal pain decrease their popularity (Fujisawa et al. 2005). This 
has shifted the search to plant-derived products such as A. melegueta for alternatives. In some previous 
studies, seed aqueous extract has exhibited good inhibitory effects toward the activities of α-amylase 
and α-glucosidase (Adefegha and Oboh, 2012: 2011). Moreover, in our comparative study, fruit EtOH 
extract was found to demonstrated higher inhibition of α-amylase and α-glucosidase actions compared 
to other solvent extract of the same or different parts of A. melegueta (Mohammed et al. 2015). 
However, in our present study, when the crude EtOH extract was solvent-solvent fractionated, the 
inhibition of the EtOAc fraction was by far better compared to even the most polar fraction (acetone) 
and acarbose as well (Table 3.5). Therefore, we may suggest the presence of more active inhibitory 
compounds in EtOAc fraction that could delay the digestion of complex carbohydrates and 
subsequently intestinal glucose absorption, thereby reducing the postprandial hyperglycemia in T2D.    
According to the kinetic parameters derived from the double reciprocal plot revealed that, the 
EtOAc fraction is a non-competitive inhibitor of α-glucosidase action (Figure 3.13A). Therefore, it is 
suggested that, EtOAc fraction binds to other site (s), apart from the active site of the enzyme, and 
induces some conformational changes in the three-dimensional structure of the enzyme. This slows 
down the activity of the enzyme. In addition, the affinity of the enzyme to the substrate is not affected 
since the KM value remains the same in the presence or absence of the inhibitor (EtOAc fraction). In the 
case of α-amylase action, it was observed that both the Vmax and KM are affected in the presence of the 
EtOAc fraction, which implied that the mode of inhibition of the fraction is a mixed inhibition type 
(Figure 3.13B). In this type of inhibition, both the KM and Vmax of the enzyme are greatly affected in 
the presence of the inhibitor. This tends to cause some conformational modifications at the active site 
of the enzyme that hinder the binding of the substrate and thus decreases the enzyme activity. It has 





favorably to the enzyme in free-form and thereby decrease the affinity of the enzyme for the substrate 
(Storey, 2004). Therefore, based on our present data, it seems that the EtOAc fraction binds to the α-
amylase in a free state before binding to its substrate (starch) and results in decrease activity.     
Based on the higher anti-oxidative and anti-diabetic actions exhibited by the EtOAc fraction, it 
was subjected to GC-MS analysis to detect possible bioactive compounds present in this fraction. It has 
been highlighted previously that A. melegueta fruit or seed extracts are rich in phenolic compounds 
such as gingerol, paradol, shagaol and eugenol (Mohammed et al. 2015; Ilic et al. 2010). This is in line 
with our present data and could possibly be attributed to the observed higher actions of EtOAc fraction 
than other solvent fractions. It is also possible from our results that, other compounds detected from the 
EtOAc fraction might further contribute significantly to the higher anti-oxidative and enzyme inhibitory 
actions of the EtOAc fraction (Table 3.6 and Figure 3.14B). In a nutshell, these compounds may act 




In conclusion, various solvent fractions derived from the fruit ethanolic extract of A. melegueta 
possessed anti-oxidative as well as α-amylase and α-glucosidase inhibitory actions in vitro. The EtOAc 
fraction has exhibited higher activities compared to other fractions. Thus, it is recommended for further 




















According to the anti-oxidative and anti-diabetic study of the various solvent fractions derived from 
ethanolic extract of A. melegueta fruit stated above, ethyl acetate fraction exhibited higher activities 
compared to other solvent fractions. Therefore it was selected for the in vivo studies. 
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3.3.1 Abstract 
Objectives: In West Africa, various preparations of the fruit, seed and leaf of Aframomum melegueta 
K. Schum. are reputably used for the management of diabetes mellitus (DM) and other metabolic 
disorders. The present study evaluated the anti-diabetic effects of A. melegueta ethyl acetate fraction 
(AMEF) from fruit ethanolic extract in a type 2 diabetes (T2D) model of rats.  
Methods: T2D was induced in rats by feeding a 10% fructose solution ad libitum for two weeks 
followed by a single intraperitoneal injection of streptozotocin (40 mg/kg body weight) and the animals 
were orally treated with 150 or 300 mg/kg body weight (bw) of the AMEF once daily for four weeks.  
Results: At the end of the intervention, diabetic untreated animals showed significantly higher serum 
glucose, serum fructosamine, LDH, CK-MB, serum lipids, liver glycogen, insulin resistance (HOMA-
IR), AI, CRI and lower serum insulin, β-cell function (HOMA- β) and glucose tolerance ability 
compared to the normal animals. Histopathological examination of their pancreas revealed 
corresponding pathological changes in the islets and β-cells. These alterations were reverted to near-
normal after the treatment of AMEF at 150 and 300 mg/kg bw when, the effects were more pronounced 
at 300 mg/kg bw compared to the 150 mg/kg bw.  
Conclusion:  The results of our study suggest that AMEF treatment at 300 mg/kg bw showed potent 
anti-diabetic effect in a T2D model of rats. 








Diabetes mellitus (DM) is a condition that causes hyperglycemia due to either decreased insulin 
secretion or insulin sensitivity of target tissues (Panni, 2013). Recent data indicate that more than 387 
million people have DM and this figure is likely to be doubled by 2035 (IDF, 2014). Among the major 
types of diabetes (type 1 and type 2), type 2 is the most prevalent one, accounting for more than 90% 
of all diabetic cases. Type 2 diabetes (T2D) is a heterogeneous disorder characterized by insulin 
resistance and partially dysfunctional pancreatic β-cells which cannot properly secrete insulin in 
response to hyperglycemia (Hui et al. 2007). Insulin resistance usually occurs in the early stage of T2D 
after which a further decline of β-cells is induced, resulting in hyperglycemia and hyperlipidemia 
(Robertson et al. 2004).  
The current treatment option for T2D include mainly oral anti-diabetic drugs, such as- 
sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones and dipeptidyl peptidase-4 
(DPP-4) inhibitors among others. But these drugs do not adequately improve the consequences of T2D 
and have caused characteristic profiles of serious side effects, which include hypoglycemia, weight 
gain, hypersensitivity, gastrointestinal discomfort, nausea, liver and heart failure, and diarrhoea (Hung 
et al. 2012). Therefore, search for novel molecules has been extended to natural plant-based remedies, 
as they are considered more effective, safe, natural and cause less adverse effects compared to modern 
synthetic drugs.  
Aframomum melegueta K. Schum. (Zingiberaceae) commonly known as guinea pepper is a 
herbaceous plant that grows up to 1500 cm height, with purple flowers that develop into 5-7 cm long 
pods containing small, reddish-brown aromatic and pungent seeds. The fruits are ovoid with reddish 
color and numerous small brownish angular seeds with a cardamorn flavor   (Iwu, 2014). Fruit, seed 
and leaf of A. melegueta are commonly used as spices in various food preparations and have been locally 
used in the treatment of DM and other metabolic disorders in Nigeria (Gbolade, 2009). In a recent study, 
Sugita et al. (2013) reported that A. melegueta seed alcoholic extract stimulates brown adipose tissue 
and increases whole-body energy expenditure in human subjects which is directly linked with the 
pathogenesis of T2D. In a very recent study, we showed that different solvent extracts from the various 
parts (fruit, leaf and stem) of A. melegueta demonstrated anti-oxidative and anti-diabetic potentials in 
vitro (Mohammed et al. 2015a). Similarly, in vitro anti-diabetic as well as anti-oxidative potentials of 
the aqueous seed extracts of A. melegueta have been reported in many recent studies  (Adefegha and 
Oboh 2012; Kazeem et al., 2012; Adefegha and Oboh 2011; Etoundi et al., 2010). In another study, 
Onoja et al. (2014) have reported the anti-oxidative potentials of seed methanolic extracts of A. 
melegueta both in vitro and in vivo. Additionally, phenolics such as gingerols, shogaols, paradols are 
compounds reported to be rich in the crude ethanolic extract of the seed which showed minimum 
toxicity after a four week oral treatment in rats (Ilic et al., 2010). In preliminary studies, seed (Adesokan 





glucose lowering ability in alloxan-induced diabetic rats. However, the detail in vivo anti-diabetic study 
on any part, extract or fraction of this plant has not yet been conducted either in humans or in 
experimental animals till today.  
Therefore, the present study was designed to investigate the in vivo anti-diabetic effects of the 
ethyl acetate fraction derived from the fruit ethanolic extract of A. melegueta in a T2D model of rats.  
 
3.3.3 Materials and methods 
For sample collection, identification and preparation of the fraction, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.5.1 to 2.5.8.  
 
3.3.4 Results 
The results of weekly mean body weight (bw) are presented in Figure 3.15. Although fructose 
feeding for two weeks did not significantly affect the mean bw of the treated animals compared to 
untreated animals, after STZ injection, the bw of DBC group was decreased for the entire intervention 
period. On the other hand, AMEF oral treatment ameliorated this reduction when significant (p < 0.05) 
amelioration was observed after the 2nd, 3rd and 4th week of intervention. Additionally, no significant 
difference of bw was observed between the AMEF treated groups (DAML and DAMH) and NC and 
DMF groups (Figure 3.15).  
 
Figure 3.15. Mean body weight change in all animal groups during the entire study period. Data are presented as the mean ± 
SD of 5-7 animals. a-bValues with different letter near the lines for a given week are significantly different from each other 
group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; DAML, 
Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, Diabetic Metformin; NAMH, Normal A. 
melegueta high dose. 
The results of feed and fluid intake in different group of animals are presented in Figure 3.16. 





































and fluid intake compared to NC group (Figure 3.16). Treatment with various dosages of AMEF for 
weeks to diabetic animals significantly (p < 0.05) ameliorated the alterations of feed and fluid intake 
which are comparable to the DMF group (Figure 3.16).  
 
Figure 3.16. Mean food and fluid intake of different animal groups during 4-week intervention period. Data are presented as 
the mean ± SD of 5-7 animals. a–dValues with different letters over the bars for a given parameter are significantly different 
from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic 
Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, Diabetic Metformin; 
NAMH, Normal A. melegueta high dose. 
 
The results of weekly NFBG and FBG (last week only) are presented in Figure 3.17. The data 
showed that the induction of T2D significantly (p < 0.05) increased NFBG in diabetic animals compared 
to the normal animals (NC). On the other hand, the oral administration of AMEF significantly (p < 0.05) 
decreased NFBG in DAML and DAMH groups compared to the DBC group when no significant 
difference was observed between the AMEF (DAML and DAMH) and metformin (DMF) treated 
groups. This effect was more pronounced in the DAMH group compared to the DAML group. 
Additionally, no significant difference was observed between the last week FBG of DAMH and NC 







































Figure 3.17. Weekly NFBG of all animal groups during the entire experimental period. Data are presented as the mean ± SD 
of 5-7 animals. a–cValues with different letters near the lines for a given week are significantly different from each other group 
of animals (Tukey's-HSD multiple range post hoc test, p<0.05). NC, Normal Control; DBC, Diabetic Control; DAML, Diabetic 
A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, Diabetic Metformin; NAMH, Normal A. melegueta 
high dose; NFBG, Non-fasting blood glucose; FBG, Fasting blood glucose. 
 
The data of oral glucose tolerance test (OGTT) are presented in Figure 3.18. According to the 
results, the glucose tolerance ability of the animals in AMEF treated groups was significantly better 
than the DBC group for the entire period of the test when the results were significantly better in the 
AMEF treated groups compared to the DMF group from 60-120 min of the test period. No significant 
difference was observed between the glucose tolerance ability of AMEF treated groups and NC group 
during this period as well (Figure 3.18). Furthermore, the calculated area under curve (AUC) for DBC 
group was significantly (p < 0.05) higher compared to NC group when that of DAML and DAMH 
groups were significantly (p < 0.05) lower compared to DBC groups and were comparable to the DMF 















































Figure 3.18. Oral glucose tolerance test (OGTT) in all animal groups in the last week of the 4-week experimental period. Data 
are presented as the mean ± SD of 5-7 animals. a–cValues with different letters near the lines for a given parameter are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, 
Diabetic Metformin; NAMH, Normal A. melegueta high dose. 
 
Table 3.7. Area under the curve (AUC) of different animal groups at the end of the experimental period   
 NC DBC DAML DAMH DMF NAMH 
AUC*x103 15.75 ± 0.97a 60.15 ± 7.50 c 24.54 ± 3.50 b 25.32 ± 5.64 b 28.68 ± 7.21 b 15.78 ± 0.97 a 
Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter along a row for a given parameter are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p<0.05). NC, Normal 
Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, 
Diabetic Metformin; NAMH, Normal A. melegueta high dose, AUC, Area under curve. 
 
  The data for serum insulin, fructosamine and calculated HOMA-IR and HOMA-β scores are 
presented in Table 3.8. Serum insulin level and the calculated HOMA-β scores were decreased 
significantly (p < 0.05) whereas serum fructosamine as well as HOMA-IR were increased significantly 
(p < 0.05) in the DBC group compared to the NC group (Table 3.8). Oral intervention of AMEF for 
four weeks to diabetic animals elevated serum insulin and HOMA-β scores with subsequent attenuation 
of serum fructosamine level and HOMA-IR scores in DAML and DAMH groups compared to the DBC 
group. These effects were found to be more pronounced in the DAMH group compared to the DAML 








































Table 3.8. Serum insulin and fructosamine levels, HOMA-IR and HOMA-β scores of different animal groups at the end of the experimental period 
 NC DBC DAML DAMH DMF NAMH 
Insulin (pmol/L) 76.50 ± 6.26b 47.05 ± 9.02a 59.86 ± 11.45b 64.81 ± 8.77b 75.88 ± 14.23b 65.49 ± 11.87b 
Fructosamine 
(μmol/L) 
239.20 ± 47.49a 365.43 ± 44.94b 298.00 ± 23.39a 247.86 ± 28.96a 283.14 ± 32.46a 274.00 ± 19.95a 
HOMA-IR0.27 ± 2.50 ٭a 6.30 ± 1.64c 3.75 ± 0.53b 3.11 ± 0.61b 3.82 ± 0.90b 2.11 ± 0.44a 
HOMA-β43.71 ± 127.66 ٭٭d 7.33 ± 1.26a 26.17 ± 10.18b 44.32 ± 9.86b,c 52.57 ± 25.76c 108.60 ± 19.24d 
Data are presented as the mean ± SD of 5-7 animals. a–dValues with different letters along the rows for a given parameter are significantly different from each other group of animals (Tukey's-
HSD multiple range post hoc test, p<0.05). NC, Normal Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, Diabetic 
Metformin; NAMH, Normal A. melegueta high dose; HOMA-IR, Homeostasis model assessment-insulin resistance; HOMA-β, Homeostasis model assessment-β 
 .(HOMA-β = (Fasting serum insulin in U/l x 20/Fasting blood glucose in mmol/L-3.5٭٭.[HOMA-IR = [(Fasting serum insulin in U/l x Fasting blood glucose in mmol/L)/22.5٭
 
Figure 3.19. Histopathological examination of the pancreatic islets of different animal groups at the end of the intervention period. The NC had a larger islet with high number of β-cells while the 
DBC had a smaller islet and morphologically deformed β-cells. The DAML, DAMH and DMF groups had relatively larger islets with higher number of β-cells compared to the DBC group. NC, 





The slides of pancreatic histopathology are presented in Figure 3.19. There was a significant 
degeneration of pancreatic islets with subsequent reduction on the number of β-cells in the DBC group 
compared to the NC group. However, treatment with the various dosages of AMEF as well as standard 
drug attenuated the diabetes induced pancreatic damage and restored the pancreatic morphology to near 
normal when the number of β-cells were significantly higher in the DAMH group compared to the 
DAML group (Figure 3.19). 
The results of liver weight, relative liver weight and liver glycogen levels are presented in Table 
3.9. The induction of T2D did not affect the absolute liver weight but significantly (p < 0.05) increase 
the relative liver weight and liver glycogen level in the DBC group compared to the NC group. A 
significant (p < 0.05) reduction of relative liver weight and liver glycogen levels was observed in the 
DAML and DAMH groups compared to the DBC group when the results were not significantly different 
compared to the NC and DMF groups (Table 3.9).    
The data for serum lipid profile and calculated atherogenic index (AI) and coronary risk index 
(CRI) are presented in Table 3.10. Elevated serum concentrations of TC, TG and LDL-cholesterol 
levels as well as calculated AI and CRI with subsequent reduction on serum HDL-cholesterol were 
observed in the DBC group compared to the NC group (Table 3.10). Treatment with AMEF to diabetic 
animals significantly (p < 0.05) and dose-dependently reduced TC, TG and LDL-cholesterol, AI and 
CRI in DAML and DAMH groups compared to the DBC group. Although dose-dependent increase in 
serum HDL-cholesterol level was observed in the AMEF treated groups compared to the DBC and 
DMF groups, the data were not significantly different (Table 3.10).  
The data for serum ALT, AST, ALP, urea, uric acid, creatinine, LDH and CK-MB are presented 
in Table 3.11.  At the end of the experimental period, the concentrations of all of the above-mentioned 
serum parameters were increased in the DBC group compared to the NC group, when serum AST level 
was not affected by the induction of diabetes. On the other hand, oral administration of AMEF to 
diabetic animals significantly (p < 0.05) ameliorated these alterations in DAML and DAMH groups. 
The effects were more pronounced in the DAMH group compared to the DAML group which did not 
differ significantly (p < 0.05) compared to the DMF group regarding most of the parameters. Similarly, 
treatment of AMEF to non-diabetic animals demonstrated no significant (p < 0.05) effect on these serum 





Table 3.9. Effect of AMEF on liver weights and liver glycogen concentrations in different animal groups as the end of the experimental period. 
 NC DBC DAML DAMH DMF NAMH 
Liver weight(g) 9.25 ± 1.04 10.34 ± 0.31 9.79 ± 0.30 9.75 ± 0.40 9.10 ± 1.33 9.02 ± 0.70 
Relative liver weight (%)0.29 ± 2.89 ٭a 4.55 ± 0.34b 3.36 ± 0.04a 3.31 ± 0.40a 3.10 ± 0.45a 2.90 ± 0.25a 
Liver glycogen (mg/g 
tissue) 
6.76 ± 0.81a 8.25 ± 0.83b 7.03 ± 0.53a 6.98 ± 0.63a 6.92 ± 0.56a 6.80 ± 0.57a 
Data are presented as the mean ± SD of 5-7 animals. a-bValues with different letter along a row for a given parameter are significantly different from each other group of animals (Tukey's-HSD 
multiple range post hoc test, p<0.05). NC, Normal Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, Diabetic Metformin; 
NAMH, Normal A. melegueta high dose. 



















Table 3.10. Serum lipid profiles atherogenic and coronary risk indices of different animal groups at the end of the experimental period 
 NC DBC DAML DAMH DMF NAMH 
TC (mg/dL) 76.20 ± 7.40a 116.00 ± 12.92c 94.86 ± 10.17b 83.29 ± 8.40a,b 95.71 ± 7.74b 78.00 ± 7.91a 
TG (mg/dL) 70.20 ± 18.10a 150.86 ± 24.57b 107.71 ± 38.13a 81.14 ± 23.78a 100.71 ± 32.47a 68.80 ± 5.50a 
LDL-Cholesterol 
(mg/dL)* 
12.96 ± 4.16a 57.54 ± 14.45c 40.03 ± 11.21b 30.34 ± 7.28a,b 42.86 ± 8.93b,c 22.84 ± 10.72a 
HDL-Cholesterol 
(mg/dL) 
49.20 ± 8.35b 28.29 ± 6.25a 33.29 ± 6.99a 36.71 ± 8.52a,b 32.71 ± 7.43a 41.40 ± 6.62a,b 
AI 0.57 ± 0.13a 3.30 ± 1.08c 2.00 ± 0.91b 1.36 ± 0.54a,b 2.06 ± 0.69b 0.93 ± 0.38a,b 
CRI 1.57 ± 0.13a 4.30 ± 1.08c 3.00 ± 0.91b 2.36 ± 0.54a,b 3.06 ± 0.69b 1.93 ± 0.38a,b 
Data are presented as mean ± SD of 5-7 animals. a–cValues with different superscript letters along a row for a given parameter are significantly different from each other group of animals (Tukey's-
HSD multiple range post hoc test, p<0.05). NC, Normal Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, Diabetic 
Metformin; NAMH, Normal A. melegueta high dose; TC, Total cholesterol; TG, Triglyceride; LDL-cholesterol, Low density lipoprotein-cholesterol; HDL-cholesterol; High density lipoprotein-
cholesterol; AI, Atherogenic index; CRI, Coronary risk index.  

















Table 3.11. Serum ALT, AST, ALP and other biochemical parameters different animal groups at the end of the experimental period 
 NC DBC DAML DAMH DMF NAMH 
ALT (U/L) 77.40 ± 20.38a,b 116.14 ± 37.37c 70.14 ± 10.07a,b 74.14 ± 8.86a,b 93.57 ± 6.86b 58.80 ± 21.67a 
AST (U/L) 88.40 ± 11.41 83.29 ± 15.57 80.29 ± 4.19 85.57 ± 10.97 94.71 ± 9.39 82.20 ± 7.46 
ALP (U/L) 149.40 ± 11.33a 451.14 ± 35.10c 230.14 ± 31.76b 200.86 ± 26.82a,b 208.86 ± 27.58b 158.60 ± 22.55a 
Creatinine (mg/dL) 2.52 ± 0.78b 3.12 ± 0.45b 1.73 ± 0.52a 1.53 ± 0.42a 1.68 ± 0.27a 2.42 ± 0.77a,b 
Urea (mg/dL) 22.00 ± 4.69a 60.71 ± 15.71b 21.29 ± 7.80a 29.29 ± 7.11a 26.00 ± 5.00a 27.80 ± 3.90a 
Uric acid (mg/dL) 2.06 ± 0.67 2.85 ± 1.18 2.28 ± 0.84 2.77 ± 0.84 2.56 ± 1.36 1.69 ± 1.05 
LDH (U/L) 284.00 ± 62.56a 458.86 ± 68.05b 419.14 ± 95.60b 395.14 ± 57.94a,b 361.57 ± 80.66a,b 321.20 ± 78.44a 
CK-MB (U/L) 374.54 ± 82.56a 1064.36 ± 537.18b 692.53 ± 128.69a,b 368.16 ± 83.06a 743.97 ± 75.29a,b 508.68 ± 127.34a 
Data are presented as mean ± SD of 5-7 animals. a–cValues with different superscript letters along a row for a given parameter are significantly different from each other group of animals (Tukey's-
HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, Diabetic 










In the present study, we have investigated the effect of oral administration of a low and a high 
dose of A. melegueta ethyl acetate fraction (AMEF) of fruit ethanolic extract in a T2D model of rats 
through four weeks post-treatment period. This is obviously the first study that comprehensively 
reported the anti-diabetic effect of A. melegueta despite the reported ethnobotanical potentials of A. 
melegueta in the management of diabetes. 
It is evident from the results of this study that induction of T2D decreased bw and caused 
polyphagia and polydipsia, the classical symptoms of DM (Figures 3.15 and 3.16). The observed 
polydipsia could possibly be linked to polyuria due to the excessive fluid retention in uncontrolled 
diabetic condition (Kitabchi et al. 2009). Interestingly, post-treatment of AMEF for four weeks 
ameliorated these alterations even at a lower dose administered (150 mg/kg bw), indicating possible 
recovery from the diabetic state (Figures 3.15 and 3.16). The data were further supported by the 
significant reduction in hyperglycemia in AMEF treated groups (Figure 3.17). 
It is well known that the successful treatment of T2D requires an effective control of 
hyperglycemia and hence search for active anti-hyperglycemic agents cannot be underscored (Bavarva 
and Narasimhacharya, 2008). In our study, the marked appearance of hyperglycemia in DBC group 
throughout the study period is an indication of successful induction of diabetes. On the other hand, the 
AMEF treated diabetic animals responded positively to the treatment and significantly reduced 
diabetes-induced hyperglycemia to near normal just after a four-week post-administration period 
(Figure 3.17). Similar reduction on blood glucose level was also reported previously when alloxan-
induced diabetic rats were treated with seed aqueous extract (Adesokan et al. 2010). Moreover, in our 
present study, the more pronounced anti-hyperglycemic effect in the DAMH group compared to the 
DAML group suggests the dose-dependent effects AMEF, which has been further supported by the 
significantly better glucose tolerance ability of the animals in treated groups compared to the DBC 
group (Table 3.7). Additionally, the AMEF treatment at higher dose (300 mg/kg bw) to normal animals 
did not affect the blood glucose levels and therefore confirmed the anti-hyperglycemic ability of AMEF 
but not hypoglycemic effect (Figure 3.17), which has been again supported by the pancreatic β-cell 
ameliorating as well as insulin secreting effects of AMEF in this study (Figure 3.19 and Table 3.7).  
T2D is a heterogeneous disorder characterized by insulin resistance and pancreatic β-cell 
dysfunction that cannot properly secrete insulin in response to hyperglycemia (Hui et al. 2007). In this 
study, decreased insulin levels and loss of β-cell integrity were observed in the DBC group compared 
to the NC group (Table 3.8). In the diabetic AMEF treated as well as DMF groups, these effects were 
significantly ameliorated and the morphology of pancreas was restored near to normal. The improved 
serum insulin levels in the AMEF treated diabetic animals (DAML and DAMH) (Table 3.8) could be 
due to the regeneration of pancreatic islets observed in the pancreatic histology (Figure 3.19), which 





treated groups compared to the DBC group (Table 3.8). The significantly lower HOMA-IR index in 
the DAML and DAMH groups compared to the DBC group also confirmed the improvement of insulin 
sensitivity as well as the stimulation of peripheral glucose absorption in these groups (Table 3.8). 
Therefore, the anti-hyperglycemic effect of AMEF could partly be mediated via decreasing insulin 
resistance and not only by hyperinsulinomic mechanism. The anti-hyperglycemic effect of AMEF is 
further supported by the significantly lower serum fructosamine levels in the DAML and DAMH groups 
compared to the DBC group which did not differ significantly with the NC and DMF groups (Table 
3.8). This could be attributed to some of the phenolic compounds such as gingerols, shogaols and 
paradols that were reported to possessed anti-oxidative potentials (Ilic et al. 2014; 2010).   
On the other hand, increase liver weight as well as accumulations of liver glycogen are some 
common pathological features of metabolic disorders including T2D which apparently lead to 
hepatomegaly (Paschos and Paletas, 2009). In our study, the relative liver weight was found to decrease 
in AMEF treated diabetic rats whereas no significant effect was observed in the normal treated animals 
(Table 3.9), which is contradictory with an earlier report  (Ilic et al. 2010). Ilic et al. (2010) highlighted 
an increase on the absolute and relative liver weight in normal animals after the supplementation of 
seed ethanolic extract, which could be attributed to the higher dosages (450 and 1500 mg/kg bw) used 
in the reported study when the lower dose (120 mg/kg bw) did not cause any significant increase on 
absolute and relative liver weight of normal treated animals (Ilic et al. 2010). Similarly, it was also 
observed a reduction on glycogen content in the liver of treated diabetic animals, which apparently 
indicates the modulation of hepatic glycogenesis. This could possibly be another anti-hyperglycemic 
mechanism exhibited by AMEF and has been a possible mode of action by several anti-diabetic plant-
derived formulations and compounds (Bnouham et al. 2006; Grover et al. 2002) which was further 
supported by the anti-hyperlipidemic effect of AMEF (Table 3.10). 
There has been a significant elevation on serum lipid profiles and calculated AI and CRI indices 
with a reduction on serum HDL-cholesterol in DBC group compared to the NC group (Table 3.10). 
This might be due to the effect of fructose feeding on DBC group. Fructose metabolism has been shown 
to be independent of insulin action, which is an important factor for the regulation of fats production as 
well as energy utilization by the cells (Basciano et al. 2005). In addition, fructose induced more 
hyperlipidemic condition by increasing the levels of LDL, VLDL and total cholesterol in experimental 
animals compared to other carbohydrates molecules (Benado et al. 2004). Oral intervention of AMEF 
at lower and higher dosages as well as the standard drug prevents diabetes-induced dyslipidemia, 
reduced the risk of atherogenesis and coronary artery disease and augmented serum HDL-cholesterol 
level (Table 3.10).  
In addition to decreased dyslipidemia as well as the risk of atherogenesis and coronary artery 
diseases, diabetic AMEF treated animals demonstrated a lower serum LDH and CK-MB levels, 
suggesting the cardio-protective effects of AMEF (Table 3.11). The CK-MB occurs to a much greater 





infarction (Baird et al. 2012). Furthermore, the serum levels of ALT, ALP and urea were significantly 
elevated in DBC group compared to NC group (Table 3.11). In many disease conditions such as DM, 
hepatocellular damage increases the release of serum ALT, ALP and urea into circulation which is an 
indication of hepatic injuries, infarction and functional disturbance of hepatic cells (Abolfathi et al. 
2012). It was observed from the result that serum AST level was not affected by the diabetes (Table 
3.11). In comparison with ALT, AST is less specific for the detection of hepatic injury (Center, 2007). 
This is partly due to the fact that, the half-life of ALT is much longer compared to AST in experimental 
animals (Ramaiah, 2007; Meyer and Harvey, 2004). Therefore, in a condition of acute liver injury, there 
will be an increase in both serum ALT and AST levels. However, the serum AST level may likely return 
to normal more rapidly compared to the level of serum ALT, which make ALT more sensitive in 
assessing hepatic damage in disease conditions (Ramaiah, 2007; Meyer and Harvey, 2004). Therefore, 
the unaffected serum AST level in our present result could be link to above-stated factor. Hence, the 
hepato-protective ability of AMEF is supported by the reduced serum ALT, ALP and urea levels in the 
DAML and DAMH groups compared to the DBC group (Table 3.11). Furthermore, the moderate 
reduction on serum creatinine, urea and uric acid demonstrate the ability of AMEF to attenuate diabetic 
nephropathy (Fogo and Kon, 2001). The significantly lower serum creatinine, urea and uric acid in the 
AMEF treated groups compared to the DBC group suggest its possible effects on the amelioration of 
diabetic nephropathy (Table 3.11).  
 
3.3.6 Conclusion  
In conclusion, various doses of A. melengueta ethyl acetate fraction from fruit possess strong 
anti-T2D activity via improving bw gain, reducing food and fluid intake and hyperglycemia, improving 
glucose tolerance ability, insulin sensitivity, amelioration of pancreatic β-cell and β-cell functions,  
improving dyslipidemia and number of organ specific diabetic-complications related parameters. 
Hence, ethyl acetate fraction of A. melengueta fruit from crude ethanolic extract may be an excellent 
anti-diabetic natural product with no considerable side effects. Further clinical study is required to 
confirm its effects in human subjects. The isolation and partial characterization of the active principle 
from AMEF is currently underway to find the compounds responsible for this activity in addition to its 











3.4 Anti-oxidant potential of Aframomum melegueta fruit ethyl 
acetate fraction in a type 2 diabetes model of rats 
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3.4.1 Abstract 
Objectives: The present study evaluated the in vivo anti-oxidative actions of Aframomum melegueta 
ethyl acetate fraction (AMEF) from fruit ethanolic extract in a type 2 diabetes (T2D) model of rats.  
Methods: T2D was induced in rats by feeding a 10% fructose solution ad libitum for two weeks 
followed by a single intraperitoneal injection of streptozotocin (40 mg/kg body weight (bw)) and the 
animals were orally treated with 150 or 300 mg/kg bw of the AMEF once daily for four weeks.  
Results: After four weeks of intervention, diabetic untreated animals showed significantly higher levels 
of thiobarbituric acid reactive substances (TBARS) and lower levels of reduced glutathione (GSH) in 
the serum and organs (liver, kidney, heart and pancreas) compared to the normal animals. The activities 
of endogenous anti-oxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and 
reductase) were greatly altered in the serum and organs of diabetic untreated animals compared to the 
normal animals. These alterations were reverted to near-normal after the treatment of AMEF, especially 
at the dose of 300 mg/kg bw.  
Conclusion:  The results of our study suggest that AMEF treatment at 300 mg/kg bw showed potent 
anti-oxidative action in a T2D model of rats. 
 
Keywords: Aframomum melegueta, Anti-oxidant, Ethyl acetate fraction, Fruit ethanolic extract, Type 
2 diabetes, Rats. 
 
3.4.2 Introduction  
The progressive increase of DM is quite alarming and the disease affects people mostly living 
in the low- and middle-income countries. Recent data from the International Diabetes Federation (IDF) 
indicates that DM affects over 387 million people and this figure is likely to be increased to 592 million 
by 2035 (IDF, 2014; Guariguata et al. 2014). Between the two major types of diabetes, type 2 diabetes 
(T2D) is the most prevalent one and about 90-95% of diabetic patients suffer from T2D (van-Dam et 





cell dysfunction, leading to hyperglycemia (Hui et al. 2007). As a result of the hyperglycemia in T2D, 
various macro- and micro-vascular complications develop which have been attributed to oxidative 
stress, a major contributor to pancreatic β-cell damage (Quilliot et al. 2005).   
Oxidative stress is a condition due to an imbalance between the generations of reactive oxygen 
species (ROS) and the quenching of those free radicals by in vivo anti-oxidant system (AS), thereby 
shifting the ROS/AS balance in favor of stress (Rahimi et al. 2005). The ROS are derived from the 
normal physiological processes but become harmful when they are not quenched by the cascade of anti-
oxidant defense systems. It has been highlighted that, the major contributors of hyperglycemia-induced 
oxidative stress include glucose toxicity, protein glycosylation, increased production of glycation end 
products and mitochondrial ROS, the polyol, hexosamine and protein kinase C pathways (Giacco and 
Brownlee, 2010; Chang and Chuang, 2010; Chung et al. 2003; Maritim et al. 2003). Therefore, the 
increased intake of anti-oxidants is necessary to prevent the oxidative damages due to oxidative stress. 
However, the use of synthetic anti-oxidants such as butylated hydroxy anisole (BHA), butylated 
hydroxy toluene (BHT), tertiary butylated hydroquinon and gallic acid esters in food protection and 
disease control have been associated with unwanted consequences. This has motivated researchers to 
look for options from plant-derived anti-oxidants that may offer better protection with lesser side effects 
(Michael et al. 2005).  
 Aframomum melegueta K. Schum. (Zingiberaceae) is a plant which fruits, seeds and leaves are 
commonly used as spices in various food preparations and have been locally used in the treatment of 
DM and other metabolic disorders in Nigeria (Gbolade, 2009). In our previous study, fruit EtOH extract 
of A. melegueta has demonstrated potent anti-oxidant action and anti-diabetic actions in vitro 
(unpublished data). Additionally several studies reported previously, various seed extracts of A. 
melegueta have shown interesting anti-oxidative as well as anti-oxidative actions in vitro (Adefegha 
and Oboh 2012; Kazeem et al. 2012; Adefegha and Oboh 2011; Etoundi et al. 2010). Our recent findings 
have shown that, A. melegueta ethyl acetate fraction (AMEF) fruit EtOH extract exhibited anti-
hyperglycemic action, ameliorated pancreatic β-cell dysfunction and other major diabetes-related 
parameters in a T2D model of rats (Mohammed et al. 2015b). In a recent preliminary study, Onoja et 
al. (2014) reported that the seed EtOH extract of A. melegueta improved the serum anti-oxidant 
parameters in normal rats, when the detail in vivo anti-oxidant action of any part of the A. melegueta 
has not yet been conducted. 
Therefore, in the present study we intend to comprehensively study the in vivo anti-oxidant 
potentials of the ethyl acetate fraction derived from the fruit ethanolic extract of A. melegueta in a T2D 








3.4.3 Materials and methods 
For sample collection, identification and preparation of the fraction, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.5.1 to 2.5.8.  
 
3.4.4 Results 
The results of thiobarbituric acid reactive substances (TBARS) expressed as malondialdehyde 
(MDA) concentration of serum and organs (liver, kidney, heart and pancreas) of all the groups are 
presented in Figure 3.20. According to the data, induction of diabetes significantly (p < 0.05) elevated 
the serum, liver, heart and pancreas MDA levels in DBC group compared to the NC group. The increase 
in the kidney of the DBC group did not differ significantly (p < 0.05) compared to the NC group. 
However, oral treatment of AMEF especially at the higher dose (300 mg/kg bw) for 4-weeks to diabetic 
animals significantly (p < 0.05) decreased the of serum and organs MDA levels, which were comparable 
to the DMF group (Figure 3.20).      
 
Figure 3.20. Serum and organs thiobarbituric acid reactive substances of all animal groups at the end of the intervention 
period. Data are presented as the mean ± SD of 5-7 animals. a-dValues with different letter over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, 
Diabetic Metformin; NAMH, Normal A. melegueta high dose; MDA, Malondialdehyde. 
 
The data of reduced glutathione (GSH) levels of serum and organs of all the groups are 
presented in Figure 3.21. The concentration of GSH in serum, liver and pancreas was significantly (p 
< 0.05) decreased in DBC group compared to NC group. The reduction of GSH levels in the kidney 





(Figure 3.21). After 4 weeks of oral intervention, the levels of GSH of DAML and DAMH groups 
significantly (p < 0.05) improved in dose-dependent manner (Figure 3.21). Furthermore, the serum and 
organs GSH levels were not affected in NAMH group throughout the experimental period. 
 
 
Figure 3.21. Serum and organs reduced glutathione (GSH) content in all animal groups at the end of the study period. Data 
are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are significantly 
different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, 
Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, Diabetic 
Metformin; NAMH, Normal A. melegueta high dose; GSH, Reduced glutathione. 
 
The results of the activity of superoxide dismutase (SOD) of serum and organs of all the groups 
are presented in Figure 3.22. It was observed from the results that the activity of SOD in serum, liver, 
heart and pancreas of DBC group was significantly (p < 0.05) decreased, when the reduction in the 
kidney of the DBC group was not reduced compared to the NC group. Treatment of AMEF to diabetic 
animals, especially the DAMH group showed a significant (p < 0.05) increased SOD activity which 
was comparable to the NC group (Figure 3.22). Additionally, the activity of SOD in the heart of NAMH 








Figure 3.22. Superoxide dismutase (SOD) activities in the serum and organs of different animal groups at the end of the study 
period. Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a sample week are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, 
Diabetic Metformin; NAMH, Normal A. melegueta high dose. 
 
 The data of catalase activity in the serum and organs of all the groups are presented in Figure 
3.23. According to the results, the activity of the catalase in the serum and organs was significantly (p 
< 0.05) decreased in the DBC group compared to the NC group. However, treatment of AMEF 
especially with high dose (300 mg/kg bw, DAMH group) significantly (p < 0.05) increased the activity 
of the enzyme in serum, liver and kidney when the increase in the heart and pancreas was not 









Figure 3.23. Catalase activities in the serum and different organs of different animal groups at the end of the study period. 
Data are presented as the mean ± SD of 5-7 animals. a-dValues with different letter over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, 
Diabetic Metformin; NAMH, Normal A. melegueta high dose. 
 
The results of the activity of glutathione peroxidase (GPx) in serum and organs of all the groups 
are presented in Figure 3.24. The activity of the GPx in the serum and organs was significantly (p < 
0.05) decreased in the DBC group compared to the NC group. Oral treatment with the fraction, 
significantly (p < 0.05) increased the GPx activity in the DAMH group which is comparable to the 
DMF group (Figure 3.24). It was also observed that the GPx activity in the serum and organs of NAMH 
group was increased although not statistically different from the NC group (Figure 3.24).  
  The data of glutathione reductase (GR) activity in the serum and organs of all the groups are 
presented in Figure 3.25. The activity of this enzyme was not affected by the induction of diabetes in 
the kidney and heart, whereas significantly (p < 0.05) decreased in the serum, liver and pancreas of the 
DBC group compared to the NC group (Figure 3.25). After treatment with AMEF for 4-weeks, the GR 
activity was significantly (p < 0.05) increased in the serum, liver and pancreas of the DAMH group, 
when the effect was not statistically different in the kidney and heart compared to the DBC group 
(Figure 3.25). In addition, the activity of GR in heart of NAMH group was significantly (p < 0.05) 







Figure 3.24. Glutathione peroxidase activities in the serum and organs of different animal groups at the end of the study period. 
Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letters over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, 
Diabetic Metformin; NAMH, Normal A. melegueta high dose. 
 
 
Figure 3.25. Glutathione reductase activities in the serum and organs of different animal groups at the end of the study period. 
Data are presented as the mean ± SD of 5-7 animals. a-dValues with different letters over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DAML, Diabetic A. melegueta low dose; DAMH, Diabetic A. melegueta  high dose; DMF, 






In our recent findings, EtOAc fraction derived from fruit EtOH extract of A. melegueta 
exhibited anti-hyperglycemic action, ameliorated pancreatic β-cell dysfunction and other major 
diabetes-related parameters in a T2D model of rats (unpublish data). Therefore we hypothesized that 
AMEF may attenuate serum and organs oxidative-stress induced by hyperglycemia in type 2 diabetic 
rats. The results of our present study are quite promising as oral treatment of the AMEF ameliorated 
most of the alterations caused by the induction of diabetes in the serum and various organs. 
In a recent study, Onoja et al. (2014) reported that the treatment of A. melegueta seed extract 
(400 mg/kg bw) to normal rats decreased the serum MDA levels which is in line with our present study. 
According to the data of our present study, the treatment of AMEF even at a lower dose (300 mg/kg 
bw) has showed potent anti-oxidative action (Figure 3.20). It has been postulated that increase ROS 
production in T2D initiates peroxidation of lipids and stimulates hemoglobin and other protein glycation 
which in turn causes cellular and tissue damages (Sabu and Kuttan, 2002; Boynes, 1991). Therefore the 
reductions of MDA levels in the serum and organs by AMEF treatment supports the results of ours and 
many previous studies that showed the strong ability of extracts or fractions from A. melegueta in 
scavenging the deleterious effects of ROS in vitro (Mohammed et al. 2015; Adefegha and Oboh 2012; 
Kazeem et al. 2012; Adefegha and Oboh 2011; Etoundi et al. 2010). The reduction of MDA levels was 
further supported by the increase of reduced glutathione levels in the serum and organs as well (Figure 
3.21). 
Glutathione is a tripeptide that contributes immensely to the reduction of the deleterious cellular 
damages induced by lipid peroxidation (Lu, 1999). In our present study, the reduction of reduced 
glutathione (GSH) in the DBC group signifies the higher utilization of GSH due to diabetes-induced 
oxidative stress (Figure 3.21). Treatment of AMEF augmented the serum and organs GSH levels in 
dose-dependent manner (Figure 3.21). Therefore we suggest that AMEF may likely to improve the 
biosynthesis of GSH or attenuated the oxidative processes leading to GSH reduction, or exhibited both 
effects. Our results were further supported by the ability of the AMEF to increase the activity of 
superoxide dismutase (Figure 3.22).  
There is a close relationship between hyperglycemia in T2D and the elevation of cellular 
superoxide radical production (Rahimi et al. 2005). An enzyme superoxide dismutase (SOD) scavenges 
the superoxide radical by converting the radical to hydrogen peroxide (H2O2) and molecular oxygen 
(Sati et al. 2010). In a recent study, Onoja et al. (2014) indicated that, a significant increase of serum 
SOD levels was observed in normal rats after 4-weeks treatment period of seed methanolic extract (400 
mg/kg bw). This was similarly observed in our present data (Figure 3.22). Therefore, the anti-oxidative 
actions of A. melegueta may partly be mediated via an increase in the activities of SOD, which again 
was further supported by the increasing activities of catalase in the serum and other related organs 





The H2O2 release by the SOD is also harmful and can cause deleterious damages to cells. 
Catalase, an iron containing enzyme catalyzes the conversion of H2O2 to water and oxygen molecules 
and thus protects cellular and tissue oxidative damages. The catalase activity was reported to increase 
about 8-fold in normal animals treated with 400 mg/kg bw seed methanolic extract of A. melegueta 
(Onoja et al. 2014). However, according to our results, the catalase activity was greatly improved 
especially in the DAMH group which is comparable to the metformin treated groups (Figure 3.23). It 
was also observed that, the activity of catalase was less compared to that of SOD, which may be linked 
to the protective action of the SOD to catalase from the toxic effects of superoxide radical (Rajasekaran 
et al. 2005).  
The activities of glutathione peroxidase (GPx) a selenium containing enzyme and glutathione 
reductase (GR) are entirely dependent on the GSH concentration. GPx in the presence of GSH catalyzes 
the reduction H2O2 to water and oxidized glutathione (GSSG). GR then converts GSSG to GSH, 
utilizing protons from NADPH molecules, which can also be used by GPx (Manonmani et al. 2005). 
According to the results of our study, oral intervention of AMEF for 4-weeks to diabetic animals 
especially in DAMH group attenuated the alterations in the GPx and GR activities, especially in DAMH 
group (Figures 3.24 & 3.25). Therefore, the anti-oxidant action of AMEF may partly be mediated via 
increased production of GPx and GR in the serum and organs as well.   
 
3.4.6 Conclusion  
In conclusion, oral treatment of AMEF especially at higher dose demonstrated a potent anti-
oxidant activity via reduction of lipid peroxidation, improving glutathione levels and endogenous anti-
oxidants enzymes in serum and organs mostly affected by diabetic-complications. Hence, AMEF from 
crude ethanolic extract A. melegueta fruit may be an excellent anti-oxidant natural product with no 


















4.0 In vitro and in vivo anti-diabetic and anti-oxidative effects of 
various extracts and fractions from different parts of Xylopia 
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4.1.1 Abstract 
Objective: Various parts of Xylopia aethiopica (Dunal) A. Rich. are used for traditional treatment of 
different diseases such as diabetes, microbial infections and diarrhea in Africa. This study investigated 
and compared the in vitro anti-oxidative, anti-diabetic effects and possible compounds present in 
various solvent extracts of fruit, leaf, stem and root of X. aethiopica.  
Methods: Samples were sequentially extracted using solvents of increasing polarity. They were 
subjected and investigated for 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging activity, 
ferric reducing power, inhibition of hemoglobin glycation, α-amylase and α-glucosidase activities as 
markers of in vitro anti-diabetic effects at various doses (30-240 µg/mL). Possible compounds were 
analyzed using Gas Chromatography-Mass Spectroscopic (GC-MS) analysis.  
Results: The ethanolic (EtOH) extracts from the fruit and leaf have exhibited higher total polyphenol 
and flavonoid contents compared to other extracts. Furthermore, for all the in vitro models used in this 
study, EtOH extracts from the fruit and leaf demonstrated significantly lower IC50 values compared to 
other extracts, when fruit EtOH extract showed the lowest IC50 value (DPPH: 0.04 ± 0.01 mg/mL; 
inhibition of hemoglobin glycation: 0.16 ± 0.01 mg/mL; -amylase: 0.21 ± 0.01 mg/mL; -glucosidase: 
0.08 ± 0.01 mg/mL). The GC-MS analysis of the most active extracts (EtOH fruit and leaf) revealed the 
presence of majorly terpenes and aromatic compounds and other fatty acids derivatives as possible 
compounds.  
Conclusion: Fruit EtOH extract exhibited higher anti-oxidative and anti-diabetic effects compared to 
other solvent extracts in vitro and thus require further work to fully validate these effects in vivo. 







 Diabetes mellitus (DM) is the fast growing metabolic disorder and a leading cause of morbidity 
in developing countries. It is a heterogeneous group of metabolic disorders characterized by persistent 
hyperglycemia (Neelesh et al. 2010) and alteration in the metabolism of major cellular biomolecules as 
a result of defects in insulin secretion and/or insulin action (Maritim et al. 2003). Type 2 diabetes (T2D) 
is most prevalent among the major forms of DM. T2D is a heterogeneous disorder characterized by 
insulin resistance and pancreatic β-cell dysfunction leading to hyperglycemia (Hui et al. 2007). In 
chronic uncontrolled hyperglycemia, there is an increased production of reactive oxygen species (ROS) 
and reduced anti-oxidant defense system, which is referred as oxidative stress. This leads to initiation 
of the major processes that underlay the various diabetic associated complications, and in the absence 
of effective treatment result to death (ADA, 2015; Surampud et al. 2009; Maritim et al. 2003). 
 The current treatment option for T2D that is widely receiving much interest include the control 
of postprandial hyperglycemia by the use of inhibitors of carbohydrate digesting enzymes (Ademiluyi 
and Oboh, 2013).The inhibitors of carbohydrate digesting enzymes such as α-glucosidase and α-
amylase can significantly delay the intestinal absorption of dietary glucose and therefore help in 
lowering postprandial hyperglycemia (Imam, 2015). However, the major available glucosidase 
inhibitors such as acarbose and miglitol, were reported to cause diarrhea and other gastrointestinal 
disturbances (Fujisawa et al. 2005). Therefore with increasing interest in alternatives for the control of 
T2D, search for anti-diabetic agent has been extended to plant-based remedies as less adverse effects 
are associated with plant-based therapy (Singh, 2001; Calixto, 2000). 
 Xylopia aethiopica (Dunal) A. Rich. (Annonaceae) commonly known as Ethiopian pepper is a 
spice widely used as flavoring and coloring agents. In addition, X. aethiopica is utilized in folk 
medicines for the treatment of diabetes in Africa (Soladoye et al. 2012; Diallo et al. 2012; Karou et al. 
2011; Diéye et al. 2008). Recent studies have shown that the extracts from X. aethiopica fruit possesses 
anti-oxidative (Adefegha and Oboh, 2012a,c; 2011; Etoundi et al. 2010; Odukoya et al. 2005; George 
and Osiama, 2011), anti-microbial (Esekhiagbe et al. 2009), anti-cancer (Kuete et al. 2013; 2011; 
Choumessi et al. 2012) and anti-diabetic (Adefegha and Oboh, 2012a,c; 2011; Etoundi et al. 2010) 
activities in vitro. However, the majority of scientific investigations had only focused on the fruit only. 
No data is available on the validity or potential of extracts of the other parts of the plant. Therefore the 
present study was aimed to investigate and compare the anti-oxidative and anti-diabetic effects of 
various extracts from different parts (including fruit) of X. aethiopica using several in vitro models. 
Additionally, phytochemical analysis of the possible bioactive compounds present in most active 







4.1.3 Materials and methods 
For plant sample collection, identification and preparation of the extracts, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.4.  
 
4.1.4 Results  
The yields recovered, total polyphenols and flavonoids contents from different solvent extracts 
of various parts of X. aethiopica are presented in Table 4.1. The ethanolic (EtOH) fruit extract showed 
significantly (p < 0.05) higher yield, total polyphenols and flavonoids contents compared to other 
solvent extracts of the same or different parts of X. aethiopica (Table 4.1). The polyphenols and 
flavonoids contents of the leaf and stem EtOH extracts were also higher compared to the ethyl acetate 
(EtOAc) and aqueous extracts of these parts. In addition, the polyphenols and flavonoids contents of 
the roots were not detected.  
 
Table 4.1: Percentage yield, total polyphenol and flavonoid contents in the various solvent extracts of 
X. aethiopica parts 
Samples Yield (%) Total polyphenols (mg/gGAE) Total flavonoids (mg/gQE) 
Fruit    
Ethyl acetate 2.05 3.69 ± 0.09c 1.86 ± 0.29c 
Ethanol 7.35 25.36 ± 0.32f 8.06 ± 0.88e 
Aqueous 3.15 4.83 ± 0.15d 0.17 ± 0.06a 
Leaf    
Ethyl acetate 1.05 2.82 ± 0.26b 0.69 ± 0.12b 
Ethanol 2.00 9.45 ± 0.34e 3.50 ± 0.18d 
Aqueous 4.45 3.83 ± 0.34c 0.36 ± 0.18a,b 
Stem    
Ethyl acetate 0.78 0.88 ± 0.14a ND 
Ethanol 2.95 5.13 ± 0.05d 1.11 ± 0.18b,c 
Aqueous 1.05 ND ND 
Data are presented as mean ± SD of triplicate determinations. a-g Values with different superscripted letters for a given 
parameter within a column are significantly different from each other extracts (Tukey’s-HSD multiple range post hoc test, p 
< 0.05). ND, Not determined. 
 
The data of ferric (Fe3+) reducing anti-oxidant power (expressed as gallic acid equivalents) of 
various extracts are presented in Figure 4.1. The fruit EtOH extract demonstrated significantly (p < 





part (Figure 4.1). The activity of leaf EtOH extract was also significantly (p < 0.05) higher than the 
other extracts from this part, when the action of stem EtOH extract was not significantly (p < 0.05) 




Figure 4.1. Ferric reducing power (relative to gallic acid) of fruit (A), leaf (B) and stem (C) extracts of X. aethiopica. Data are 
presented as mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of 





The results of DPPH radical scavenging activities and the calculated IC50 values of various 
extracts from different parts of X. aethiopica are presented in Figure 4.2 and Table 4.2, respectively. 
According to the data, the fruit and leaf EtOH extracts had exhibited significantly (p < 0.05) lower IC50 
values (fruit: 0.04 ± 0.01 mg/mL; leaf: 0.08 ± 0.01 mg/mL) compared to other extracts that are 
comparable to the standards used in this study (ascorbic acid: 0.03±0.02 mg/mL; gallic acid: 0.05 ± 
0.01 mg/mL). In all the parts investigated, EtOH extracts were the most active followed by EtOAc 
extracts while aqueous extracts were the least active (Table 4.2). Various extracts derived from the root 




Figure 4.2. DPPH Radical scavenging activity (%) of fruit (A), leaf (B) and stem (C) extracts of X. aethiopica. Data are 
presented as mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of 



















Fruit     
Ethyl acetate 0.15 ± 0.01b 0.66 ± 0.05a,b 17.42 ± 1.77e 0.78 ± 0.13c 
Ethanol 0.04 ± 0.01a 0.16 ± 0.01a 0.21 ± 0.01a 0.08 ± 0.01a 
Aqueous 0.10 ± 0.01a,b 8.04 ± 0.28c 5.50 ± 0.66d 2.20 ± 0.13d 
Leaf     
Ethyl acetate 0.12 ± 0.02a,b 0.51 ± 0.07a,b 119.64 ± 23.05g 65.85 ± 5.48e 
Ethanol 0.08 ± 0.01a 0.27 ± 0.03a 2.40 ± 0.11c 0.28 ± 0.01b 
Aqueous 0.15 ± 0.01b 0.73 ± 0.10b 71.90 ± 6.63f 0.95 ± 0.09c 
Stem     
Ethyl acetate 1.01 ± 0.08c ND ND ND 
Ethanol 0.26 ± 0.05b ND ND ND 
Aqueous 5.98 ± 2.61d ND ND ND 
Ascorbic acid 0.03 ± 0.02 a ND ND ND 
Gallic acid 0.05 ± 0.01a 0.20 ± 0.01a ND ND 
Acarbose ND ND 0.37 ± 0.03b 0.21 ± 0.01b 
Data are presented as mean ± SD of triplicate determinations. a-g Values with different superscript letters presented within a 
column for a given parameter are significantly different from each other extract (Tukey’s-HSD multiple range post hoc test, p 
< 0.05). ND, Not determined. 
 
The results of the inhibition of hemoglobin glycation by the extracts from different parts of X. 
aethiopica are presented in Figure 4.3 and Table 4.2 (IC50 values). The EtOH and EtOAc extracts from 
the fruit and leaf parts had showed significantly (p < 0.05) lower calculated IC50 values compared to 
other solvent extracts from the same or different parts. The calculated IC50 value (0.16 ± 0.01 mg/mL) 
exhibited by the fruit EtOH extract was the least and comparable to the gallic acid (0.20 ± 0.01 mg/mL) 
used as a standard (Table 4.2). Moreover, all the extracts from the stem and root parts showed no 







Figure 4.3. Inhibition of hemoglobin glycosylation (%) of fruit (A) and leaf (B) extracts of X. aethiopica.  Data are presented 
as mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract 
are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
The data of inhibition of α-amylase action by various extracts from X. aethiopica are presented 
in Figure 4.4 and Table 4.2 (IC50 values). It was observed from the results that, the calculated IC50 
value (0.21 ± 0.01 mg/mL) exhibited by the fruit EtOH extract was significantly (p < 0.05) lower 
compared to other solvent extracts of the same or different parts and the acarbose as well (Table 4.2). 
The leaf EtOH extract was also observed to show an IC50 value (2.40 ± 0.11 mg/mL) that was 







Figure 4.4. α-Amylase inhibition (%) of fruit (A) and leaf (B) extracts of X. aethiopica.  Data are presented as mean ± SD of 
triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract are significantly 
different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
The results of the α-glucosidase inhibitory action by various solvent extracts from X. aethiopica 
are presented in Figure 4.5 and Table 4.2. According to the results, fruit EtOH extract had demonstrated 
potent α-glucosidase inhibitory action with the calculated IC50 value (0.08 ± 0.01 mg/mL) was 
significantly (p < 0.05) lower compared to the acarbose (0.21 ± 0.01 mg/mL). The inhibition of α-
glucosidas action exhibited by leaf EtOH extract was not significantly (p < 0.05) compared to acarbose 









Figure 4.5. α-Glucosidase inhibition (%) of fruit (A) and leaf (B) extracts of X. aethiopica.  Data are presented as mean ± SD 
of triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
The results of the phytochemical analysis of the most active extracts (EtOH fruit and leaf) from 
X. aethiopica are presented in Figures 4.6 (GC-MS) and Table 4.3 (list of compounds). Several peaks 
appeared in the chromatogram of the fruit EtOH extract and were identified and compared with 
standards from the NIST library (Figure 4.6A). The available constituents (1-16) in fruit EtOH extract 
include terpenes; p-menth-1-en-8-ol (1), camphene (4), caryophyllene (5), octahydro-1,4,9,9-
tetramethyl-methanoazulene (6), cis-α-copaene-8-ol (7), 3-ethenyldodecahydro-pentamethyl naphthol 
(11), androst-5-en-4-one (15) and 4-methylcholesten-3-ol (16), aromatic compounds; 2-ethyl-4,5-





benzenedicarboxylic acid, butyl 2-methylpropyl (9) and other long chain fatty acid derivatives; 
hexadecanoic acid, ethyl ester (10), ethyl oleate (12), linoleic acid ethyl ester (13) and octadecanoic 
acid, ethyl ester (14) (Figure 4.6A and Table 4.3).  Furthermore peaks visible from the chromatogram 
of leaf EtOH extract (Figure 4.6B) lead to identification of terpenes; 3-methyl-6-(1-methylethyl)- 2-
cyclohexen-1-one (17), lilac alcohol formate C (18), camphene (4) and hexahydro-9-hydroxy trimethyl 
naphthol (25), a sugar 4-methyl-myo-inositol (20) and majorly long chain fatty acids and esters (19), 5-
hydroxy-spiro[2,4] heptane-5-methanol (21), n-hexadecanoic acid (22), 9-octadecenoic acid, methyl 
ester (23) and 9-octadecenoic acid (24) (Table 4.3).   
 
 






Table 4.3: Identified compounds from the fruit, leaf and stem EtOH extracts of X. aethiopica analyzed 
by GC-MS 
Extracts Compounds Retention time (min) Mass/amu 
Fruit    
1 p-Menth-1-en-8-ol 5.51 139 [M]+ 
2 2-Ethyl-4,5-dimethyl-phenol 6.26 150 [M]+ 
3 3-Hydroxy-4-pteridinone 6.68 164 [M]+ 
4 Camphene 7.23 136 [M]+ 
5 Caryophyllene 7.47 204 [M]+ 
6 Octahydro-1,4,9,9-tetramethyl-
methanoazulene 
8.26 191 [M]+ 
7 cis-α-Copaene-8-ol 8.54 220 [M]+ 
8 1-Formylethyl-4-(1-buten-3-yl)-
benzene 
8.95 188 [M]+ 
9 1,2-Benzenedicarboxylic acid, butyl 2-
methylpropyl 
10.30 278 [M]+ 
10 Hexadecanoic acid, ethyl ester 10.40 284 [M]+ 
11 3-Ethenyldodecahydro-pentamethyl 
naphthol  
10.76 275 [M]+ 
12 Ethyl oleate 11.25 310 [M]+ 
13 Linoleic acid ethyl ester 11.27 308 [M]+ 
14 Octadecanoic acid, ethyl ester 11.36 312 [M]+ 
15 Androst-5-en-4-one 11.94 272 [M]+ 
16 4-Methylcholesten-3-ol 12.05 400 [M]+ 
Leaf     
17 3-Methyl-6-(1-methylethyl)-2-
cyclohexen-1-one 
5.99 152 [M]+ 
18 Lilac alcohol formate C 6.61 198 [M]+ 
19 Hex-4-ynoic acid, methyl ester 7.21 125 [M]+ 





20 4-Methyl-myo-inositol  7.61 179 [M]+ 
21 5-Hydroxy-spiro[2,4] heptane-5-
methanol 
8.23 124 [M]+ 
22 n-Hexadecanoic acid 10.23 256 [M]+ 
23 9-Octadecenoic acid, methyl ester 10.94 296 [M]+ 
24 9-Octadecenoic acid 11.11 282 [M]+ 
25 Hexahydro-9-hydroxy trimethyl 
naphthol  
11.25 264 [M]+ 
 
4.1.5 Discussion 
 In most of the previous studies, various extracts from X. aethiopica fruit were reported to be 
rich in polyphenols and flavonoids as well (Adefegha and Oboh, 2012a,c; 2011; George and Osioma, 
2011; Etoundi et al. 2010; Esekhiagbe et al. 2009; Odukoya et al. 2005). The highest amounts of 
polyphenols (4.2 ± 0.0 mg/g) and flavonoids (3.5 ± 0.6 mg/g) were that reported in X. aethiopica fruit 
aqueous extract (Adefegha and Oboh, 2012c). This is far lower compared to that of fruit EtOH extract 
(polyphenols: 25.36 ± 0.32 mg/g; flavonoids: 8.06 ± 0.88 mg/g) obtained in our present study (Table 
4.1). Additionally, even the polyphenolic content of the fruit aqueous extract (4.83 ± 0.15 mg/g) 
obtained in our present study was higher than that reported earlier (Adefegha and Oboh, 2012c). These 
variations could be due to many factors, but not limited to the method and the solvent used for the 
extraction. It was also evident from our present results that polyphenolic and flavonoid contents vary 
from one part to another (Table 4.1). This again might be attributed to genetic and environmental factors 
(nature of the soil, high temperature and rain fall) in addition to growth or maturation stages for most 
of the parts of the plants (Mamphiswana et al. 2010; Pandey and Rizvi, 2009). 
 In a previous study, Odukoya et al. (2005) have reported that the X. aethiopica fruit aqueous 
extract showed excellent ferric (Fe3+) reducing anti-oxidant ability. This is in line with the results of our 
present study, when the fruit EtOH extract was the most potent than other extracts (Figure 4.1). In 
addition although no correlation analysis was conducted in our present study, the reducing anti-oxidant 
ability of the various extracts correlates well with the polyphenolic and flavonoid contents (Table 4.1). 
It was also observed that extracts derived from the leaf part are good source for anti-oxidant molecules 
as they exhibited good anti-oxidant activity. The reducing anti-oxidant ability of various X. aethiopica 
extracts was further supported by the potent potent DPPH radical scavenging actions (Table 4.2). 
The anti-radical potentials of X. aethiopica fruit aqueous extract (IC50: 0.3 mg/mL) has been 
reported recently (Adefegha and Oboh, 2012a, c; 2011). However, according to our results, the 





reported by Adefegha and Oboh (2012c), when that of EtOH extract (0.04 ± 0.01 mg/mL) was by far 
lower compared to the aqueous extract (Table 4.2). This could be the least IC50 value for DPPH 
scavenging of any extract from X. aethiopica so far reported. The higher activity of the fruit EtOH 
extract might be attributed to the higher polyphenol and flavonoid content mentioned above. This again 
could be the reason behind the higher anti-radical ability of the EtOH extracts from other parts of X. 
aethiopica than other solvent extracts (Table 4.2).  
 In order to further evaluate the anti-oxidant capacity of various extracts from different parts of 
X. aethiopica, the inhibitory effect of hemoglobin glycation by these extracts was investigated. 
Glycation is a non-enzymatic reaction that occurs when proteins such as hemoglobin and albumin are 
exposed to excess reducing sugars and contributes greatly to formation of advanced glycation end 
products that lead to oxidative stress (Yamagishi et al. 2008; Rahbar and Figarola, 2003; Brownlee et 
al. 1984). According to the results of previous studies, there is a positive correlation between 
polyphenolic contents and anti-glycation ability of several plant-derived extracts (Ramkissoon et al. 
2013; Povichit et al. 2010; Rahbar and Figarola, 2003). Therefore, the higher anti-glycation of the EtOH 
extracts from fruit and leaf of X. aethiopica observed in our present study might be due to the greater 
amount of polyphenols in these parts (Table 4.1 and 4.2). The result was further supported by the 
inhibition of the activities of α-amylase and α-glucosidase by various extracts from X. aethiopica (Table 
4.2).  
 It has been reported that X. aethiopica fruit aqueous extract exhibited moderate inhibition of α-
amylase as well as α-glucosidase actions (Adefegha and Oboh, 2012a; Etoundi et al. 2010). The 
calculated IC50 values were 2.81 ± 0.79 mg/mL and 2.57 ± 1.15 mg/mL for α-amylase and α-glucosidase 
actions, respectively (Adefegha and Oboh, 2012a). However, according to our present results, the IC50 
values (α-amylase: 0.21 ± 0.01 mg/mL α-glucosidase: 0.08 ± 0.01 mg/mL) demonstrated by the most 
potent extract (fruit EtOH) was lower than other extracts, indicating higher inhibitory actions than the 
aqueous extract reported previously (Adefegha and Oboh, 2012a; Etoundi et al. 2010). Therefore, it is 
suggested that the availability of bioactive inhibitors from X. aethiopica are higher in the fruit EtOH 
extract compared to other extracts of the same or different parts (Table 4.2). The inhibitors of α-amylase 
and α-glucosidase actions can significantly control the postprandial hyperglycemia by delaying the 
process of carbohydrate hydrolysis and absorption as well (Imam, 2015; Kwon et al. 2006). 
 Furthermore, the higher α-amylase and α-glucosidase actions as well as the anti-oxidant 
activities of fruit and leaf EtOH extracts indicated the presence of promising compounds and were 
therefore subjected to GC-MS analysis. Karioti et al. (2004) have reported that monoterpene 
hydrocarbons are the major compounds detected in the essential oils derived from the fruit, leaf stem 
and root barks. This is in line with our present data (Figure 4.6 and Table 4.3). Moreover, compounds 
such as p-menth-1-en-8-ol (1), camphene (4) and caryophyllene (5) detected in fruit EtOH extract were 
also reported previously (Karioti et al. 2004). Additionally, Karioti et al. (2004) have also attributed the 





compounds. Therefore, the higher anti-oxidative and anti-diabetic actions of the fruit and leaf EtOH 
extracts might be due the presence of these compounds and constituents detected from the extracts. 
 
4.1.6 Conclusions 
In conclusion, various solvent extracts from fruit and leaf of X. aethiopica have demonstrated 
anti-oxidative as well as anti-diabetic effects in vitro when stem and root extracts showed very low or 
no significant activities in these regards. The fruit EtOH extract exhibited higher actions compared to 
other extracts of the same or different parts. Thus, it is selected for further study in order to fully 























According to the in vitro anti-oxidative and anti-diabetic studies of the various solvent extracts derived 
from different parts of X. aethiopica stated above, fruit ethanolic extract demonstrated higher activities 
compared to other extracts. Therefore it was selected for further studies. 
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4.2.1 Abstract 
Objectives: Xylopia aethiopica (Dun.) A. Rich (Annonaceae) has been widely used in food 
preparations and is locally used in treatment of various diseases. The present study was carried out to 
assess the anti-oxidative and anti-diabetic potentials of solvent-solvent fractions from crude ethanolic 
extract of X. aethiopica fruit using various in vitro models.  
Methods: Crude ethanolic extract was fractionated using hexane, dichloromethane, ethyl acetate and 
acetone. They were subjected and investigated for 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical 
scavenging activity, ferric reducing anti-oxidant power (FRAP), inhibition of hemoglobin 
glycosylation, α-amylase and α-glucosidase activities as markers of in vitro anti-diabetic effects at 
various doses (30-240 µg/mL). Possible bioactive compounds were analyzed using Gas 
Chromatography-Mass Spectrometry (GC-MS) analysis.  
Results: The results indicated that acetone fraction exhibited significantly (p < 0.05) higher total 
polyphenols and flavonoids contents and recorded lower IC50 values in all the models used (DPPH: 
84.47 ± 0.71 µg/mL; inhibition of hemoglobin glycosylation: 148.15 ± 3.57 µg/mL; -amylase: 155.41 
± 1.83 µg/mL; -glucosidase: 86.23 ± 0.30 µg/mL) compared to other solvent fractions. Possible 
phytochemical present in acetone fraction were mostly phenolics and fatty acid derivatives. This finding 
clearly demonstrates that acetone fraction possesses anti-oxidative and anti-diabetic effects.  
 







 Xylopia aethiopica (Dun.) A. Rich (Annonaceae) also known as Ethiopian pepper is a plant, 20 
m in height with short roots and smooth grey bark and usually scented when fresh (Iwu, 2014). Its 
popularity as a spice in many local dishes employed by various traditions in Africa (Kingsley, 2012). 
In addition, different parts of X. aethiopica are used locally either alone or in combination with other 
plant in the treatment of different disease conditions (Fall et al. 2003). In Nigeria, either X. aethiopica 
fruit decoction alone or in equal proportion with Alstonia congensis bark were reported to be used in 
the treatment of diabetes (Soladoye et al. 2012; Ogbonnia et al. 2008). The fruit is also used as pain 
reliever and in the treatment of stomach aches, dysentery, ulceration, skin infections and coughs 
(Ezeikwesili et al. 2010). Previous studies have reported that X. aethiopica fruit extracts and/or its 
essential oils possess anti-cancer (Kuete et al. 2013; Choumessi et al. 2012), anti-anaphylactic and anti-
inflammatory (Obiri and Osafo, 2013), hypolidemic (Etoundi et al. 2013) and anti-microbial 
(Esekhiagbe et al. 2009) effects. Furthermore, fruit aqueous extract from X. aethiopica was reported to 
exhibit anti-oxidative and carbohydrate digesting enzymes inhibitory effects in vitro (Adefegha and 
Oboh, 2012a; Etoundi et al. 2010; Odukoya et al. 2005; George and Osiama, 2011). In addition, our 
recently concluded study had showed that fruit ethanolic (EtOH) extract from X. aethiopica fruit 
demonstrated potent anti-oxidative and anti-diabetic actions in vitro (unpublished data). Therefore in 
our search for the plant-derived products with potent anti-oxidative and anti-diabetic effects, the fruit 
EtOH extract was further partitioned and fractionated using solvents of increasing polarity.  The 
fractions obtained were subjected to anti-oxidative and anti-diabetic effects using various in vitro 
models. Phytochemical analysis of the fraction with higher activity was assessed using GC-MS analysis. 
 
4.2.3 Materials and methods 
For sample collection, identification and preparation of the fractions, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.4.  
 
4.2.4 Results  
 The results of percentage yield recovered, total polyphenols and flavonoids contents of all the 
fractions derived from X. aethiopica fruit are presented in Table 4.4. According to the data hexane 
fraction was observed to recover the highest yield while acetone fraction recovered the least amount. It 
was also observed that acetone fraction exhibited significantly (p < 0.05) higher total polyphenols and 
flavonoids contents compared to other solvent fractions (Table 4.4). In addition the flavonoids content 





Table 4.4: Percentage yield, total polyphenol and flavonoid contents of various fractions from ethanolic 
fruit extract of X. aethiopica  
Solvent Yield (%) Total polyphenols (mg/gGAE) Total flavonoids (mg/gQE) 
Hexane 17.80 0.63 ± 0.16a  ND  
Dichloromethane 10.54 1.14 ± 0.34a 0.07 ± 0.02a 
Ethyl acetate 9.60 2.31 ± 0.05b 0.23 ± 0.04b 
Acetone 8.70 13.46 ± 0.05c 5.13 ± 0.05c 
Data are presented as mean ± SD values of triplicate determinations. a-c Different superscripted letters for a given value within 
a column are significantly different from each other fractions or standards (Tukey’s-HSD multiple range post hoc test, p < 
0.05), ND, Not determined. 
 
 The results of ferric (Fe3+) reducing anti-oxidant power (FRAP) of the various fractions are 
presented in Figure 4.7. It was observed that acetone fraction showed a significantly (p < 0.05) higher 
and concentration dependent Fe3+ to Fe2+ reducing power compared to other solvent fractions, although 
the results were significantly (p < 0.05) lower than the ascorbic acid (Figure 4.7). The ethyl acetate 
(EtOAc) fraction exhibited moderate activity, whereas the hexane fraction was the least active.  
 
Figure 4.7. Total reducing power (relative to gallic acid) of fruit (A) and leaf (B) extracts of X. aethiopica. Data are presented 
as mean ± SD of triplicate determinations. a-e Different letters presented over the bars for a given concentration of each extract 
are significantly different from each other fractions or standards (Tukey’s-HSD multiple range post hoc test, p < 0.05).  
 
The data of the DPPH radical scavenging ability of various fractions are presented in Table 4.5 
and Figure 4.8. From the results, acetone fraction demonstrated significantly (p < 0.05) lower IC50 
value (84.47 ± 0.71 µg/mL) for the DPPH radical scavenging activity compared to other fractions and 
this was also comparable to the standards used (Ascorbate: 25.34 ± 6.19 µg/mL; Gallic acid: 20.01 ± 
4.42 µg/mL). The IC50 value depicted by the EtOAc fraction was significantly (p < 0.05) lower 






Figure 4.8. DPPH Radical scavenging activity (%) of various fractions from fruit ethanolic extract of X. aethiopica. Data are 
presented as mean ± SD of triplicate determinations. a-d Values with different letters presented for a given concentration for 
each extract are significantly different from each other fractions or standards (Tukey’s-HSD multiple range post hoc test, p 
< 0.05).  
The data of inhibition of hemoglobin glycation and the calculated IC50 values of various 
fractions are presented in Figure 4.9 and Table 4.5 (IC50 values). According to the results the acetone 
fraction demonstrated significantly (p < 0.05) lower IC50 value (148.15 ± 3.57 µg/mL) compared to 
other solvent fractions and comparable to the gallic acid (199.09 ± 2.85 µg/mL). The IC50 values 
exhibited by the dichloromethane and EtOAc fractions were not significantly (p < 0.05) different from 
each other (Table 4.5). 
 
Table 4.5: IC50 values of various solvent fractions from ethanolic fruit extract of X. aethiopica in 









inhibition   
α-glucosidase 
inhibition 
Hexane 3190.52 ± 147.53e 5373.39 ± 90.74d 2517.02 ± 194.33c 4155.78 ± 188.35e 
Dichloromethane 1172.05 ± 5.81d 4892.59 ± 53.78c 6818.32 ± 804.96e 1315.41 ± 122.27d 
Ethyl acetate 317.74 ± 6.29c 4912.24 ± 541.03c 4086.76 ± 153.59d 652.60 ± 58.47c 
Acetone 84.47 ± 0.71b 148.15 ± 3.57a 155.41 ± 1.83a 86.23 ± 0.30a 
Ascorbic acid 25.34 ± 6.19a ND ND ND 
Gallic acid 20.01 ± 4.42a 199.09 ± 2.85b  ND ND 
Acarbose ND ND 374.95 ± 26.81b  211.59 ± 3.32b 
Data are presented as mean ± SD values of triplicate determinations. a-e Different superscripted letters for a given value within 
a column are significantly different from each other fractions or standards (Tukey’s-HSD multiple range post hoc test, p < 







Figure 4.9: Inhibition of hemoglobin glycation (%) of various fractions from fruit ethanolic extract of X. aethiopica. Data are 
presented as mean ± SD of triplicate determinations. a-e Values with different letters presented for a given concentration for 
each extract are significantly different from each other fractions or standards (Tukey’s-HSD multiple range post hoc test, p 
< 0.05). 
 
The results of α-amylase inhibition by the various fractions and the calculated IC50 values are 
presented in Figure 4.10 and Table 4.5 (IC50 values). According to the data, acetone fraction showed 
a significantly (p < 0.05) lower calculated IC50 value (155.41 ± 1.83 µg/mL) for α-amylase inhibition 
compared to other solvent fractions and acarbose as well (Table 4.5). The IC50 values exhibited by the 
EtOAc and hexane fractions were not significantly (p < 0.05) difference compared to the standard 
acarbose, when that of dichloromethane fraction was the highest (Table 4.5). 
 
Figure 4.10: α-Amylase inhibition (%) of various fractions from fruit ethanolic extract of X. aethiopica. Data are presented as 
mean±SD of triplicate determinations. a-e Values with different letters presented for a given concentration for each extract are 





The data of α-glucosidase inhibition by the various fractions and the calculated IC50 values are 
presented in Figure 4.11 and Table 4.5 (IC50 values). It was observed that the acetone fraction 
demonstrated significantly (p < 0.05) lower IC50 value (86.23 ± 0.30 µg/mL) for α-glucosidase 
inhibition compared to other solvent fractions as well as acarbose (211.59 ± 3.32 µg/mL) (Table 4.5). 
The IC50 value depicted by the EtOAc fraction was not significantly different compared to the acarbose, 
when the other fractions showed the highest calculated IC50 values (Table 4.5). 
 
 
Figure 4.11: α-glucosidase inhibition (%) of various fractions from fruit ethanolic extract of X. aethiopica. Data are presented 
as mean ± SD of triplicate determinations. a-d Values with different letters presented for a given concentration for each extract 
are significantly different from each other fractions or standards (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
The results of the kinetics of the mode of the α-glucosidase and amylase inhibition by the most 
active fraction (acetone) are presented in Figure 4.12. It was observed from the results that the acetone 
fraction showed a mixed inhibition type for α-amylase action. The KM value (control: 0.06%; with 
acetone: 0.09%) increased when the value of Vmax (control: 35.67 µmol/min; with acetone: 21.58 
µmol/min) was observed to decrease and the Ki value for inhibiting α-amylase was 45.94 µg/mL Figure 
4.12A. Furthermore, the data revealed that the acetone fraction is a non-competitive inhibitor of α-
glucosidase with The KM value remains unchanged (1.10 mmol/L), whereas the Vmax was found to 
decreases from 471.56 µmol/min to 98.20 µmol/min and the equilibrium constant for inhibitor binding 







Figure 4.12: Lineweaver-Burke’s plot of (A) α-amylase and (B) α-glucosidase catalyzed reactions in the presence and absence 
of the acetone fraction derived from the X. aethiopica fruit ethanolic extract. 
 
The results of the phytochemical analysis of the most active fraction (acetone) are presented in 
Figure 4.13 and Table 4.6. Several peaks appeared in the chromatogram of the acetone fraction and 
were identified and compared with those in the NIST library (Figure 4.13). The major peaks correspond 
to 3-methyl phenol (1), 1,2-dimethoxy-4-(2-propenyl) benzene (2), 2-methoxy-4-(1-propenyl)-phenol 
(3), 4-methoxy-6-(2-propenyl)-1,3-benzodioxole (4), 1,2,3-trimethoxy-5-(2-propenyl) benzene (5), 2,6-
dimethoxy-4-(2-propenyl)-phenol (6), isoelemicin (7), trans-Z-α-bisabolene epoxide (8), cumminic 
aldehyde (9) butyl isobutyl phthalate (10), oleic acid (11), kauran-16-ol (12), 4-[2,3-dihydro-7-
methoxy-3-methyl-5-(1-propenyl)-2-benzofuranyl]-2-methoxy-phenol (13) and N-(4-methoxyphenyl)-






















































                 Figure 4.13. GC-MS Chromatogram of the acetone fraction from fruit ethanolic extract of X. aethiopica 
 
Table 4.6: Identified compounds from the acetone fraction from fruit ethanolic extract of X. aethiopica 
by GC-MS 
Solvent Compounds Retention time (min) Mass/amu 
Acetone    
1 3-Methyl phenol 4.45 108 [M]+ 
2 1,2-Dimethoxy-4-(2-propenyl) 
benzene  
6.96 178 [M]+ 
3 2-Methoxy-4-(1-propenyl)-phenol 7.34 164 [M]+ 
4 4-Methoxy-6-(2-propenyl)-1,3-
benzodioxole 
7.82 192 [M]+ 
5 1,2,3-Trimethoxy-5-(2-propenyl) 
benzene 
7.91 208 [M]+ 
6 2,6-Dimethoxy-4-(2-propenyl)-
phenol  
8.25 194 [M]+ 
7 Isoelemicin 8.54 208 [M]+ 
8 trans-Z-α-Bisabolene epoxide 9.150 220 [M]+ 
9 Cumminic aldehyde 10.22 256 [M]+ 
10 Butyl isobutyl phthalate 10.26 278 [M]+ 
11 Oleic acid 11.12 264 [M]+ 




14.58 326 [M]+ 
14 N-(4-Methoxyphenyl)-2-
hydroxyimino-acetamide 





                                                        
 






It has been reported that aqueous and methanolic extracts from X. aethiopica fruit contained 
high amount of polyphenols and flavonoids (Adefegha and Oboh, 2012a,c; 2011; George and Osioma, 
2011; Etoundi et al. 2010; Esekhiagbe et al. 2009; Odukoya et al. 2005). Likewise in our recent study, 
the fruit EtOH extract was observed to contain higher polyphenols and flavonoids compared to other 
extracts from the different parts of X. aethiopica (unpublished data). However, according to our present 
results the most polar solvent fraction (acetone) contained the highest amounts, indicating the role of 
polarity in the extraction of the polyphenols and flavonoids (Table 4.4). That is a positive correlation 
exists between the polyphenolic contents and polarity of the solvents. The polyphenols are the most 
available and diverse constituents in plant-derived extracts and impact crucial role in the prevention of 
the deleterious action of free radicals (Brewer, 2011; Cohen and Kennedy, 2010). The data were further 
supported by the higher anti-radical actions of the acetone fraction (Table 4.5). 
The anti-radical scavenging abilities of the fruit aqueous extract have been reported in some 
recent studies (Adefegha and Oboh, 2012a,c). In addition, our recent data showed that the fruit EtOH 
extract exhibited the most active Fe3+ to Fe2+ and DPPH (IC50: of 0.04 ± 0.01 mg/mL) reducing potentials 
(unpublished data). Moreover, based on our present results, fractionation of the crude EtOH extract 
yielded another potent anti-radical scavenger (acetone fraction), which was further supported by the 
higher Fe3+ to Fe2+ reducing potentials of this fraction (Figure 4.7 and Table 4.5). Therefore the higher 
electron quenching ability of the acetone fraction might be associated to the higher polyphenolic 
content, as previous studies have shown strong correlation between the polyphenolic content and the 
anti-oxidant activity of plant-derived products (Miladi and Demak, 2008; Pulido et al. 2000). 
Additionally, radical scavenging is among the underlying mechanisms by which plant-derived products 
prevent the delitarious oxidative damages in diabetes and aging-related complications (Perron and 
Brumaghim, 2009). 
In some diseases such as diabetes, elevation of blood glucose levels and the increasing 
production of free radicals lead to glycation of the proteins such a as albumin and hemoglobin. This 
process contributes significantly to tissue and cellular damage in diabetics increase the production of 
advanced glycation endproducts (AGEs) as well (Lobo et al. 2010). However in a number of studies 
reported earlier, plant-derived extracts and/or fractions have showed potent anti-glycation that was 
attributed to their phenolic contents (Mudgal et al. 2010; Pandey and Rizvi, 2009; Rice-Evans et al. 
1996). Therefore, the potent anti-glycation exhibited by the acetone fraction might be attributed to the 
higher phenolic contents of this fraction as well (Table 4.5). This result is partly supported by the higher 
inhibition of α-amylase and α-glucosidase actions by the acetone fraction (Table 4.5).   
Inhibition of the activities of α-amylase and α-glucosidase is an important strategy for delaying 
carbohydrate digestion and subsequent intestinal absorption of the monosaccharides, and is thus crucial 





X. aethiopica fruit aqueous exhibited good inhibition of α-amylase as well as α-glucosidase actions 
(Adefegha and Oboh, 2012a; Etoundi et al. 2010). This in addition to our recent study that showed 
potent action of fruit EtOH extract (IC50 value: α-amylase: 0.21 ± 0.01 mg/mL; α-glucosidase: 0.08 ± 
0.01 mg/mL) compared to other extracts of X. aethiopica (unpublished data). According to our present 
data, the inhibition of acetone fraction derived from the fruit EtOH extract was the highest (IC50 value: 
α-amylase: 155.41 ± 1.83 µg/mL; α-glucosidase: 86.23 ± 0.30 µg/mL), indicating the greater 
availability of potent α-amylase and α-glucosidase inhibitors in this fraction (Table 4.5).  
Furthermore, kinetic parameters calculated from the double reciprocal plot revealed that the 
mode of α-amylase inhibition exhibited by the acetone fraction is a mixed inhibition type (Figure 
4.12A). In this type of inhibition, both the Km and Vmax are greatly altered in the presence or absence 
of the inhibitor. This causes some conformational modifications at the active site of the enzyme that 
hinder the binding of the substrate and thus decreases the enzyme activity. On the other hand, acetone 
fraction was observed to be a non-competitive inhibitor of the α-glucosidase action (Figure 4.12B). In 
this type, the km value remains unchanged in the presence or absence of the inhibitor. In the same way 
as in the mixed inhibition type, non-competitive inhibitors bound at separate site(s) (not the active site) 
of the enzyme (α-glucosidase) and caused conformational modification at the active site. This leads to 
the delay of effective binding of the substrate to the enzyme active site and consequently reducing the 
activity of the enzyme. 
Based on the consistently higher anti-oxidant and anti-diabetic actions in vitro of the acetone 
fraction, it was subjected to GC-MS analysis to find possible phytochemicals present. In a previous 
study, Karioti et al. (2004) have reported that monoterpene hydrocarbons are the major compounds 
detected in the essential oils derived from the fruit, leaf stem and root barks of X. aethiopica, which was 
further supported by our recent study (Unpublished data). However in our present study, fractionation 
of the crude EtOH extract yielded mostly terpenes and aromatic compounds (Table 4.6). The presence 
of compounds such as trans-Z-α-bisabolene epoxide, terpinen-4-ol, cumminic aldehyde and kauran-16-
ol were previously linked to the potent anti-oxidative action of oil derived from the X. aethiopica fruit 
(Karioti et al., 2004). In another study, butyl isobutyl phthalate and cumminic aldehyde 
(cuminaldehyde) were reported demonstrated anti-diabetic action using various in vitro and in vivo 
models (Liu et al., 2011; Bu et al., 2010; Lee, 2005). Therefore, the promising anti-oxidative and anti-
diabetic actions of acetone fraction observed in our present study might be attributed to the presence of 
these compounds and other aromatic molecules detected as well. 
 
4.2.6 Conclusions 
Conclusively, various solvent fractions from X. aethiopica fruit exhibited anti-oxidative as well 





polar, has exhibited higher activities compared to other fractions. Therefore, it is recommended for in 







































According to the anti-oxidative and anti-diabetic study of the various solvent fractions derived from 
ethanolic extract of X. aethiopica fruit stated above, acetone fraction exhibited higher activities 
compared to other solvent fractions. Therefore it was selected for the in vivo studies. 
 
4.3 Anti-diabetic effect of Xylopia aethiopica (Dunal) A. Rich. fruit 
acetone fraction in a type 2 diabetes model of rats 
 
Aminu Mohammed1,2 and Md. Shahidul Islam1* 
1Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, (Westville 
Campus), Durban, 4000, South Africa 
2Department of Biochemistry, Faculty of Science, Ahmadu Bello University, Zaria-Nigeria 
 
Published in the Journal of Ethnopharmacology 180: 131-139. 
 
4.3.1 Abstract 
Objective: In the traditional medicine from West Africa, fruit decoction of Xylopia aethiopica (Dunal) 
A. Rich. is widely used for the treatment of diabetes mellitus (DM) either alone or in combination with 
other plants. The present study is designed to investigate the anti-diabetic effects of X. aethiopica 
acetone fraction (XAAF) from fruit ethanolic extract in a type 2 diabetes (T2D) model of rats.  
Methods: T2D was induced in rats by feeding a 10% fructose solution ad libitum for 2 weeks followed 
by a single intraperitoneal injection of streptozotocin (40 mg/kg body weight) and the animals were 
orally treated with 150 or 300 mg/kg body weight (bw) of the XAAF once daily for four weeks.  
Results: After 4 weeks study period, diabetic untreated animals exhibited significantly higher serum 
glucose, serum fructosamine, LDH, CK-MB, serum lipids, liver glycogen, insulin resistance (HOMA-
IR), AI, CRI and lower serum insulin, β-cell function (HOMA-β) and glucose tolerance ability 
compared to the normal animals. Histopathological examination of their pancreas revealed 
corresponding pathological changes in the islets and β-cells. These alterations were reverted to near-
normal after the treatment of XAAF at 150 and 300 mg/kg bw when, the effects were more pronounced 
at 300 mg/kg bw compared to the 150 mg/kg bw.  
Conclusion:  The results of our study suggest that XAAF treatment showed excellent anti-diabetic 
effect in a T2D model of rats. 
 








The progressive increase of diabetes mellitus (DM) constitutes a global public health problem. 
The recent report by the International Diabetes Federation (IDF) estimate that DM affects more than 
378 million people and this figure is likely to double by 2035, and type 2 diabetes (T2D) is the most 
prevalent one (IDF, 2014). T2D is a heterogeneous disorder characterized by insulin resistance and 
partially dysfunctional pancreatic β-cell to properly secrete insulin in response to hyperglycemia (Hui 
et al. 2007). Despite the currently available conventional drugs (sulfonylureas, biguanides, α-
glucosidase inhibitors, thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors), the treatment 
of T2D has been a difficult task. This is due to the unwanted side effects associated with the use of the 
conventional drugs, which include hypoglycemia, weight gain, hypersensitivity, gastrointestinal 
discomfort, nausea, liver and heart failure, and diarrhoea (Hung et al. 2012). Therefore, in order to curve 
these problems, search for anti-diabetic agents has been extended to plant-derived products, since fewer 
side effects have been reported with the use of plants in the treatment of several diseases (Singh, 2001; 
Calixto, 2000).    
Xylopia aethiopica (Dunal) A. Rich. (Annonaceae) also known as Ethiopian pepper is an 
indigenous spice widely distributed in almost all parts of Africa. It is an aromatic, evergreen plant, 20 
m height, fruits in carpels, forming dense cluster, twisted bean-like pods, dark brown, cylindrical, 1.5-
6 cm long and 4-7 mm thick (Iwu, 2014; Orwa et al. 2009). The fruit is popularly used as condiment in 
many local dishes by different traditions in Africa and Asia (Kingsley, 2012). In addition, X. aethiopica 
fruit is widely used locally in the treatment of various ailments and also as an excipient to many other 
medicines (Freiesleben et al. 2015). In Nigerian, Guinean, Togolese and Senegalese traditional 
medicines, the fruit decoction is widely used in the treatment of diabetes (Soladoye et al. 2012; Diallo 
et al. 2012; Karou et al. 2011; Diéye et al. 2008). Additionally, there are some anti-diabetic recipes such 
as Okudiabet, in Nigeria and Togo that are used for the treatment of diabetes containing X. aethiopica 
fruit as one of the ingredients of the poly-herbal drug (Soladoye et al. 2012; Karou et al. 2011; Ogbonnia 
et al. 2010; 2008).  Moreover, previous studies have shown that various extracts from X. aethiopica 
fruit possessed anti-cancer (Kuete et al. 2013; 2011; Choumessi et al. 2012), anti-fertility (Nwangwa, 
2012), anti-sickling (Uwakwe and Nwaoguikpe, 2008), anti-microbial (Esekhiagbe et al. 2009), anti-
oxidative actions and inhibits the activities of carbohydrate hydrolyzing enzymes in vitro as well 
(Adefegha and Oboh, 2012a,c; 2011; Etoundi et al. 2010; Odukoya et al. 2005; George and Osiama, 
2011).  
Furthermore, the toxicological studies so far conducted have indicated that oral administration 
of X. aethiopica fruit aqueous extract for 2 weeks was found to cause less side effects in rats 
(Johnkennedy et al. 2011; Taiwo et al. 2009). Xylopic acid (15β-acetoxy-(-)-kaur-16-en-19-oic acid), 
kaurenoic, 15-oxo-kaurenoic acid, and kauran-16-α-ol are some of the compounds isolated from X. 





to exhibit hypolidemic and anti-oxidant actions in hypercholesterolemic rats (Nwozo et al. 2011). In a 
more recent study, Etoundi et al. (2013) have indicated that X. aethiopica fruit ethanolic extract 
improved glucose tolerance ability in high-sucrose containing diet-fed animals, when the detail anti-
diabetic action of either extract or fraction from X. aethiopica fruit has not yet been conducted either in 
humans or in experimental animals. 
Therefore, the present study was designed to investigate the in vivo anti-diabetic effects of the 
acetone fraction derived from the fruit ethanolic extract of X. aethiopica in a T2D model of rats. 
 
4.3.3 Materials and methods 
For sample collection, identification and preparation of the fraction, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.5.1 to 2.5.8.  
 
4.3.4 Results 
The data of weekly body weight (bw) change of all the animals are presented in Figure 4.15. 
It was observed from the result that before the STZ injection, fructose feeding did not affect the bw of 
the animals. However, after one week of STZ injection, the bw of the diabetic animals were significantly 
(p < 0.05) decreased compared to non-diabetic animals. Treatment of X. aethiopica acetone fraction 
(XAAF) to diabetic animals for 4-weeks significantly (p < 0.05) increased the bw to near normal and 
comparable to metformin treated animals (Figure 4.15). The effect was more pronounced in DXAH 
group compared to DXAL group, when the increased in bw of NXAH group was observed not differ 
significantly (p < 0.05) compared to NC group (Figure 4.15).  
  
Figure 4.15. Mean body weight change of all animal groups during the study period. Data are presented as the mean ± SD of 
5-7 animals. a-c Values with different letter near the lines for a given week are significantly different from each other group of 
animals (Tukey's-HSD multiple range post hoc test, p< 0.05).  NC, Normal Control; DBC, Diabetic Control; DXAL, Diabetic 










































The results of daily feed and fluid intake of all the animals are presented in Figure 4.16. 
According to the data, the feed and fluid intake of DBC group were significantly (p < 0.05) increased 
compared to the NC group. However, oral administration of the XAAF to diabetic animals significantly 
decreased the feed and fluid intake compared to the DBC group, when the reduction of fluid intake of 
the DXAH group was significantly (p < 0.05) lower compared to the DXAL group (Figure 4.16). 
Furthermore, the daily feed and fluid intake of NXAH group were not affected throughout the study 
period.
 
Figure 4.16. Food and fluid intake in different animal groups during the experimental period. Data are presented as the mean 
± SD of 5-7 animals. a–dValues with different letters over the bars for a given parameter are significantly different from each 
other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05).  NC, Normal Control; DBC, Diabetic Control; 
Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, Diabetic Metformin; NXAH, Normal X. 
aethiopica high dose. 
 
The weekly blood glucose levels (NFBG and FBG) of all the animals throughout the study 
period are presented in Figure 4.17. It was observed that, one week after the confirmation of diabetes 
(week 0), the blood glucose level of the diabetic animals was significantly (p < 0.05) elevated compared 
to the non-diabetic animals. But the treatment of XAAF for four weeks significantly (p < 0.05) reduced 
the elevated blood glucose compared to the DBC group and this reduction was comparable with the 
metformin-administered DMF group (Figure 4.17). Although not significant, better reduction was 
observed in the DXAH group compared to the DXAL group. It was also observed that, the NXAH 







































Figure 4.17. Weekly NFBG in all animal groups during the intervention period. Data are presented as the mean SD of 5-7 
animals. a–dValues with different letter near the lines for a given week are significantly different from each other group of 
animals (Tukey's-HSD multiple range post hoc test, p < 0.05).  NC, Normal Control; DBC, Diabetic Control; Diabetic X. 
aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, Diabetic Metformin; NXAH, Normal X. aethiopica 
high dose.  
 
The results of oral glucose tolerance test (OGTT) and the calculated area under the curve (AUC) 
are presented in Figure 4.18 and Table 4.7, respectively. It was observed that, induction of the diabetes 
significantly (p < 0.05) affected the glucose tolerance of the DBC group compared to the NC group. On 
the other hand, significantly (p < 0.05) better glucose tolerance ability was observed in the DXAH and 
DXAL groups compared to the DBC group, when the effect was more pronounced in the DXAH group 
compared to the DXAL group, which is comparable to the DMF group (Figure 4.18). Similarly, the 
calculated AUC for DBC group was significantly (p < 0.05) higher compared to NC group when that 
of DXAL and DXAH groups were significantly (p < 0.05) lower compared to DBC groups and were 

























































Figure 4.18. Oral glucose tolerance test (OGTT) in all animal groups at the last week of the 4-week intervention period. Data 
are presented as the mean ± SD of 5-7 animals. a–cValues with different letter near the lines for a given time are significantly 
different from each other group of animals (Tukey's-HSD multiple range post hoc test, p<0.05). NC, Normal Control; DBC, 
Diabetic Control; Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, Diabetic Metformin; 
NXAH, Normal X. aethiopica high dose. 
 
Table 4.7. Area under the curve (AUC) of different animal groups at the end of the experimental period   
 NC DBC DXAL DXAH DMF NXAH 
AUC*x103 15.75 ± 0.97a 60.15 ± 7.50 c 33.89 ± 7.83 b 30.65 ± 8.85 b 28.68 ± 7.21 b 15.78 ± 0.79 a 
Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter along a row for a given parameter are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p<0.05). NC, Normal 
Control; DBC, Diabetic Control; DXAL, Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, 
Diabetic Metformin; NXAH, Normal X. aethiopica high dose, AUC, Area under curve. 
 
The results of serum insulin and fructosamine levels including the calculated HOMA-IR and 
HOMA-β scores are presented in Table 4.8. From the results, the serum insulin level and the calculated 
HOMA-β scores were decreased significantly (p < 0.05) whereas serum fructosamine as well as 
HOMA-IR scores were increased significantly (p < 0.05) in the DBC group compared to the NC group 
(Table 4.8). After 4-week treatment of XAAF, the serum insulin level was significantly (p < 0.05) 
increased and the serum fructosamine and HOMA-IR scores were significantly (p < 0.05) decreased in 
DXAH and DXAL groups compared to the DBC group (Table 4.8). The calculated HOMA-β scores of 
the diabetic treated animals was significantly (p < 0.05) in the DXAH and DMF group compared to the 
















































Table 4.8. Effect of XAAF on serum insulin and fructosamine levels and calculated HOMA-IR and HOMA-β scores in different animal groups at the end of 
the intervention period. 
 NC DBC DXAL DXAH DMF NXAH 
Insulin (pmol/L) 76.50 ± 6.26c 47.05 ± 9.02a 54.42 ± 6.01a 67.07 ± 10.00b 75.88 ± 14.23c 73.03 ± 6.18b 
Fructosamine 
(μmol/l) 
239.20 ± 47.49a 365.43 ± 44.94c 301.00 ± 16.58b 288.00 ± 23.26a,b 283.14 ± 32.46a,b 235.00 ± 24.59a 
HOMA-IR0.27 ± 2.50 ٭a 6.30 ± 1.64b 3.43 ± 0.71a 3.17 ± 0.48a 3.82 ± 0.90a 2.33 ± 0.26a 
HOMA-β43.71 ± 127.66 ٭٭d 7.33 ± 1.26a 25.07 ± 7.13b 46.51 ± 12.09c 52.57 ± 25.76c 127.03 ± 22.24d 
Data are presented as the mean ± SD of 5-7 animals. a–dValues with different letters along the rows for a given parameter are significantly different from each other group of animals (Tukey's-
HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, Diabetic Metformin; 
NXAH, Normal X. aethiopica high dose.٭HOMA-IR = [(Fasting serum insulin in U/l x Fasting blood glucose in mmol/L)/22.5].٭٭HOMA-β = (Fasting serum insulin in U/l x 20/Fasting blood 
glucose in mmol/L-3.5). 
 
Figure 4.19. Histopathological examination of the pancreatic tissues of different animal groups at the end of the intervention period. The NC had a larger islet with high number of β-cells while 
the DBC had a smaller islet and morphologically deformed β-cells. The DXAL, DXAH and DMF groups had relatively larger islets with higher number of β-cells compared to the DBC group. 





The histopatological slides of the pancreas for all the groups are presented in Figure 4.19. The 
slides revealed that, there were fatty infiltrations, reduce number of pancreatic β-cells and smaller size 
of the pancreatic islet of the DBC group compared to the NC group. However, treatment with XAAF 
to diabetic animals reduced fatty infiltrations, improved the number of pancreatic β-cells and the 
pancreatic islet size in the DXAL and DXAH groups (Figure 4.19). Additionally, the fatty infiltrations 
in the DXAH group were less compared to that of DXAL group. Furthermore, the pancreatic 
morphology was not affected by the higher dose of XAAF in the NXAH group (Figure 4.19).   
The results of absolute and relative liver weight including liver glycogen contents are presented 
in Table 4.9. According to the data, although the absolute liver weight was not affected by the induction 
of diabetes, the significantly (p < 0.05) increased relative liver weight and glycogen content was 
observed in the DBC group compared to the NC group. Oral administration of the XAAF significantly 
(p < 0.05) restored the relative liver weight and glycogen content in the DXAH and DXAL groups 
which is comparable to the NC and DMF groups (Table 4.9). The liver weights and glycogen content 
of the NXAH group were not affected by the administration of XAAF throughout the experimental 
period. 
In Table 4.10, the serum lipid profile and calculated atherogenic index (AI) and coronary risk 
index (CRI) are presented. The increased serum total cholesterol (TC), triglycerides (TG) and low 
density lipoprotein (LDL) cholesterol as well as calculated AI and CRI along with the reduction of 
serum high density lipoprotein (HDL) cholesterol were observed in the DBC group compared to the 
NC group. After 4-week of oral intervention with XAAF, the serum TC, TG, LDL-cholesterol, 
calculated AI and CRI were significantly (p < 0.05) decreased in the DXAL and DXAH groups 
compared to the DBC group in a dose-dependent manner (Table 4.10) when, the serum HDL-
cholesterol level of diabetic treated groups was not significantly (p < 0.05) difference compared to the 
DBC group. Administration of the high dose of the fraction to non-diabetic animals did not affect these 
parameters in the NXAH group compared to the NC group (Table 4.10).    
The results of serum ALT, AST, ALP, urea, uric acid, creatinine, LDH and CK-MB are 
presented in Table 4.11. It was observed from the data that, the serum ALT, ALP, urea, creatinine, 
LDH and CK-MB levels were elevated in the DBC group compared to the NC group, when the serum 
ALP and uric acid levels were not affected by the induction of diabetes (Table 4.11). Treatment with 
XAAF to diabetic animals significantly (p < 0.05) reduced serum ALT, ALP, urea, creatinine, LDH and 
CK-MB levels compared to the DBC group (Table 4.11). Moreover, treatment to non-diabetic animals 





Table 4.9. Effect of XAAF on liver weights and liver glycogen concentrations in T2D rats 
 NC DBC DXAL DXAH DMF NXAH 
Liver weight(g) 9.25 ± 1.04  10.34 ± 0.31  9.62 ± 0.84  10.05 ± 1.03  9.10 ± 1.33  9.42 ± 0.35  
Relative liver weight (%)0.29 ± 2.89 ٭a 4.55 ± 0.34b 3.27 ± 0.35a 3.40 ± 0.22a 3.10 ± 0.45a 2.93 ± 0.18a 
Liver glycogen (mg/g tissue) 6.76 ± 0.81a  8.25 ± 0.83b 7.17 ± 0.46a 6.93 ± 0.45a 6.92 ± 0.56a 6.58 ± 0.62a  
Data are presented as the mean ± SD of 5-7 animals. a-bValues with different letter along the rows for a given parameter are significantly different from each other group of animals (Tukey's-HSD 
multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, Diabetic Metformin; 
NXAH, Normal X. aethiopica high dose.  




















Table 4.10. Serum lipid profiles and other biochemical parameters in different animal groups at the end of the intervention period 
 NC DBC DXAL DXAH DMF NXAH 
TC (mg/dL) 76.20 ± 7.40a 116.00 ± 12.92c 76.29 ± 8.36a 78.86 ± 5.21a 95.71 ± 7.74b 73.20 ± 8.23a 
TG (mg/dL) 70.20 ± 18.10a 150.86 ± 24.57b 86.57 ± 26.05a 91.86 ± 8.15a,b 100.71 ± 32.47b  69.80 ± 3.83a  
LDL-Cholesterol (mg/dL)* 12.96 ± 4.16a 57.54 ± 14.45c 32.26 ± 11.55b 31.63 ± 5.69b 42.86 ± 8.93b,c 26.64 ± 7.96b  
HDL-Cholesterol (mg/dL) 49.20 ± 8.35b 28.29 ± 6.25a  26.71 ± 7.30a 28.86 ± 5.87a 32.71 ± 7.43a 32.60 ± 4.51a 
AI 0.57 ± 0.13a 3.30 ± 1.08c 2.04 ± 0.90b 1.81 ± 0.48a,b 2.06 ± 0.69b 1.27 ± 0.32a,b 
CRI 1.57 ± 0.13a 4.30 ± 1.08c 3.04 ± 0.90b 2.81 ± 0.48a,b 3.06 ± 0.69b 2.27 ± 0.32a,b 
Data are presented as the mean SD of 5-7 animals. a–c Values with different letters along the rows for a given parameter are significantly different from each other group of animals (Tukey's-HSD 
multiple range post hoc test, p<0.05). NC, Normal Control; DBC, Diabetic Control; Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, Diabetic Metformin; NXAH, 
Normal X. aethiopica high dose; TC, Total cholesterol; TG, Triglyceride; LDL-cholesterol, Low density lipoprotein-cholesterol; HDL-cholesterol; High density lipoprotein-cholesterol; AI, 
Atherogenic index; CRI, Coronary risk index 
















Table 4.11. Serum biochemical parameters in different animal groups at the end of the intervention period 
 NC DBC DXAL DXAH DMF NXAH 
ALT (U/L) 77.40 ± 20.38a 116.14 ± 37.37c 81.29 ± 8.46a 87.57 ± 9.86a,b 93.57 ± 6.86b 73.80 ± 14.1a 
AST (U/L) 88.40 ± 11.41 83.29 ± 15.57 80.29 ± 13.09 83.43 ± 9.45 94.71 ± 9.39 82.60 ± 16.33 
ALP (U/l) 149.40 ± 11.33a 451.14 ± 35.10d 317.71 ± 33.60c 234.86 ± 25.79b 208.86 ± 27.58b 146.40 ± 19.32a 
Creatinine (mg/dL) 2.52 ± 0.78b 3.12 ± 0.45b 2.27 ± 0.34b 2.13 ± 0.40b 1.68 ± 0.27a 1.35 ± 0.34a 
Urea (mg/dL) 22.00 ± 4.69a 60.71 ± 15.71c 29.43 ± 6.43b 30.00 ± 8.91b  26.00 ± 5.00b 17.80 ± 4.66a 
Uric acid (mg/dL) 2.06 ± 0.67  2.85 ± 1.18  2.05 ± 1.07  2.40 ± 1.20  2.56 ± 1.36  1.48 ± 0.40  
LDH (U/L) 284.00 ± 62.56a   458.86 ± 68.05c  339.86 ± 64.41b  301.71 ± 36.94b  361.57 ± 80.66a,b 295.60 ± 37.96a 
CK-MB (U/L) 374.54 ± 82.56a 1064.36 ± 537.18b 582.53 ± 86.00a 492.01 ± 51.28a 743.97 ± 75.29a,b 371.52 ± 9.06a 
Data are presented as mean ± SD of 5-7 animals. a–dValues with different superscript letters along a row for a given parameter are significantly different from each other group of animals (Tukey's-







In the traditional medicine from West Africa, X. aethiopica fruit is used locally for anti-diabetic 
remedy and other related metabolic disorders (Soladoye et al. 2012; Diallo et al. 2012; Karou et al. 
2011; Diéye et al. 2008). In addition, the acetone fraction derived from the fruit ethanolic extract has 
demonstrated higher inhibitory effect of α-glucosidae and α-amylase actions in vitro (unpublished data) 
compared to other fractions and therefore was selected for the present study. This is the first 
comprehensive study that reports the anti-diabetic potential of X. aethiopica fruit, despite the popularity 
of the plant in the treatment of diabetes in West Africa. The result of our present study is quite promising 
as the both dosages of the fraction (150 and 300 mg/kg bw) used have demonstrated strong anti-diabetic 
activity in the diabetic animals.  
  Etoundi et al. (2013) have reported that the daily administration of X. aethiopica fruit ethanolic 
extract (400 mg/kg bw) for 30 days reverted the gained body weight in high-sucrose fed rats. In another 
study, non-diabetic animals maintained in diets with 2% and 4% of X. aethiopica fruit for 2 weeks 
showed no effect on the bw of the treated animals (Adefegha and Oboh, 2012a). However, the effect X. 
aethiopica fruit ethanolic extracts or fruit itself may be different from the X. aethiopica acetone fraction 
of fruit ethanolic extract. Additionally, the effects of X. aethiopica fruit extracts or fraction may not be 
similar in non-diabetic and diabetic animals.  Hence, the effects XAAF in our study are not exactly 
consistent with the above-mentioned studies. However, despite of lower feed and fluid intake (Figure 
4.16) the significantly improved body weight in the XAAF administered groups (DXAL and DXAH) 
compared to the DBC group (Figure 4.15) revealed its potent anti-diabetic effects, when no significant 
alteration was observed in the NXAH group (Figure 4.15 and 4.16). The result was further supported 
by the significantly reduced blood glucose level in the DXAL and DXAH groups compared to the DBC 
group (Figure 4.17).  
In our present study, the persistent hyperglycemia was observed in the DBC group throughout 
the experimental period (Figure 4.17), which is an indication of successful induction of diabetes. At 
the same time, significantly higher HOMA-IR scores and significantly lower HOMA-β scores in the 
DBC group compared to the NC group (Table 4.7) confirmed the induction of insulin resistance and 
partial pancreatic beta-cell dysfunction. However, a dose-dependent reduction of blood glucose level 
was observed in the diabetic treated animals (Figure 4.17), which was further supported by the OGTT 
data (Figure 4.18). In a previous study, Etoundi et al. (2013) have reported that, high-sucrose fed rats 
treated with 400 mg/kg bw of fruit ethanolic extract improved the blood glucose tolerance ability, which 
is in line with our present data. This could be due to the potent inhibitory effects of X. aethiopica fruit 
on the activities of carbohydrate hydrolyzing enzymes as reported previously (Adefegha and Oboh, 
2012a; Etoundi et al. 2010). The inhibitors of these enzymes cause a decrease in the digestion of 
carbohydrates and intestinal absorption of glucose and therefore reduced the hyperglycemia in T2D 





compared to the earlier study (Etoundi et al. 2013), the significantly lower blood glucose levels and 
better glucose tolerance ability of the DXAL and DXAH groups compared to DBC the group (Figures 
4.17 and 4.18) revealed the potential anti-diabetic effects XAAF, at least in the case of type 2 diabetes. 
It has been reported that chronic uncontrolled hyperglycemia in T2D causes an impairment or 
decline in insulin secretion (Nattrass and Bailey, 1999), with subsequent distortion of pancreatic 
architecture, β-cell integrity and function as well (Bonner-Weir and O'Brien, 2008). These effects were 
fully manifested in the DBC group in our present study (Table 4.8 and Figure 4.19). On the other hand, 
the oral treatment of XAAF dose dependently improved serum insulin levels, decreased insulin 
resistance and restored the pancreatic morphology to near normal in diabetic animals. In one of our 
previous studies, the XAAF was also found to possess high in vitro anti-oxidative activity (data not 
shown) in addition to other studies conducted on the crude extracts of X. aethiopica fruit (Adefegha and 
Oboh, 2012a; 2011; Etoundi et al. 2010; Odukoya et al. 2005; George and Osiama, 2011). Therefore, 
we may propose that the protection of the pancreatic islets morphology could be mediated through the 
anti-oxidant potentials because oxidative stress is the major causal factor for the pancreatic β-cell 
damage inT2D (Huang et al. 2011). Interestingly, the above hypothesis was further supported by the 
significant attenuation of the serum fructosamine level in diabetic treated animals (Table 4.8). The 
reduction of serum fructosamine level by XAAF is an indication of decrease in protein glycosylation, a 
major contributor to the production of advanced glycation ends products in diabetic condition.  
In consistent with the earlier reports, the absolute liver weight was not affected but the relative 
liver weight and liver glycogen content were significantly increased by the induction of diabetes (Clore 
et al. 1992; Oliveira et al. 2008). The elevation of hepatic glycogen content could possibly be linked to 
the fructose feeding that triggers hepatic glycogenesis via stimulation of glucose-6-phosphatase activity 
and cause higher accumulation of glycogen in the liver despite low circulating insulin (Ciudad et al. 
1988). However, these effects were completely attenuated to near normal in DXAH and DXAL groups 
and were comparable to DMF group (Table 4.9). This suggests that, XAAF may modulate glycogen 
biosynthesis by suppressing the activity of glucose-6-phosphatase through a reduction in glucose-6-
phosphate/ATP ratio and therefore, decreases the hepatic glycogen synthesis and storage as well. 
Though the diabetic treated animals have shown insulinotropic ability, which invariably mobilize 
hepatic glucose input for glycogenesis, the hepatic glycogen level was maintained within the normal 
range. This has demonstrated that treatment of XAAF to diabetic animals restored the normal metabolic 
processes altered by the induction of diabetes, which was further supported by the anti-hyperlipidemic 
effect of XAAF (Table 4.10). 
Considerable evidence has been accumulated to correlate insulin resistance in the etiology of 
dyslipidemia in T2D. It has been postulated that the insulin resistance stimulate lipolysis from the fats 
depots, which promote the activity of HMG-CoA reductase and decrease lipoprotein lipase, which lead 
to the elevation of TG and TC levels (De Silva and Frayling, 2010; Hotamisligil, 2000). In a previous 





for 2 weeks exhibited hypolipidemic action (Johnkennedy et al. 2011). Moreover, Adefegha and Oboh 
(2012a) also reported similar findings when X. aethiopica fruit (2% and 4%) was included in the diet 
of the same animal model and for the same period of time. In another study, administration of X. 
aethiopica aqueous extract (250 mg/kg bw) for 8 weeks demonstrated potent anti-hyperlipidemic effect 
in hypercholesterolemic rats (Nwozo et al. 2011). Conversely, in a more recent study, Etoundi et al. 
(2013) have shown that ethanolic extract (400 mg/kg bw) did not show any significant anti-
hyperlipidemic action after 2-day post-treatment period in hyperlipidemic rats. However, in our study, 
the X. aethiopica fruit acetone fraction showed potent anti-hyperlipidemic ability with no alterations in 
serum lipid profile of NXAH group (Table 4.10). Therefore, the lipid-lowering effect of X. aethiopica 
fruit can only be achieved after prolong treatment (sub-chronic or chronic) against the acute treatment 
as recently reported by Etoundi et al. (2013). In addition, the anti-hyperlipidemic action of XAAF 
observed in our present study could be attributed to the reduction of insulin resistance in the diabetic 
treated animals.  
On the other hand, Etoundi et al. (2013) have also reported the hepato-protective ability of X. 
aethiopica fruit (400 mg/kg bw) in hyperlipidemic rats via reduction of serum ALT and AST levels in 
the treated animals. Additionally, no significant alterations of serum ALT, AST and ALP were observed 
in non-diabetic animals treated with X. aethiopica fruit (3% and 4%) in diet for 2 weeks (Adefegha and 
Oboh, 2012a). This was apparently in line with our present data (Table 4.11). Treatment of the fraction 
protects the integrity of the liver as well as heart via reductions of serum ALT, ALP, urea, creatinine, 
LDH and CK-MB in the treated diabetic animals. The serum AST was found not to be affected by the 
diabetes throughout the study period. In comparison with ALT, AST is less specific for the detection of 
hepatic injury due to its shorter half-life compared to ALT, particularly in experimental animals (Center, 
2007). 
 
4.3.6 Conclusion  
In conclusion, oral intervention of X. aethiopica fruit acetone fraction (150 and 300 mg/kg bw) 
have demonstrated anti-diabetic actions via improving bw gain, reducing food and fluid intake and 
hyperglycemia, improving glucose tolerance ability, insulin sensitivity, amelioration of pancreatic β-
cell histology and β-cell functions and improving dyslipidemia in T2D model of rats. Hence, our 
findings suggest that acetone fraction derived from X. aethiopica fruit may provide an excellent anti-
diabetic remedy with no considerable side effects. Further clinical study is required to confirm the 
effects in human subjects. The isolation and partial characterization of the active principle from XAAF 




4.4 In vivo anti-oxidant potential of Xylopia aethiopica fruit acetone 
fraction in a type 2 diabetes model of rats 
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4.4.1 Abstract 
Objectives: The present study investigated the in vivo anti-oxidative actions of Xylopia aethiopica 
acetone fraction (XAAF) from fruit ethanolic extract in a type 2 diabetes (T2D) model of rats.  
Methods: T2D was induced in rats by feeding a 10% fructose solution ad libitum for two weeks 
followed by a single intraperitoneal injection of streptozotocin (40 mg/kg body weight(bw)) and the 
animals were orally treated with 150 or 300 mg/kg bw of the XAAF once daily for four weeks.  
Results: After four weeks of intervention, diabetic untreated animals showed significantly higher levels 
of thiobarbituric acid reactive substances (TBARS) and reductions of reduced glutathione (GSH) in the 
serum and organs (liver, kidney, heart and pancreas) compared to the normal animals. The activities of 
endogenous anti-oxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and 
reductase) were greatly impaired in in the serum and organs of diabetic untreated animals compared to 
the normal animals. These alterations were reverted to near-normal after the treatment of XAAF, 
especially at the dose of 300 mg/kg bw.  
Conclusion:  The results of our study suggest that XAAF treatment at 300 mg/kg bw showed potent 
anti-oxidative action in a T2D model of rats. 
 
Keywords: Xylopia aethiopica, Anti-oxidant, acetone fraction, Fruit ethanolic extract, Type 2 diabetes, 
Rats. 
 
4.4.2 Introduction  
Recently, tremendous evidences are available, correlating the cellular injury arising from ROS 
in the etiology of some diseases such as Alzheimer disease, inflammation, viral infections and T2D 
(Kroner, 2009; Atawodi, 2005; Rahimi et al. 2005). In T2D, the mechanisms involve in hyperglycemia-
induced cellular and tissue damages have been previously described (Sabu and Kuttan, 2002; Boynes, 
1991; Collier et al. 1990). This condition causes a depletion of in vivo anti-oxidant defense system and 




overall in vivo defense system, the increased intake of anti-oxidants cannot be underestimated. 
Interestingly, within the last two decades, there has been an upsurge of interest in the utilization of 
natural anti-oxidants present in plants such as Xylopia aethiopica (Dunal) A. Rich. (Annonaceae)  in 
attenuating the deleterious ROS-induced tissue damage (Sangeetha et al. 2011). 
X. aethiopica also known as Ethiopian pepper is an indigenous spice widely distributed in 
almost all parts of Africa (Iwu, 2014). In some previous studies, extracts derived from the X. aethiopica 
fruit have showed potent anti-oxidative activity using various in vitro models (Adefegha and Oboh, 
2012a,c; 2011; Etoundi et al. 2010; Odukoya et al. 2005; George and Osiama, 2011). In another study, 
the seed aqueous extract was reported to exhibit hypolidemic and anti-oxidant actions in 
hypercholesterolemic rats (Nwozo et al. 2011). In addition, our recent investigation have shown that X. 
aethiopica acetone fraction (XAAF) from fruit EtOH extract demonstrated anti-oxidative potential in 
vitro, ameliorated β-cell dysfunction and decreased blood glucose levels in a T2D model of rats 
(Mohammed and Islam, 2015; Unpublished work). Therefore in order to fully validate the anti-diabetic 
action of XAAF, our present study investigate the effect of XAAF in attenuating hyperglycemia-
induced alterations on the in vivo anti-oxidant defense system in type 2 diabetic animals.  
 
4.4.3 Materials and methods 
For sample collection, identification and preparation of the fraction, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.5.1 to 2.5.8.  
 
4.4.4 Results 
The data of the lipid peroxidation, expressed as malondialdehyde (MDA) concentration of the 
serum and organs (liver, kidney, heart and pancreas) of all the groups are presented in Figure 4.20. 
According to the results, the MDA concentration of diabetic control (DBC) group has significantly (p 
< 0.05) increased in the serum, liver, heart and pancreas compared to the NC group. Additionally, the 
elevation of MDA level in the kidney of the the DBC group was not significantly (p < 0.05) affected 
by the diabetes (Figure 4.20). However, oral administration of XAAF has significantly (p < 0.05) 
reduced the MDA levels in the serum, liver and pancreas of the DXAL and DXAH groups, comparable 
to the DMF group. The reduction of MDA in the kidney and heart of the diabetic treated groups was 





Figure 4.20. Serum and organs thiobarbituric acid reactive substances of all animal groups at the end of the intervention 
period. Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DXAL, Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, 
Diabetic Metformin; NXAH, Normal X. aethiopica high dose; MDA, Malondialdehyde. 
    
The results of the reduced glutathione (GSH) concentrations of the serum and organs of all the 
groups are presented in Figure 4.21. The concentration of GSH in the serum, liver and pancreas was 
significantly (p < 0.05) decreased in the DBC group compared to the NC group, when the reduction in 
kidney and heart was not statistically difference (p < 0.05) compared to the NC group (Figure 4.21). 
Oral treatment of the fraction in the DXAH group significantly (p < 0.05) increased the levels of GSH 
in the serum, liver and pancreas compared to the DBC group (Figure 4.21). Furthermore, the increase 
of GSH was not greatly affected in in the kidney and heart of the diabetic treated groups compared to 






Figure 4.21. Serum and organs reduced glutathione (GSH) content in all animal groups at the end of the study period. Data 
are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are significantly 
different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, 
Diabetic Control; DXAL, Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, Diabetic 
Metformin; NXAH, Normal X. aethiopica high dose; GSH, Reduced glutathione. 
 
The results of the activity of superoxide dismutase (SOD) of serum and organs of all the groups 
are presented in Figure 4.22. It was observed from the results that the activity of SOD in serum and 
organs of the DBC group was significantly (p < 0.05) decreased. After oral intervention of XAAF for 
4 weeks, the activity of SOD significant (p < 0.05) increased in the serum and organs of the DXAH 
group compared to the DBC group (Figure 4.22). In addition, the activity of SOD in the liver of the 
NXAH group was significantly (p < 0.05) increased compared to the NC group (Figure 4.22). 
 
Figure 4.22. Superoxide dismutase (SOD) activities in the serum and organs of different animal groups at the end of the study 
period. Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DXAL, Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, 




 The results of catalase activity in serum and organs of all the groups are presented in Figure 
4.23. According to the data, the activity of the catalase in the serum and organs was significantly (p < 
0.05) decreased in the DBC group compared to the NC group. However, administration of XAAF to 
diabetic animals significantly (p < 0.05) increased the activity of catalase in the organs, when the 
increased in serum was did not differ significant (p < 0.05) compared to DBC group (Figure 4.23).  
 
 
Figure 4.23. Catalase activities in the serum and different organs of different animal groups at the end of the study period. 
Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DXAL, Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, 
Diabetic Metformin; NXAH, Normal X. aethiopica high dose. 
 
The results of the activity of glutathione peroxidase (GPx) in serum and organs of all the groups 
are presented in Figure 4.24. The activity of the GPx in the serum and organs was significantly (p < 
0.05) decreased in the DBC group compared to the NC group. Treatment of XAAF especially in the 
DXAH group significantly (p < 0.05) increased the GPx activity comparable to the DMF group (Figure 
4.24). The activity of GPx in the serum and organs of the NXAH group was altered within the study 





Figure 4.25. Glutathione peroxidase activities in the serum and organs of different animal groups at the end of the study period. 
Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letters over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DXAL, Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, 
Diabetic Metformin; NXAH, Normal X. aethiopica high dose. 
 
  The data of glutathione reductase (GR) activity in the serum and organs of all the groups are 
presented in Figure 4.25. The activity of this enzyme was not affected by the diabetes in the kidney and 
heart, whereas significantly (p < 0.05) decreased in the serum, liver and pancreas of the DBC group 
compared to NC group (Figure 4.25). However, oral administration of the XAAF especially in the 
DXAH significantly (p < 0.05) and dose-dependently increased in activity of GR in serum, liver, 
kidney and pancreas, when in the eart the effect was not statistically different from the DBC group 
(Figure 4.25). In addition, treatment of XAAF had significantly (p < 0.05) increased the activity of GR 
in the liver, kidney and heart of NAMH compared to the NC group (Figure 4.25).      
 
Figure 4.25. Glutathione reductase activities in the serum and organs of different animal groups at the end of the study period. 
Data are presented as the mean ± SD of 5-7 animals. a-dValues with different letter over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DXAL, Diabetic X. aethiopica low dose; DXAH, Diabetic X. aethiopica  high dose; DMF, 





In a previous study, Nwozo et al. (2011) have reported that administration of X. aethiopica 
aqueous extract (250 mg/kg bw) for 8 weeks decrease MDA level in the serum, liver and kidney of 
hypercholesterolemic rats. This is in line with the result of our present study and was similarly observed 
in the heart and pancreas of the diabetic treated animals (Figure 4.20). Additionally, the result is 
promising even at the lower dose (150 mg/kg bw) of XAAF used in our present study. Lipid 
peroxidation manifested due to impair lipid metabolism plays a crucial role in the pathogenesis of 
cellular damage in T2D (Fenercioglu et al. 2010; Memısogullari et al. 2003). Therefore, the potent 
reduction of MDA levels after treatment of XAAF indicated the ability of the XAAF in modulating 
diabetes-induced cellular injury and oxidative stress as well. The data was further supported by the 
increase in reduced glutathione (GSH) levels of the diabetic treated animals (Figure 4.21). 
GSH is an important cellular anti-oxidant biomolecule that prevents the oxidative damage by 
alleviating the ROS mediated lipid peroxidation (Rahimi et al. 2005). Previously, treatment of X. 
aethiopica fruit aqueous extract at 250 mg/kg bw for 8 weeks to hypercholesterolemic rats was reported 
to elevate serum GSH level to near normal (Nwozo et al. 2011). This again accord with the result of our 
present study, when the effect was more pronounced in the DXAH group than DXAL group (Figure 
4.21). The increase of GSH concentrations in the serum and organs of diabetic treated animals might 
be due to the reduction of lipid peroxidation highlighted above. This also shows that the ratio of 
GSH/GSSG greatly improved in diabetic treated groups than in the DBC group, which was further 
supported by improved activity of superoxide dismutase (Figure 4.22). 
The termination of the deleterious effect of superoxide radical is achieved in a reaction 
catalyzed by superoxide dismutase (SOD) to less harmful hydrogen peroxide (Sati et al. 2010). 
Moreover in a study by Nwozo et al. (2011), the SOD activity was observed to greatly improve after 8 
weeks treatment of X. aethiopica fruit aqueous extract (250 mg/kg bw) in hypercholesterolemic rats. 
However in our present study, when the dose was increased to 300 mg/kg bw and treated for 4 weeks, 
the activity of SOD in the DXAH group was even comparable to the NC group (Figure 4.22). This 
indicates that the higher dose of XAAF can shown better activity in a shorter period of time, when no 
alteration in the SOD activity was observed in the NXAH group.  
Furthermore, in the same study by Nwozo et al. (2011), daily treatment of X. aethiopica fruit 
aqueous extract (250 mg/kg bw) to hypercholesterolemic rats increased the catalase activity in the 
serum, liver and kidney. This is also in line with our present data, when the catalase activity in the 
organs of the DXAL group was even comparable to the NC group. Interestingly, the catalase activity in 
the serum and organs correlate well with the activity of SOD, as these enzymes mostly work closely to 
attenuate the oxidative damage mediated by lipid peroxidation (Figure 4.23). 
On the other hand, the decrease in the activities of glutathione dependent enzymes; GPx and 




concentration (Memısogullari et al. 2003). Treatment of XAAF revealed positive response and 
attenuated the reduction of GPx and GR activities of the diabetic treated groups to near normal (Figure 
4.24 and Figure 4.25).This reflects the potency of the XAAF in ameliorating oxidative stress associated 
with T2D. 
 
4.4.6 Conclusion  
Oral administration of XAAF especially at higher dose showed excellent anti-oxidant activity 
via reduction of lipid peroxidation, increasing glutathione levels and endogenous anti-oxidants enzymes 
in serum and organs mostly affected by diabetic-complications. Therefore, XAAF is a good anti-oxidant 
agent with no considerable side effects. Further clinical study is required to confirm its efficacy in 






























5.0 In vitro and in vivo anti-diabetic and anti-oxidative effects of 
various extracts and fractions from the different parts of Capsicum 
annuum 
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5.1.1 Abstract  
Objective: Capsicum annuum L. is widely consumed as spice worldwide and is endowed with abundant 
medicinal properties. The present study examined the anti-oxidative as well as anti-diabetic effects of 
various solvent extracts from fruit, leaf and stem of Capsicum annuum L. using various in vitro models.  
Methods: The plant samples were sequentially extracted using solvents of increasing polarity and 
investigated for 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging activities, total reducing 
power, inhibition of hemoglobin glycosylation, α-amylase and α-glucosidase activities as markers of in 
vitro anti-diabetic effects.  
Results: Our results showed that fruit and leaf ethanolic (EtOH) extracts exhibited significantly (p < 
0.05) higher total polyphenols and flavonoids contents with greater anti-oxidative and anti-diabetic 
actions, when that of fruit EtOH extract showed higher activity compared to the leaf EtOH extract. 
Furthermore, various solvent extracts from the stem part showed no ant-diabetic effect. The GC-MS 
analysis of the most active extracts (fruit and leaf EtOH) revealed the presence of phenolic compounds 
such as phenol-4-methyl, gingerol, Phenol, 2-methoxy-4-(2-propenyl)-, and eugenol acetate.  
Conclusion: The EtOH fruit extract exhibited strong anti-oxidative and anti-diabetic effects compared 
to other solvent extracts and thus recommended for further studies to confirm these effects in-vivo 






Oxidative modifications are crucial for the survival of cells. A side effect of this process is the 
increased reactive oxygen species (ROS) production (Winrow et al. 1993). ROS are normal products of 
biochemical reactions, capable of oxidizing cellular and tissue molecules (Cui et al. 2004). Increase 
production of ROS and depletion of endogenous defense system lead to oxidative stress, and this has 
been observed in several metabolic disorders, such as obesity, atherosclerosis and type 2 diabetes (T2D) 
(Atawodi, 2005). In T2D, oxidative stress is a major contributor to the pancreatic β-cell failure and the 
overproduction of ROS usually occurs via but not limited to; protein kinase C dependent activation of 
NADH/NADPH oxidase (Inoguchi et al. 2003), increased flux of glucose through the polyol pathway 
(Brownlee, 2001), increased formation of advanced glycation end products (AGEs) and their receptors 
(Giocco and Brownlee, 2010) and over activity of the hexosamine pathways (Ceriello and Testa, 2009). 
Therefore, in the context of T2D, oxidative stress can also be regarded as a trigger of postprandial 
hyperglycemia which is a prime target for the control of T2D (Ademiluyi and Oboh, 2013; Brownlee, 
2005).  
There are several approaches employed to control the postprandial hyperglycemia in T2D, 
among such strategy is by delaying the activities of α-amylase and α-glucosidase, which are key 
enzymes involved in the digestion of carbohydrates and absorption of glucose in the small intestinal 
tract (Tucci et al. 2010; Ortiz-Andrade et al. 2007). Therefore, inhibition of these enzymes will limit 
the absorption of glucose to bloodstream and hence, achieved in reduction of hyperglycemia in T2D. 
However, the major drawback to this is the unwanted side effects associated with the use of the 
conventional α-glucosidase inhibitors, such as acarbose and miglitol (Fujisawa et al. 2005). This cause 
a shift to look for option from natural products that pose limited adverse consequences. Furthermore, 
convincing evidences are now available that strongly correlate inhibitory effects of α-amylase and α-
glucosidase by the plant-derived products (Xiao et al. 2013a,b; Rastija et al. 2012; Hsieh et al. 2010; 
Hanhineva et al. 2010), which again have reported to possess high anti-oxidant actions as well (Sati et 
al. 2010; Rahimi et al. 2005; Chanwitheesuk et al. 2005).   
In view of this, there is a growing interest in T2D therapy and control by natural anti-oxidants 
from plants source capable of decreasing the production of ROS as well as delaying glucose absorption 
at intestinal tract. Among such species endowed with tremendous potentials is Capsicum annuum L. It 
belongs to Solanaceae family and is readily available in almost all parts of the world. The fruit is widely 
consumed in vast quantities as flavoring agent in various traditional foods (Khan et al. 2014), and also 
used as a blood tonic, stimulant and in the treatment of nerve weakness due to diabetes in some parts of 
Africa and Asia (Iwu, 2014; Jayakumar et al., 2010).   
Previous studies have demonstrated that C. annuum fruit possessed high polyphenolic contents 
and strong anti-oxidative activities (Deepa et al. 2007; Ghasemnezhad et al. 2011; Chen et al. 2012; 




oxidative effects of C. annuum fruit in vitro (Tundis et al. 2013; Tundis et al. 2011; Kwon et al. 2007). 
Furthermore, Kim et al. (2011) reported the anti-radical scavenging effect of fruit and leaf, when the 
detail anti-oxidant and anti-diabetic actions of leaf and stem of C. annuum have not yet been conducted. 
Additionally, to our knowledge no study is available that investigated and compared the anti-oxidative 
and anti-diabetic effects of C. annuum fruit, leaf and stem in a single study either in vitro or in vivo. 
Therefore, this study is aimed to investigate and compare the anti-oxidative and anti-diabetic effects of 
the various solvent extracts from fruit, leaf and stem of C. annuum. In addition, possible phytochemicals 
content in the most active extract (s) were also analyzed by using GC-MS. 
 
5.1.3 Materials and methods 
For sample collection, identification and preparation of the extracts, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.4.  
 
5.1.4 Results  
 The results on the yield recovered, polyphenols and flavonoids contents of various solvent 
extracts from different parts of C. annuum are presented in Table 5.1. According to the data, aqueous 
extracts from different parts of C. annuum have recovered greater yield compared to other solvent 
extracts. It was also observed that ethanolic (EtOH) extracts showed significantly (p < 0.05) higher 
total polyphenols and flavonoids contents compared to other solvent extracts with fruit EtOH extract 
containing the highest amount (Table 5.1).  
 
Table 5.1: Percentage yield, total polyphenol and flavonoid contents of various solvent extracts of C. 
annuum parts 




Fruit    
Ethyl acetate 0.23 5.34 ± 0.29d 2.15 ± 0.31b 
Ethanol 1.73 19.75 ± 0.59f 9.94 ± 0.53d 
Aqueous 4.70 1.40 ± 0.11b,c 0.15 ± 0.03a 
Leaf    
Ethyl acetate 1.60 1.91 ± 0.01c   0.58 ± 0.11a 
Ethanol 2.25 14.11 ± 0.07e 5.33 ± 0.40c 
Aqueous 3.00 1.78 ± 0.08c 0.11 ± 0.08a 
Stem    
Ethyl acetate 0.15 ND ND 
Ethanol 0.30 0.98 ± 0.05b 0.15 ± 0.02a 
Aqueous 3.75 0.14 ± 0.04a 0.13 ± 0.03a 
Data are presented as mean ± SD of triplicate determinations. a-f Different superscripted letters for a given value within a 




The data of the ferric (Fe3+) ion reducing anti-oxidant potential of various extracts from C. 
annuum are presented in Figure 5.1. It was observed from the results that fruit and leaf EtOH extracts 
have demonstrated significantly (p < 0.05) higher reducing potentials compared to other solvent extracts 
from the same or different parts of C. annuum. Again the reducing ability of the fruit EtOH extract was 
higher compared to the leaf EtOH extract, when the EtOAc extracts from the fruits and leaf showed 
reducing ability which was significantly (p < 0.05) higher compared to the aqueous extracts (Figure 
5.1). Additionally, various solvent extracts from stem part exhibited no reducing potential at different 





Figure 5.1. Ferric reducing power (relative to gallic acid) of fruit (A) and leaf (B) extracts of C. annuum. Data are presented 
as mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract 





The data of DPPH radical scavenging activities of various parts of C. annuum are presented in 
Figure 5.2 and Table 5.2. Various extracts showed variable DPPH radical scavenging activities. Fruit 
and leaf EtOH extracts significantly (p < 0.05) exhibited lower IC50 values compared to other extracts, 
when that of the fruit had the least IC50 value (0.03 ± 0.01 mg/mL). The activities of the fruit and leaf 
EtOH extracts were comparable to that of the standards (Ascorbic acid: 0.03 ± 0.02 mg/mL; Gallic acid: 
0.05 ± 0.01 mg/mL) used in this study (Table 5.2). It was also observed that stem ethyl acetate (EtOAc) 
showed lower IC50 value compared to other extracts from this part (Table 5.2).  
 














Fruit     
Ethyl acetate 0.59 ± 0.05b 10.04 ± 1.48c 1.57 ± 0.04c 17.52 ± 2.83e 
Ethanol 0.03 ± 0.01a 0.22 ± 0.02a 0.15 ± 0.01a 0.05 ± 0.02a 
Aqueous 1.31 ± 0.20c 9620.74 ± 50.69e 0.94 ± 0.07c 32386.4 ± 228.79f 
Leaf     
Ethyl acetate 0.32 ± 0.01b 4.21 ± 0.04b 300.13 ± 101.53d 4.16 ± 0.25d 
Ethanol 0.09 ± 0.01a 0.30 ± 0.01a 0.29 ± 0.01a,b 2.06 ± 0.04c 
Aqueous 2.35 ± 0.27d 49.92 ± 28.86d 27100.5 ± 1450.35e 16.22 ± 0.16e 
Stem     
Ethyl acetate 5.98 ± 0.62e ND ND ND 
Ethanol 222.62 ± 36.28g  ND ND ND 
Aqueous 111.23 ± 32.36f ND ND ND 
Ascorbic acid 0.03 ± 0.02a ND ND ND 
Gallic acid 0.05 ± 0.01a 0.20 ± 0.01a ND ND 
Acarbose ND ND 0.37 ± 0.03b 0.21 ± 0.01b 
Data are presented as mean ± SD values of triplicate determinations. a-g Different superscript letters presented within a column 








Figure 5.2. DPPH Radical scavenging activity (%) of fruit (A), leaf (B) and stem (C) extracts of C. annuum. Data are presented 
as mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract 




The results of inhibition of hemoglobin glycosylation of various solvent extracts from C. 
annuum are presented in Figure 5.3 and Table 5.2. In a similar pattern with the previous anti-oxidative 
parameters, fruit and leaf EtOH extracts demonstrated significantly (p < 0.05) the least IC50 values 
(fruit: 0.22 ± 0.02 mg/mL; leaf: 0.30 ± 0.01 mg/mL) compared to other solvent extracts that were not 
significantly (p < 0.05) difference from that of gallic acid (0.20 ± 0.01 mg/mL). The degree of inhibitory 




Figure 5.3. Inhibition of hemoglobin glycosylation (%) of fruit (A) and leaf (B) extracts of C. annuum. Data are presented as 
mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract 




The results of the inhibitory effect of α-amylase action of various solvent extracts from C. 
annuum are presented in Figure 5.4 and Table 5.2. According to the data, EtOH extract derived from 
the fruit have exhibited lower IC50 value (0.15 ± 0.01 mg/mL) compared to other extracts of the same 
or different parts as well as acarbose. Various extracts from the stem part have shown no inhibitory 




Figure 5.4. The α-amylase inhibition (%) of fruit (A) and leaf (B) extracts of C. annuum. Data are presented as mean ± SD of 
triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract are significantly 





The data of the inhibitory effect towards α-glucosidase action of various solvent extracts from 
C. annuum are presented in Figure 5.5 and Table 5.2. Interestingly, fruit EtOH extract had 
demonstrated significantly (p < 0.05) lower IC50 value (0.05 ± 0.02 mg/mL) compared to other extracts 
from the same or different parts and acarbose (0.21 ± 0.01 mg/mL) as well (Table 5.2). The pattern of 
inhibition of the fruit and leaf extracts were in the decreasing order of EtOH> EtAOc> aqueous. 
Additionally, various solvent extracts from stem part exhibited no inhibitory effect towards α-glucoside 




Figure 5.5. The α-Glucosidase inhibition (%) of fruit (A), leaf (B) and stem (C) extracts of C. annuum. Data are presented as 
mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration of each extract 
are significantly different from each other (Tukey’s HSD multiple range post hoc test, p < 0.05). 




The results of the GC-MS analyses of the most active extracts (fruit and leaf EtOH extracts) are 
presented in Table 5.3, Figures 5.6 and 5.7. The major peaks detected from the chromatogram of the 
fruit EtOH extract correspond to phenol 4-methyl (1), eugenol (2), caryophyllene (3), eugenol acetate 
(4), 4-(4-hydroxy-3-methoxyphenyl)-butanone (5), 1, 2-benzenedicarboxylic acid, butyl 2-
methylpropyl ester (6), 9-octadecenoic acid (7), 1-(4-hydroxy-3-methoxyphenyl)- 3-decanone (8), 
gingerol (9) and capsaicin (10) (Table 5.3, Figures 5.6A and 5.7). On the other hand, the based on the 
chromatogram of leaf EtOH extract, the major peaks tha correspond to the NIST library include; 
eugenol (2), tetradecanoic acid (11), dibutyl phthalate (12) and 1,2-benzene dicarboxylic acid, mono(2-
ethylhexyl) ester (13) (Table 5.3, Figures 5.6B and 5.7). 
 
 






Table 5.3: Identified compounds from the EtOH fruit, leaf and stem extracts of C. annuum by GC-MS 
Extracts Compounds Retention time (min) Mass/amu 
EtOH fruit    
1 Phenol, 4-methyl 4.44 107 [M]+ 
2 Eugenol 6.67 164 [M]+ 
3 Caryophyllene 7.22 204 [M]+ 
4 Phenol, 2-methoxy-4-(2-
propenyl)-acetate 
7.72 206 [M]+ 
5 4-(4-Hydroxy-3-
methoxyphenyl)- butanone 
8.57 194 [M]+ 
6 1,2-Benzenedicarboxylic 
acid, butyl 2-methylpropyl 
ester 
10.26 214 [M]+ 




11.63 278 [M]+ 
9 Gingerol 12.12 294 [M]+ 
10 Capsaicin 13.08 308 [M]+ 
EtOH leaf    
2 Eugenol 6.67 164 [M]+ 
11 Tetradecanoic acid 9.14 228 [M]+ 
12 Dibutyl phthalate 10.26 278 [M]+ 
    
13 1,2-Benzene dicarboxylic 
acid, mono(2-ethylhexyl) 
ester 










                                        





 In our present study, we have investigated and compared the anti-oxidative and anti-diabetic 
effects of various solvent extracts derived from different parts of C. annuum. This is the first study that 
systematically compared the activities of different parts (fruit, leaf and stem) of C. annuum in a single 
study, despite several studies that reported the anti-oxidative and anti-diabetic effects of C. annuum in 
vitro.  
The polyphenols and flavonoids contents of C. annuum fruit and leaf parts have been previously 
studies in a number of studies. Kim et al. (2011) highlighted that the polyphenolic and flavonoid 
contents of the EtOH extracts from the leaf were higher than the fruit part of C. annuum cultivated in 
Korea, which contradict our present data. This could partly be due to some genetic and environmental 
(nature of the soil, high temperature and rain fall) factors in addition to growth and maturation stages 
of the C. annuum parts (Mamphiswana et al. 2010; Pandey and Rizvi, 2009). To support our present 
data, several studies have reported the fruit EtOH extract to contain greater amount of polyphenols and 
flavonoids (Tundis et al. 2013; Deepa et al. 2007; Perucka and Materska, 2007; Materska and Perucka, 
2005). Furthermore, our present results have further support the fact that EtOH is basically the best 
solvent for proper extraction of polyphenols and other related compounds, which has been observed 
across all the parts (fruit, leaf and stem) used in our current study (Table 5.1). It was also observed that 
C. annuum leaf could be a potential source of polyphenols and flavonoids, which in most of the time is 
considered as wasted vegetable.  
In assessing the anti-oxidant status of plants species, several in vitro models were developed. 
In our present study, the in vitro methods used include the ferric (Fe3+) reducing power, DPPH radical 
scavenging ability as well as the inhibition of hemoglobin glycosylation. Deepa et al. (2007) have 
reported that fruit EtOH extracts of C. annuum obtained at different stages of maturation, have 
demonstrated variable Fe3+ to Fe2+ reducing potentials. This was similarly observed in our present data 
(Figure 5.2). Therefore, although no correlation analysis was carried out in our present study, it might 
be suggested that the Fe3+ to Fe2+ reducing potential is correlated to the polyphenols and flavonoids 
contents, which is in line with a previous published data (Pulido et al. 2000). The result was further 
supported by the DPPH radical scavenging activity by the various extracts from C. annuum (Table 5.2).  
The DPPH radical scavenging activity of various solvent extracts from the fruit of C. annuum 
has been extensively reported (Azeez et al. 2012; Chen et al. 2012; Tundis et al. 2011; Perucka and 
Materska, 2007; Conforti et al. 2007; Kwon et. 2007). In some of these studies, fruit methanolic extract 
had exhibited IC50 values of 1.15 mg/mL and 0.13 mg/mL for DPPH scavenging activity (Azeez et al. 
2012; Conforti et al. 2007). Similarly, Tundis et al. (2011) and Kim et al. (2011) have also reported an 
IC50 value of 0.15 mg/mL for fruit EtOH extract, when that of leaf EtOH extract was 0.46 mg/mL. 
However, in our present results, the IC50 values recorded for the DPPH scavenging was lower for the 




reported data (Table 5.2). The higher activity of fruit over the leaf and stem parts observed in our 
present study indicated the greater amounts of active ingredients that could scavenge and terminate the 
oxidative damages of ROS (Miladi and Demak, 2008; Manach et al. 2004). 
 Furthermore, increased protein glycation contributes significantly to the progression and 
manifestation of diabetic complications (Calisti and Tognetti, 2005). The glycation process involves a 
cascade of reactions and rearrangements between reducing sugars and proteins which ultimately forms 
AGEs (Rahbar and Figarola, 2002). Hence, inhibitors of this process could play a crucial role in the 
prevention of T2D associated complications. In our present study, fruit EtOH extract maintained higher 
anti-oxidative nature by exhibiting the lower IC50 value (0.22 ± 0.02 mg/mL) toward hemoglobin 
glycation, indicating higher activity compared to other solvent extracts. Interestingly, leaf EtOH extract 
also showed similar inhibition of glycosylation with fruit EtOH extract (Table 5.2). This could possibly 
be utilized and will reduce the over usage of fruit for nutritional and medicinal purposes.   
On the other side, inhibitors of carbohydrate hydrolyzing enzymes are recently being utilized 
as therapeutic targets in prevention and control of T2D and its associated complications (Tucci et al. 
2010; Ortiz-Andrade et al., 2007). However, the major glucosidase inhibitors, acarbose and miglitol, 
were reported to cause abdominal distension, flatulence, bowel necrosis and diarrhea (Fujisawa et al. 
2005). This paves way for search of inhibitors from plants origin. Furthermore, the α-amylase and α-
glucosidase inhibitory effects of various extracts from the fruit of C. annuum have been reported 
(Tundis et al. 2013; 2012; Kwon et al. 2007). Tundis et al. (2012) have reported that fruit EtOH extract 
is a potential inhibitor of α-amylase (IC50: 0.26 mg/mL) and α-glucosidase (IC50: 0.36 mg/mL) actions. 
However, when compared to our data, the calculated IC50 values for α-amylase and α-glucosidase 
inhibitory effects are lower, which could be the least reported for fruit of C. annuum (Table 5.2). 
Additionally, the observed higher α-glucosidase inhibitory action of the fruit EtOH extact over α-
amylase action is of enormous importance. This is because some of the unwanted effects attributed with 
the currently utilized drugs are linked to strong inhibition of α-amylase effect (Ademiluyi and Oboh, 
2013). Moreover, the better inhibitory effect of the fruit extracts than leaf extracts is an indication of 
the greater availability of the inhibitors in fruit compared to leaf part.  
Based on the higher anti-oxidative and anti-diabetic effects of fruit and leaf EtOH extracts, the 
GC-MS analysis was carried out to identify major possible phytochemicals present. It was observed 
that most of the compounds detected were phenolics in nature with some long chain fatty derivatives. 
Phenolics and other related compounds are known to directly or indirectly contribute to the anti-
oxidative and enzyme inhibitory actions of various plant-derived products (Mai et al. 2007). Therefore, 
without the exclusion of the possible contribution of other compounds present in the two extracts, the 







In conclusion, various solvent extracts from fruit and leaf possessed potent anti-oxidative and 
anti-diabetic effects in vitro, when the fruit EtOH extracts exhibited the highest. Therefore, bioassay 
guided fractionation and investigation of anti-oxidative and anti-diabetic effects in vivo of most active 

































According to the in vitro anti-oxidative and anti-diabetic studies of the various solvent extracts derived 
from different parts of C. annuum stated above, fruit ethanolic extract demonstrated higher activities 
compared to other extracts. Therefore it was selected for further studies. 
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5.2.1 Abstract 
Objectives: The present study was carried out to investigate the anti-oxidative and inhibition of the 
activities of carbohydrate digesting enzymes by various solvent fractions from crude ethanolic extract 
of C. annuum using various in vitro models.  
Methods: Crude ethanolic extract of fruit was fractionated using hexane, dichloromethane, ethyl acetate 
and acetone. They were subjected and investigated for 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical 
scavenging activity, ferric reducing anti-oxidant power (FRAP), inhibition of hemoglobin 
glycosylation, α-amylase and α-glucosidase activities as markers of in vitro anti-diabetic effects at 
various doses (30-240 µg/ml). Possible bioactive compounds were analyzed using Gas 
Chromatography-Mass Spectrometry (GC-MS) analysis.  
Results: The results indicated that acetone fraction showed significantly (p < 0.05) higher total 
polyphenols and flavonoids contents and recorded lower IC50 values in all the models used (DPPH: 
111.97 ± 2.06 µg/mL; inhibition of hemoglobin glycosylation: 150.64 ± 6.10 µg/ml; -amylase: 803.34 
± 22.18 µg/mL; -glucosidase: 65.11 ± 6.78 µg/mL) compared to other solvent fractions, and also 
demonstrated excellent reducing Fe3+ to Fe2+ power. The phytochemical studies identified six possible 
compounds (tridecanoic acid, 9, 12-octadecadienoic acid, oleic acid, kauran-16-ol, capsaicin and 1, 2-
benzenedicarboxylic acid, mono (2-ethylhexyl) ester) from the acetone fraction. This results clearly 
demonstrates that acetone fraction from C. annuum possesses potent anti-oxidative and inhibition of the 





Keywords: Anti-oxidative, Capsicum annuum, Inhibitory effect, Type 2 diabetes mellitus 
 
5.2.2 Introduction 
In recent time, natural products such as plants are regarded as good source of potential 
therapeutic agents. This is in addition to the fact that a number of widely used modern drugs were 
initially derived from plant source. For instance, the discoveries of metformin (anti-diabetic drug) and 
artemisinin (anti-malarial drug) from Galega officinalis L. and Artemisia annua L., respectively just to 
mention few (Gurib-Fakim, 2006). Similarly, plant-derived formulations or compounds were reported 
to cause limited or no adverse side effects compared to the conventional synthetic drugs (Harvey, 2014). 
In view of this, there is a widespread search for newer chemical lead from plants to treat various diseases 
which may offer better protection with lesser side effects.  
On the other hand, the prevalence of diseases such as type 2 diabetes (T2D) is quite alarming 
globally; reaching epidemic proportion. T2D is characterized by chronic insulin resistance and loss of 
pancreatic β-cell function (Hui et al. 2007). This leads to hyperglycemia, which has been associated 
with increase formation of reactive oxygen species (ROS), and eventually causes oxidative stress 
(Devasagayam et al. 2007). Oxidative stress is a condition of imbalance that exists between pro-oxidants 
and in-vivo anti-oxidant levels in such a way that pro-oxidant production overwhelms anti-oxidant 
defenses (Powers and Jackson, 2008). Moreover, oxidative stress plays a crucial role in the pathogenesis 
of diabetes associated complications such as neuropathy, nephropathy and retinopathy (Azenabor et al. 
2011). Therefore, control of oxidative stress could be a potential strategy to control T2D in addition to 
the inhibition of the activities of carbohydrate digesting enzymes, such as α-glucosidase and α-amylase 
that are currently employed to treat T2D. This process involves retarding the digestion of carbohydrates 
via inhibition of key enzymes; α-glucosidase and α-amylase, which may limit the hydrolysis and 
absorption of glucose in the into the bloodstream (Kawamura-Konishi et al. 2012). Hence, the search 
for natural inhibitors of α-glucosidase and α-amylase activities and ROS scavengers have gradually 
increased to achieve in the proper control of T2D.  
The fruit from Capsicum annuum L. has been a major component of various food preparations 
worldwide. In addition to this, C. annuum fruit has been reported to be an excellent source of vitamins, 
phenolics and other potentially active phytochemicals which are anti-oxidants that may prevent the risk 
of T2D. More importantly, there is sufficient available data that support the anti-oxidative as well as 
anti-diabetic effects of crude extracts of C. annuum in vitro (Tundis et al. 2013; Tundis et al. 2011; 
Kwon et al. 2007). Although not much comparative studies have been conducted using various solvent 
extracts, in most of the reported studies (including ours), fruit ethanolic extract showed promising and 
better activity compared to other solvent extracts (Tundis et al. 2013; 2011; Kim et al. 2011; Deepa et 




anti-diabetic effects from C. annuum, we further partition and fractionate the crude ethanolic extract 
using solvents of increasing polarity in order to find the most potent fraction with higher activities.  
Thus, this study was aimed to investigate the anti-oxidative and inhibition of the activities of 
carbohydrate digesting enzymes in vitro by various solvent fractions from the crude ethanolic extract.   
  
5.2.3 Materials and methods 
For sample collection, identification and preparation of the fractions, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.4.  
 
5.2.4 Results  
The results on yield recovered, total polyphenols and flavonoids contents from the various 
fractions are presented in Table 5.4. It was observed that acetone fraction recovered higher yield 
compared to other solvent fractions while ethyl acetate (EtOAc) fraction was the least recovered. 
Furthermore, the total polyphenols and flavonoids contents of the most polar fractions (EtOAc and 
acetone) were significantly (p < 0.05) higher compared to the less polar fractions (Table 5.4). The 
contents of the acetone fraction were significantly (p < 0.05) higher compared to the EtOAc fraction. 
In addition, the polyphenols and flavonoids contents of dichloromethane fractions and hexane fraction 
were observed not to differ significantly.  
 
Table 5.4: Percentage yield, total polyphenol and flavonoid contents of various fractions from ethanolic 
fruit extract of C. annuum  
Solvent Yield (%) Total polyphenols 
content (mg/gGAE) 
Total flavonoids content 
(mg/gQE) 
Hexane 11.0 1.44 ± 0.06a  0.22 ± 0.06a 
Dichloromethane 6.65 1.14 ± 0.41a 0.55 ± 0.16a 
Ethyl acetate 2.87 6.38 ± 0.06b 2.73 ± 0.06b 
Acetone 14.5 12.66 ± 0.05c 4.77 ± 0.12c 
Data are presented as mean ± SD values of triplicate determinations. a-c Different superscripted letters for a given value within 
a column are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
The data of ferric reducing anti-oxidant power (FRAP) assay is presented in Figure 5.8. From 
the result, a significantly (p<0.05) higher reducing ability was demonstrated by acetone fraction in 
concentration dependent response compared to other fractions, although lower than the standard 
ascorbic acid. It was also observed that the reducing potentials of the remaining solvent fractions were 





Figure 5.8. Total reducing power (relative to gallic acid) of various fractions from fruit ethanolic extract of C. annuum. Data 
are presented as mean ± SD of triplicate determinations. a-d Different letters presented over the bars for a given concentration 
of each extract are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p <0.05).  
 
The data of DPPH scavenging ability of various fractions are presented in Figure 5.9 while the 
extent of inhibition is expressed base on the calculated IC50 values is shown in Table 5.5. Acetone 
fraction demonstrated a significantly (p < 0.05) lower IC50 value (111.97 ± 2.06 µg/mL) for DPPH 
scavenging activity compared to other fractions. The IC50 values for dichloromethane and ethyl acetate 
fractions did not differ significantly (Table 5.5). Similarly, the pattern of inhibition was in the order of 
acetone> dichloromethane> ethyl acetate> hexane, with acetone been the highest.  
 
Figure 5.9. DPPH Radical scavenging activity (%) of various fractions from fruit ethanolic extract of C. annuum. Data are 
presented as mean ± SD of triplicate determinations. a-e Values with different letters presented over the bars for a given 
concentration significantly different from each other extracts. (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
The results of the abilities of the fractions to inhibit hemoglobin glycation are presented in 
Figure 5.10 and Table 5.5. It was observed that acetone fraction exhibited a significantly (p < 0.05) 




acid (199.09 ± 2.85 µg/mL). The extent of inhibitory effects of hexane and EtOAc fractions were found 
not to differ significantly, when dichloromethane fraction was observed to exhibit the highest IC50 value 
(Table 5.5).   
 
Figure 5.10: Inhibition of hemoglobin glycation (%) of various fractions from fruit ethanolic extract of C. annuum. Data are 
presented as mean ± SD of triplicate determinations. a-d Values with different letters presented for a given concentration for 
each extract are significantly different from each other. (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
Table 5.5: IC50 values of various solvent fractions from ethanolic fruit extract of C. annuum in different 











inhibition   
α-glucosidase 
inhibition   
Hexane 1862.88 ± 720.3d 844.84 ± 32.85
c
 8403.23 ± 806.97
e 724.89 ± 95.61d 
Dichloromethane 462.30 ± 14.32c 2127.97 ± 987.21
d
 2798.53 ± 143.65
d 454.01 ± 63.34c 
Ethyl acetate 503.73 ± 7.74
c 503.73 ± 7.70b 2143.46 ± 213.67c 380.31 ± 20.35b,c 
Acetone 111.97 ± 2.06b 150.64 ± 6.10a 164.11 ± 5.28a 65.11 ± 6.78a 
Ascorbic acid 25.34 ± 6.19a ND ND ND 
Gallic acid 20.01 ± 4.42a 199.09 ± 2.85a ND ND 
Acarbose ND ND 374.95 ± 26.81b 211.59 ± 3.39b 
Data are presented as mean ± SD values of triplicate determinations. a-e Different superscripted letters for a given value within 
a column are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). ND, Not determined 
The results of α-amylase inhibition of various solvent fractions from the fruit EtOH extract are 
presented in Figure 5.11 and Table 5.5. Based on the data, the IC50 value demonstrated by the acetone 
fraction (164.11 ± 5.28 µg/mL) for α-amylase inhibition was significantly (p<0.05) lower compared to 




lower compared to dichloromethane fraction, when that of hexane fraction had observed to be the 
highest (Table 5.5).  
 
Figure 5.11: α-Amylase inhibition (%) of various fractions from fruit ethanolic extract of C. annuum. Data are presented as 
mean ± SD of triplicate determinations. a-d Values with different letters presented for a given concentration for each extract are 
significantly different from each other. (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
 
Moreover, the data of α-glucosidase inhibition of various solvent fractions are presented in 
Figure 5.12 and Table 5.5. It was observed that all the fraction have exhibited considerable inhibitory 
effect of α-glucosidase action. The IC50 value demonstrated by the acetone fraction (65.11 ± 6.78 
µg/mL) was significantly (p<0.05) lower compared to other fractions and the acarbose as well. 
Similarly, IC50 values of dichloromethane and EtOAc fractions were found not to differ significantly 
(p<0.05) compared to the acarbose, when that of hexane was the highest (Table 5.5).  
 
Figure 5.12: α-Glucosidase inhibition (%) of various fractions from fruit ethanolic extract of C. annuum. Data are presented 
as mean ± SD of triplicate determinations. a-d Values with different letters presented for a given concentration for each extract 





The results of the kinetics on the inhibitory mode of the α-glucosidase and α-amylase by the 
most active (acetone fraction) are presented in Figure 5.13. According to the results, acetone fraction 
has exhibited a non-competitive inhibition towards α-amylase and α-glucosidase actions. The KM values 
remain unchanged (α-amylase: 0.05 mmol/L; α-glucosidase: 1.0 mmol/L), whereas the values of the 
Vmax were found to decrease (α-amylase:  35.67 µmol/min to 11.18 µmol/min; α-glucosidase: 471.56 
µmol/min to 166 µmol/min). The equilibrium constants for inhibitor binding (Ki) were calculated as 






Figure 5.13: Lineweaver-Burke’s plot of (A) α-amylase and (B) α-glucosidase catalyzed reactions in the presence and in the 
absence of the acetone fraction derived from the C. annuum fruit ethanolic extract. 
 
Based on the results of the above in vitro studies, acetone fraction exhibited the higher activities 
and thus, was subjected to GC-MS analysis to find possible phytochemicals present. The data of 
phytochemical analysis of the acetone fraction are presented in Figure 5.14 and Table 5.6. Six peaks 


















































compared with those present in the NIST library (Figure 5.14A). The compounds were identified as 
tridecanoic acid (1), 9, 12-octadecadienoic acid (2), oleic acid (3), kauran-16-ol (4) and two phenolics 
identified as capsaicin (5) and 1, 2-benzenedicarboxylic acid, mono (2-ethylhexyl) ester (6) (Figure 
5.14B and Table 5.6).  
 
Table 5.6: Identified compounds from the acetone fraction from fruit ethanolic extract of C. annuum 
by GC-MS 
Solvent Compounds Retention time (min) Mass/amu 
Acetone    
1 Tridecanoic acid 10.24 214 [M]+ 
2 9,12-Octadecadienoic acid 10.26 280 [M]+ 
3 Oleic acid 11.11 282 [M]+ 
4 Kauran-16-ol 11.39 290 [M]+ 























                                             
 
                          







Natural products such as plants are now considered as an integral component of health care 
system, particularly in developing countries where most people have limited resources and access to 
modern treatments. In addition, the unwanted adverse effect of most of the modern synthetic drugs for 
treatment of diseases such as T2D is also an issue of concern (Marles and Farnsworth, 1994). However, 
the number of plants with potential anti-diabetic actions is very limited and many of their anti-diabetic 
effects have not yet been scientifically validated. Therefore, our present study is designed to investigate 
the anti-oxidative potentials and inhibition of the activities of α-glucosidase and α-amylase actions by 
various fractions derived from crude EtOH extract of C. annuum fruit in vitro. 
Plant-derived bioactive compounds such as polyphenols and flavonoids are reported to 
scavenge reactive oxygen species (ROS) and also modulate the activities of α-amylase and α-
glucosidase that are crucial in treatment of T2D (Ani and Akhilender, 2008; Pulok et al. 2006; Atawodi, 
2005). The polyphenols and flavonoids contents of different extracts of C. annuum were extensively 
documented (Tundis et al. 2013; Kim et al. 2011; Deepa et al. 2007; Perucka and Materska, 2007; 
Materska and Perucka, 2005). In most of the earlier studies, crude ethanolic extract was reported to 
contain high amount of polyphenols and flavonoids. However, according to our present data, most of 
these compounds were observed to be available in the acetone fraction, which is the most polar fraction 
(Table 5.4). This is due to the greater polarity of acetone compared to other solvents and therefore 
retains most of the polyphenols from the crude extract.       
In complex systems such as living organisms, oxidative stress may arise from different ways to 
cause deleterious effects, which contribute to high levels of ROS (Hinneburg et al. 2006). The ferric 
reducing anti-oxidant power (FRAP) is a method used to assess the anti-oxidant potentials of the plant 
extracts, fractions and/or compounds. The assay depends on the reduction of the Fe3+ to Fe2+ monitored 
by via the formation of Perl’s Prussian blue at 700 nm (Chung et al. 2002). According to our present 
results, acetone fraction showed higher anti-oxidant potential by demonstrating excellent reducing 
power in concentration dependent manner partly correlated to the rich-phenolic its contents (Figure 
5.8).  
The DPPH radical scavenging activity was used to further support the anti-radical action of the 
fractions. It has been highlighted previously that extracts derived from C. annuum fruit have 
demonstrated potent DPPH radical scavenging ability (Azeez et al. 2012; Chen et al. 2012; Tundis et 
al. 2011; Perucka and Materska, 2007; Conforti et al. 2007; Kwon et. 2007). This is in line with the 
results of our present study (Table 5.5). The lower IC50 value for DPPH scavenging ability exhibited 
by the acetone fraction might be attributed to the higher polyphenols and flavonoids contents which are 
known to exert anti-oxidative effects (Sen et al. 2010; Atawodi, 2005).  
Hemoglobin glycation induced by hyperglycemia, is a non-enzymatic reaction that contributes 




complications associated with diabetes (Calisti and Tognetti, 2005). Therefore, inhibitors of AGEs 
formation may prevent and attenuate the progression and development of complications due to 
hyperglycemia. It is evident from our present data that acetone fraction is a potential inhibitor of 
hyperglycemia-induced glycation (Table 5.5). The results accord with the DPPH and FRAP assays as 
described above, which correlate well with the total polyphenols and flavonoids contents of acetone 
fraction that again supported by the α-glucosidase and α-amylase inhibitory actions (Table 5.5).  
The two important carbohydrate-digesting enzymes, α-glucosidase and α-amylase are the key 
enzymes involved in the in the breakdown of dietary carbohydrates. The α-amylase converts starch into 
disaccharides and oligosaccharides, after which α-glucosidase catalyzes the breakdown of disaccharides 
to monosaccharide (glucose) which is subsequently absorbed into bloodstream via small intestinal 
mucos (Tucci et al. 2010; Ortiz-Andrade et al. 2007). Therefore, inhibitors of these enzymes can 
slowdown carbohydrate digestion and increase the overall transit time. This will reduce the rate of 
glucose absorption, which may apparently abrupt the postprandial elevation of blood glucose levels, 
and therefore provide effective approaches in controlling T2D. Interestingly, the α-amylase and α-
glucosidase inhibitory effects of aqueous and ethanolic extracts from the fruit of C. annuum have been 
reported (Tundis et al. 2013; 2012; Kwon et al. 2007). However, when the crude ethanolic extract was 
fractionated, acetone fraction has exerted the highest inhibitions (least IC50 values), which may be due 
to the rich-polyphenolic content of the fraction (Table 5.5).  
The kinetic results have demonstrated that the nature of α-glucosidase and α-amylase 
inhibitions were of non-competitive type (Figure 5.13). This is the first study that report on the mode 
of inhibition of these enzymes by any extracts, fractions or compounds derived from C. annuum. 
Therefore acetone fraction exerts the inhibitory effect toward α-glucosidase and α-amylase actions by 
binding to the enzymes at regions other than active sites and may not be affected by higher amount of 
substrate. This induces some conformational changes in the three-dimensional structure of the enzymes 
that slowdown the activity of the enzymes. 
Based on the higher anti-oxidative and anti-diabetic actions exhibited by the acetone fraction, 
it was subjected to GC-MS analysis to detect possible bioactive compounds present in this fraction. The 
six bioactive compounds detected in the acetone fraction were previously reported to be present in the 
C. annuum fruit (Tundis et al. 2013; Conforti et al. 2007). These compounds may act individually or in 




Conclusively, various solvent fractions from C. annuum fruit exhibited anti-oxidative as well 
as inhibitory effect towards carbohydrates digesting enzymes activities in vitro. The acetone fraction, 




recommended for in vivo anti-diabetic and anti-oxidative effects and to isolate the active principle from 





































Based on the results of the study above, acetone fraction demonstrated higher anti-oxidative action and 
inhibits the activities of carbohydrate digesting enzymes in vitro compared to other solvent fractions. It 
was therefore selected for the in vivo studies. 
 
5.3 Anti-diabetic effects of Capsicum annuum L. fruit acetone 
fraction in a type 2 diabetes model of rats 
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1Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, (Westville 
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5.3.1 Abstract 
Objective: Capsicum annuum L. (Solanaceae) is a spice that is readily available in different parts of 
the world. The fruit is locally used as a blood tonic, stimulant and in the treatment of nerve weakness 
due to diabetes in some parts of Africa and Asia. The present study investigated the anti-diabetic effect 
of C. annuum acetone fraction (CAAF) derived from fruit ethanolic extract in type 2 diabetes (T2D) 
model of rats.  
Methods: T2D was induced in rats by feeding a 10% fructose solution ad libitum for two weeks 
followed by a single intraperitoneal injection of streptozotocin (40 mg/kg body weight (bw)). The 
animals were orally treated with 150 or 300 mg/kg bw of the CAAF once daily for 4 weeks.  
Results: Oral treatment of CAAF for 4 weeks especially at 300 mg/kg bw to diabetic animals 
demonstrated anti-hyperglycemic and anti-hyperlipidemic effects, improved glucose intolerance and 
insulin resistance and restored pancreatic morphology to near normal. Additionally, the alterations of 
other organ related serum markers were ameliorated in the treated diabetic animals compared to diabetic 
control group.  
Conclusion: The results of our study suggest that CAAF possessed potent anti-diabetic effect in a T2D 
model of rats when no toxicological effects were observed for the above-mentioned parameters. Hence, 
CAAF can not only be used as a potential anti-diabetic natural medicine but also can be used to find 
novel compounds to develop anti-diabetic medicine. 
 








Type 2 diabetes (T2D) is a metabolic disorder characterized by chronic insulin resistance and 
loss of functional β-cells due to relative (rather than absolute) deficiency of insulin (ADA, 2015). 
Inadequate secretion of insulin by pancreatic β-cell in type 2 diabetic individuals disrupts the regulation 
of hepatic gluconeogesis, muscles glucose uptake and lipolysis in adipose tissue. The consequence is 
postprandial hyperglycemia which subsequently causes T2D (Gastaldelli, 2011). Furthermore, the 
control of postprandial hyperglycemia is crucial for the prevention of the progression of diabetic 
complications (Rahati et al. 2014). One therapeutic strategy to reduce postprandial hyperglycemia in 
T2D is to retard absorption of glucose via inhibition of carbohydrate-digesting enzymes, such as α-
glucosidase and α-amylase located at the intestinal brush boarder (Holman et al. 1999). Acarbose and 
miglitol are the major available glucosidase inhibitors currently used in treatment of T2D. However, 
lack of effective treatment and the resulting adverse effects with the existing drugs motivated further 
search for better anti-diabetic agents with fewer side effects as well (Hung et al. 2012). Therefore, with 
the increasing interest in alternatives the use of food based approaches is emerging and receiving much 
attention. This is in addition to the fact that consumers prefer natural functional ingredients than the 
synthetic chemicals (Taveira et al. 2010). Vegetables such as spices are important food adjuncts that 
have been used as flavoring or coloring agents in various food preparations. Additionally, considerable 
evidence have shown that spices can enhance the overall health status of diabetic patients by blood 
glucose lowering ability, amelioration of dyslipidemia, improving β-cell function, body weight and 
preventing cellular oxidative damage (Asif, 2011; Srinivasan, 2005a, b; Khan and Safdar, 2003; 
Broadhurst et al. 2000). 
Capsicum annuum L. (Solanaceae) also known as red pepper is a spice that is readily available 
in almost all parts of the world. The fruit is widely consumed in vast quantities as flavoring agent in 
various traditional foods (Khan et al. 2014). The fruit is locally used as a blood tonic, stimulant and in 
the treatment of nerve weakness or pain due to diabetes in some parts of Africa and Asia (Iwu 2014; 
Jayakumar et al. 2010). In addition, C. annuum is endowed with variety of medicinal values and a good 
source of important phytochemicals such as dihydrocapsaincin, carotenoids, vitamin C, feruloyl O-
glucosides, kaempferol O-pentosyldihexosides, dihydroxyflavone O-hexoses,quercetin-3-O-L-
rhamnoside and capsaicin (Hernández-Ortega et al. 2012; Park et al. 2012; Luthria and Mukhopadhyay 
2006; Materska and Perucka, 2005). These ingredients have beneficial effects on human health and 
could play a role in the prevention of disease such as diabetes, cardiovascular and other age-related 
disorders (Materska and Perucka, 2005; Sun et al. 2007).The beneficial influence of C. annuum fruit 
and its pungent principle capsaicin as anti-oxidative agents have been well documented (Tundis et al. 
2011; 2013; Kwon et al. 2007; Materska and Perucka, 2005; Prasad et al. 2004; Kogure et al. 2002; 




to attenuate dyslipidemia, improve satiety and impact thermogenic effect in hyperlipidemic animals 
(Kempaiah and Srinivasan 2006; Kawada et al. 1986; Sambaiah et al. 1978).  
On the other hand, the anti-diabetic action of C. annuum is still poorly understood due to 
inconsistency of the anti-diabetic action of the pure capsaicin, one of the active ingredients of C. 
annuum fruit. It has been highlighted that various extracts from the whole fruit  and pure capsaicin were 
reported to inhibit the activities of α-glucosidase and α-amylase in vitro, which are potential target for 
the treatment of T2D (Tundis et al. 2011, 2013; Kwon et al. 2007). Tsui et al. (2007) have reported that 
‘substance P’ a neuropeptide released by capsaicin, was able to reduce insulin resistance and 
hyperglycemia in diabetic mice. Conversely, dietary inclusion of pure capsaicin to diabetic animals did 
not show any beneficial anti-hyperglycemic and hypolipidemic effects in diabetic animals (Babu and 
Srinivasan, 1997), when consumption of the aqueous extract of the whole fruit improved glycemic 
control in non-diabetic animals after 1 h post-treatment period (Monsereenusorn, 1980). Therefore, 
based on the above-mentioned studies and diverse array of compounds present in plant-based food, we 
may hypothesize that consumption of either extract or fraction from the whole fruit of C. annuum may 
have anti-diabetic action. Additionally, to the best of our knowledge no study is available that 
comprehensively reported the anti-diabetic effect of the extract or fraction from C. annuum whole fruit 
either in humans or in experimental animals.  
Therefore, the present study was design to investigate the in vivo anti-diabetic effects of the C. annuum 
acetone fraction (CAAF) derived from the fruit ethanolic extract in a T2D model of rats. 
 
5.3.3 Materials and methods 
For sample collection, identification and preparation of the fraction, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.5.1 to 2.5.8.  
 
5.3.4 Results 
The results of body weight (bw) change of all animals are presented in Figure 5.15. According 
to the data, before the STZ-injection, fructose feeding did not affect the mean bw of the treated animals 
compared to the untreated animals. But one week after the STZ-injection, the mean bw of the diabetic 
animals significantly decreases compared to non-diabetic groups. However, at 2nd, 3rd and 4th week of 
CAAF treatment the mean bw of diabetic treated groups were significantly (p < 0.05) increased 
compared to the DBC group (Figure 5.15) which is comparable to the DMF group. Furthermore, 
administration of the fraction to non-diabetic animals did not affect the mean bw change of the treated 





Figure 5.15. Mean body weight change of all animal groups during the study period. Data are presented as the mean ± SD of 
5-7 animals. a-c Values with different letter near the lines for a given week are significantly different from each other group of 
animals (Tukey's-HSD multiple range post hoc test, p< 0.05). NC, Normal Control; DBC, Diabetic Control; DCAL, Diabetic 
C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; NCAH, Normal C. annuum high 
dose. 
 
The data of feed and fluid intake are presented in Figure 5.16. It was observed that feed and 
fluid intake of the DBC group significantly (p < 0.05) increased compared to the NC group. Oral 
intervention of CAAF and metformin for 4 weeks to diabetic animals reduced feed and fluid intake, 
when the effect is more pronounced in the DCAH group compared to the DCAL group (Figure 5.16). 
However, treatment of CAAF at high dose did not affect the eating behavior of the non-diabetic treated 
animals. 
 
Figure 5.16. Food and fluid intake in different animal groups during the experimental period. Data are presented as the mean 
± SD of 5-7 animals. a–eValues with different letters over the bars for a given parameter are significantly different from each 
other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; 
DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; NCAH, Normal 




































































The results of weekly NFBG and FBG (last week only) of all the animal groups are presented 
in Figure 5.17. Induction of T2D significantly (p < 0.05) elevated the blood glucose levels of DBC 
group compared to the NC group. However, oral treatment of CAAF for 4 weeks significantly (p < 
0.05) decreased the blood glucose levels in the DCAL and DCAH groups, when the effect was more 
prominent in DCAH group which is comparable to DMF group. Additionally, treatment of CAAF to 
NCAH group did not affect NFBG and FBG throughout the study period (Figure 5.17).  
 
Figure 5.17. Weekly NFBG in all animal groups during the intervention period. Data are presented as the mean SD of 5-7 
animals. a–dValues with different letter near the lines for a given week are significantly different from each other group of 
animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; DCAL, Diabetic 
C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; NCAH, Normal C. annuum high 
dose; NFBG, Non-fasting blood glucose; FBG, Fasting blood glucose. 
 
The data of oral glucose tolerance test (OGTT) and the calculated area under the curve (AUC) 
are presented in Figure 5.18 and Table 5.7, respectively. The oral glucose tolerance ability of DBC 
group was significantly impaired compared to the NC group. However, significantly (p < 0.05) better 
glucose tolerance ability was observed in the DCAL and DCAH groups compared to the DBC group 
throughout the test period. Moreover, better glucose tolerance ability was observed in the DCAH group 
compared to the DCAL group when at 60 min the blood glucose of DCAH was significantly (p < 0.05) 
better compared to the DMF group. The glucose tolerance ability of NCAH group is not affected during 
the entire period of the test (Figure 5.18). The calculated AUC for DBC group was observed to be 
significantly (p < 0.05) higher compared to NC group when that of DCAL and DCAH groups were 















































Figure 5.18. OGTT of all animal groups in the last week of the 4-week intervention period. Data are presented as the mean ± 
SD of 5-7 animals. a–dValues with different letter near the lines for a given time are significantly different from each other 
group of animals (Tukey's-HSD multiple range post hoc test, p <0.05). NC, Normal Control; DBC, Diabetic Control; DCAL, 
Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; NCAH, Normal C. annuum 
high dose. 
 
Table 5.7. Area under the curve (AUC) of different animal groups at the end of the experimental period   
 NC DBC DCAL DCAH DMF NCAH 
AUC*x103 15.75 ± 0.97a 60.15 ± 7.50 c 35.97 ± 9.01 b 23.36 ± 2.97 b 28.68 ± 7.21 b 15.47 ± 0.47 a 
Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter along a row for a given parameter are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p<0.05). NC, Normal 
Control; DBC, Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic 
Metformin; NCAH, Normal C. annuum high dose, AUC, Area under curve. 
 
The results of serum insulin and fructosamine levels including the calculated HOMA-IR and 
HOMA-β scores are presented in Table 5.8. According to the data, the serum insulin level and the 
calculated HOMA-β scores were decreased significantly (p < 0.05) whereas serum fructosamine as well 
as HOMA-IR were increased significantly (p < 0.05) in the DBC group compared to the NC group 
(Table 5.8). Treatment of the fraction to diabetic animals caused a significant (p < 0.05) and dose-
dependent increase of serum insulin levels and the calculated HOMA-β scores with a concomitant 
reduction of serum fructosamine levels and HOMA-IR scores. Similarly, the reduction of serum 
fructosamine levels and HOMA-IR scores did not differ significantly (p < 0.05) within the diabetic 
treated groups (DCAL and DCAH) although more pronounced results were observed in the DCAH 
group which is also comparable to the DMF group. These parameters were not altered in the non-










































Table 5.8. Effect of CAAF on serum insulin and fructosamine levels and calculated HOMA-IR and HOMA-β scores in different animal groups at the end of 
the intervention period. 
 NC DBC DCAL DCAH DMF NCAH 
Insulin (pmol/L) 76.50 ± 6.26b 47.05 ± 9.02a 57.15 ± 16.32a 78.74 ± 6.32b 75.88 ± 14.23b 77.64 ± 4.39b 
Fructosamine 
(μmol/L) 
239.20 ± 47.49a 365.43 ± 44.94b 288.60 ± 28.43a 289.57 ± 20.94a 283.14 ± 32.46a 267.60 ± 10.29a 
HOMA-IR0.27 ± 2.50 ٭a 6.30 ± 1.64b 3.94 ± 1.30a 3.72 ± 0.54a 3.82 ± 0.90a 2.49 ± 0.22a 
HOMA-β43.71 ± 127.66 ٭٭d 7.33 ± 1.26a 21.20 ± 5.28b 57.43 ± 17.54c 52.57 ± 25.76b,c 132.17 ± 16.81d 
Data are presented as the mean ± SD of 5-7 animals. a–dValues with different letters along the rows for a given parameter are significantly different from each other group of animals (Tukey's-
HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic 
Metformin; NCAH, Normal C. annuum high dose.٭HOMA-IR = [(Fasting serum insulin in U/l x Fasting blood glucose in mmol/L)/22.5]. ٭٭HOMA-β = (Fasting serum insulin in U/l x 20/Fasting 
blood glucose in mmol/L-3.5). 
Figure 5.19: Histopathological examination of the pancreatic islets of different animal groups at the end of the intervention period. The NC had a larger islet with high number of β-cells while 
the DBC had a smaller islet and morphologically deformed β-cells. The DCAL, DCAH and DMF groups had relatively larger islets with higher number of β-cells compared to the DBC group. 




The histopatological slides of the pancreas for all the groups are presented in Figure 5.19. It 
was observed from the slides that the pancreas of the DBC group shows increased fatty infiltrations of 
the islets and reduced number of β-cells compared to the NC group (Figure 5.19). On the other hand, 
the pancreatic morphology of DCAL, DCAH and DMF groups were significantly improved with larger 
islets and higher number of β-cells compared to the DBC group. No significant difference was observed 
between the pancreatic islets integrity of NCAH and NC group. 
The data of absolute and relative liver weight including liver glycogen contents are presented 
in Table 5.9. Although absolute liver weight was not affected by the induction of diabetes, the relative 
liver weight and hepatic glycogen content of DBC group were significantly (p < 0.05) increased 
compared to the NC group (Table 5.9). Oral intervention of CAAF to diabetic animals did not 
significantly (p < 0.05) affect the relative liver weight and hepatic glycogen content compared to the 
DBC group (Table 5.9). Similarly, the glycogen content of NCAH group was not altered at the end of 
the intervention period.  
The data for serum lipid profile and calculated atherogenic index (AI) and coronary risk index 
(CRI) are presented in Table 5.10. The serum total cholesterol (TC), triglycerides (TG) and low density 
lipoprotein (LDL) cholesterol as well as calculated AI and CRI with subsequent reduction on serum 
high density lipoprotein (HDL) cholesterol were observed in the DBC group compared to the NC group 
(Table 5.10). Treatment of CAAF to the diabetic animals significantly (p < 0.05) decreased serum TC, 
TG and LDL-cholesterol levels, calculated AI and CRI indices compared to the DBC group. Moreover, 
the increased on serum HDL-cholesterol level in CAAF diabetic treated groups did not differ 
significantly (p < 0.05) compared to the DBC group. Additionally, the levels of the above-mention 
parameters were not affected in NCAH group at the end of the intervention period (Table 5.10).  
The results of serum ALT, AST, ALP, urea, uric acid, creatinine, LDH and CK-MB are 
presented in Table 5.11. According to the data, the serum ALT, ALP, urea, creatinine, LDH and CK-
MB levels were elevated in DBC group compared to the NC group, when the serum creatinine, ALP 
and uric acid levels were not affected by the induction of diabetes (Table 5.11). However, oral 
intervention of CAAF for 4 weeks to diabetic animals significantly reduced serum ALT, ALP, urea, 
creatinine, LDH and CK-MB levels compared to the DBC group. Although these reductions were not 
significantly (p < 0.05) different between DCAL and DCAH groups, they were comparable with the 
DMF group. Furthermore, treatment of CAAF did not cause any alterations in the serum levels of the 





Table 5.9. Effect of CAAF on liver weights and liver glycogen concentrations in T2D rats 
 NC DBC DCAL DCAH DMF NCAH 
Liver weight(g) 9.25 ± 1.04 10.34 ± 0.31 9.52 ± 0.35 9.62 ± 0.85 9.10 ± 1.33 9.65 ± 0.41 
Relative liver weight (%)0.29 ± 2.89 ٭a 4.55 ± 0.34b 4.31 ± 0.10b 4.27 ± 0.20b 3.10 ± 0.45a,b 2.85 ± 0.13a 
Liver glycogen (mg/g tissue) 6.76 ± 0.81a 8.25 ± 0.83b 8.12 ± 0.32b 8.08 ± 0.49b 6.92 ± 0.56a 6.72 ± 0.27a 
Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter along the rows for a given parameter are significantly different from each other group of animals (Tukey's-HSD 
multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; 
NCAH, Normal C. annuum high dose. 



















Table 5.10. Serum lipid profiles and other biochemical parameters in different animal groups at the end of the intervention period 
 NC DBC DCAL DCAH DMF NCAH 
TC (mg/dl) 76.20 ± 7.40a 116.00 ± 12.92c 83.14 ± 13.69a,b 79.43 ± 7.91a,b 95.71 ± 7.74b 75.80 ± 9.39a 
HDL-Cholesterol (mg/dl) 49.20 ± 8.35b 28.29 ± 6.25a  32.57 ± 7.30a 30.57 ± 4.47a 32.71 ± 7.43a 30.40 ± 3.21a 
LDL-Cholesterol (mg/dl)* 12.96 ± 4.16a 57.54 ± 14.45c 33.26 ± 9.10b 34.31 ± 9.97b 42.86 ± 8.93b,c 32.84 ± 12.74a,b 
TG (mg/dl) 70.20 ± 18.10a  150.86 ± 24.57b 86.57 ± 29.40a  72.71 ± 20.89a  100.71 ± 32.47a  62.80 ± 6.06a  
AI 0.57 ± 0.13a 3.30 ± 1.08c 1.60 ± 0.37a,b 1.63 ± 0.38a,b 2.06 ± 0.69b 1.53 ± 0.38a,b 
CRI 1.57 ± 0.13a 4.30 ± 1.08c 2.60 ± 0.37a,b 2.63 ± 0.38a,b 3.06 ± 0.69b 2.93 ± 0.38a,b 
Data are presented as the mean ± SD of 5-7 animals. a–cValues with different letters along the rows for a given parameter are significantly different from each other group of animals (Tukey's-
HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic 
Metformin; NCAH, Normal C. annuum high dose; TC, Total cholesterol; TG, Triglyceride; LDL-cholesterol, Low density lipoprotein-cholesterol; HDL-cholesterol; High density lipoprotein-
cholesterol; AI, Atherogenic index; CRI, Coronary risk index.  















Table 5.11. Serum biochemical parameters in different animal groups at the end of the intervention period 
 NC DBC DCAL DCAH DMF NCAH 
ALT (U/l) 77.40 ± 20.38a 116.14 ± 37.37b 78.43 ± 6.63a 71.43 ± 15.87a 93.57 ± 6.86a,b 73.80 ± 8.93a 
AST (U/l) 88.40 ± 11.41 83.29 ± 15.57 87.86 ± 1158 81.86 ± 17.07 94.71 ± 9.39 85.80 ± 10.33 
ALP (U/l) 149.40 ± 11.33a 451.14 ± 35.10c 205.43 ± 46.62b 207.57 ± 16.44b 208.86 ± 27.58b 154.20 ± 29.88a,b 
Creatinine (mg/dL) 2.52 ± 0.78b 3.12 ± 0.45b 1.66 ± 0.31a 2.00 ± 0.10a 1.68 ± 0.27a 1.86 ± 0.19a 
Urea (mg/dL) 22.00 ± 4.69a 60.71 ± 15.71b 25.57 ± 10.10a 26.00 ± 9.31a  26.00 ± 5.00a 26.20 ± 6.02a 
Uric acid (mg/dL) 2.06 ± 0.67  2.85 ± 1.18  2.32 ± 0.78  2.40 ± 1.20  2.56 ± 1.36  2.14 ± 0.84  
LDH (U/l) 284.00 ± 62.56a   458.86 ± 68.05b  424.43 ± 107.14b  372.71 ± 72.63a,b  361.57 ± 80.66a,b 287.60 ± 34.50a 
CK-MB (U/l) 374.54 ± 82.56a 1064.36 ± 537.18b 714.33 ± 69.02a,b 579.44 ± 71.72a 743.97 ± 75.29a,b 399.02 ± 58.82a 
Data are presented as mean ± SD of 5-7 animals. a–dValues with different superscript letters along a row for a given parameter are significantly different from each other group of animals (Tukey's-




5.3.5 Discussion  
Apart from dietary and life style modifications, the current treatment options of T2D involve in the 
use of conventional oral hypoglycemic drugs. However, the use of oral hypoglycemic drugs was associated 
with a number of short- and long-time consequences. For instance α-glucosidase inhibitors are reported to 
cause diarrhea, bloating, flatulence, cramping and abdominal pain (Fujisawa et al. 2005). Therefore, this 
has triggered researchers to scientifically investigate the anti-diabetic actions of a number of plants 
including plant-based spices as possible alternative therapies for diabetes. This is partly because plant-
derived preparations are important component of health care delivery system, particularly in developing 
countries and were reported to cause minimum side effects (Cragg and Newman, 2013; Balunas and 
Kinghorn, 2005). Spices are important food supplements which have been used as flavoring agents and 
their ethnobotanical usage in the treatment of diabetes has been documented for a long time (Srinivasan, 
2005). In the present study, we have evaluated the effect of the 4-week oral administration of a low (150 
mg/kg bw) and a high (300 mg/kg bw) dose of C. annuum acetone fraction (CAAF) of fruit ethanolic extract 
in a T2D model of rats. Although a number of recent and previous studies reported the anti-diabetic effects 
of C. annum fruit extract in vitro (Tundis et al. 2013; Tundis et al. 2011; Kwon et al. 2007), as per our 
knowledge, this is the first in vivo study that comprehensively conducted the anti-diabetic effect of C. 
annuum fruit. 
According to the American Diabetes Association (ADA), diabetes causes polyuria, increase 
catabolic processes and weight loss, in addition to increase of feed and fluid intake (ADA, 2015). On the 
other hand, capsaicin is the major bioactive compound of C. annum and it has been reported that dietary 
inclusion of capsaicin (0.015%) for 8 weeks to diabetic animals did not show any effect on the bw change 
(Babu and Srinivasan, 1997). In another study, consumption dietary C. annuum (0.9 g four times daily) 
increased energy expenditure, decreased appetite and food intake in human subjects within 2 days of study 
period (Westerterp-Plantenga et al. 2005). However, in our study, oral treatment of CAAF to diabetic 
animals for 4 weeks caused a significant increase in bw despite of lower feed and fluid intake compared to 
DBC group (Figure 5.15 and 5.16). In the above-mentioned studies, either pure capsaicin or whole dietary 
C. annum was used when acetone fraction of the fruit ethanolic extract was used in our study which 
chemical compositions might be different from the above. Hence, the other compounds from the C. annuum 
might be contributed to this activities compared to the major active principle, capsaicin, or whole C. annum. 
Furthermore, the effects were more pronounced in DCAH group compared to the DCAL and were 
comparable to the DMF group. This indicates possible recovery from the diabetes-induced alterations in 
eating behavior of the treated animals, which was further supported by the significant decrease in blood 




Successful control of either fasting or postprandial blood glucose levels remains a prime target in 
preventing and attenuating diabetes and its associated complications (Bavarva and Narasimhacharya, 
2008). Babu and Srinivasan (1997) have reported that diabetic animals maintained on capsaicin (0.015%) 
containing diet, for 8 weeks have shown no significant reduction on blood glucose levels. Likewise, in 
another study, ʺsubstance Pʺ (a neuropeptide released by capsaicin) was reported to cause fluctuations in 
blood sugar levels in human subjects (Brown and Vale, 2011). Conversely, Monsereenusorn, (1980) has 
reported that intraperitoneal injection of fruit extract (500-700 mg/kg bw) showed a significant 
hypoglycemic action after 30 minutes post-treatment period. In our study, oral intervention of the CAAF 
to diabetic animals for 4 weeks significantly lowered blood glucose levels, when it was more pronounced 
in DCAH group compared to DCAL group (Figure 5.17). This has shown a dose-dependent anti-
hyperglycemic response in the diabetic treated groups, which was further supported by the OGTT data 
(Figure 5.18). In the OGTT result, better glucose utilizing capacities was observed in CAAF diabetic 
treated animals compared to DBC group, when it was more prominent in the DCAH group compared to the 
DCAL group and was comparable to DMF group. This again supports the possible contribution of other 
compounds in CAAF apart from the major capsaicin in the observed anti-hyperglycemic action of CAAF. 
On the other hand, the CAAF did not show any effect on the blood glucose level of NCAH group throughout 
the study period, when in another study higher dosages (500-700 mg/kg bw) of the extract have shown 
hypoglycemic effects in non-diabetic animals (Monsereenusorn, 1980). This could be due to the lower 
dosages (300 mg/kg bw) of the fraction used in our study. The anti-hyperglycemic action of CAAF could 
be attributed to the higher α-glucosidase and α-amylase inhibitory actions which apparently could delay the 
intestinal absorption of glucose (Imam, 2015) in addition to the pancreatic β-cell ameliorating as well as 
insulin secreting effects of CAAF in our study (Figure 5.19 and Table 5.8).  
It has been reported that chronic hyperglycemia in T2D causes an impairment or decline in insulin 
secretion (Nattrass and Bailey, 1999), with subsequent distortion of pancreatic architecture (Bonner-Weir 
and O'Brien, 2008). Based on the current available data, this is the first study that investigates the effect of 
CAAF of fruit on serum insulin levels and pancreatic β-cell integrity in diabetic state. According to our 
results, treatment of CAAF to diabetic animals especially at the higher dose (300 mg/kg bw) have shown a 
significant insulinotropic effect, lowered peripheral insulin resistance, stimulated pancreatic β-cell function 
and restored the pancreatic morphology to near normal compared to the DBC group (Figure 5.19 and Table 
5.8). Therefore, the anti-hyperglycemic effect of CAAF could partly be mediated via insulinotropic actions 
and decreasing insulin resistance. This was further supported by the significantly lower serum fructosamine 
levels in the DCAL and DCAH groups compared to the DBC group which did not differ significantly with 




fruit (extracts or fractions) reported in previous studies (Tundis et al. 2013; Tundis et al. 2011; Kwon et al. 
2007; Oboh et al. 2007).  
On the other side, previous studies have shown that supplementation of 0.015% capsaicin 
containing diet to high-fat diet-fed diabetic animals for 8 weeks have shown no significant effect on the 
relative liver weight (Kempaiah and Srinivasan, 2006; Babu and Srinivasan, 1997), which was similarly 
observed in our present data (Table 5.9). Additionally, oral treatment of CAAF did not show any 
significantly effect on the hepatic glycogen content of the treated diabetic animals (Table 5.9). Hence, our 
data are in line with the previous capsaicin-based studies. 
On the other side, C. annuum and its pungent principle capsaicin have been reported to play 
beneficial role on lipid metabolism in a number of previous studies. Capsaicin (0.015%) included in diet 
for 8 weeks was reported to decrease serum TC, TG and LDL-cholesterol levels in diabetic and high-fat 
diet animals (Kempaiah and Srinivasan, 2006; Babu and Srinivasan, 1997 and). Similarly, in a chronic 
study, oral treatment of capsaicin (50 mg/kg bw) or whole fruit extract (500 mg/kg bw) for 2 months 
demonstrated hypolidemic actions (Monsereenusorn, 1983). Our results are also in line with the above-
mentioned studies. Additionally, a moderate increase of serum HDL-cholesterol levels was also observed 
in DCAL and DCAH groups which did not differ significantly from DBC groups (Table 5.10). These 
indicate the anti-hyperlipidemic effect of CAAF in diabetic animals. Moreover significantly lower 
calculated AI and CRI indices in DCAL and DCAH groups compared to the DBC in our study again support 
the anti-hyperlipidemic effect of CAAF in diabetic condition (Table 5.10).  
In some disease conditions such as T2D, an increase of serum ALT, ALP, creatinine, urea, LDH 
and CK-MB into blood circulation induces hepatic injuries, myocardial infarction and functional 
disturbance of hepatic and renal tissues (Abolfathi et al. 2012; Jaramillo-Juarez et al. 2008). Therefore, 
based on the results of the above-mentioned parameters, treatment of CAAF has demonstrated hepato-
protective, cardio-protective as well as reno-protective effects in diabetic condition, when serum AST level 
was not affected anyway (Table 5.11). In comparison with ALT, AST is less specific for the detection of 
hepatic injury due to its shorter half-life compared to ALT, particularly in experimental animal (Center, 
2007). Therefore, in a condition of acute or sub-chronic liver injury, there will be an elevation in both serum 
ALT and AST levels. However, the serum AST level may likely return to normal more rapidly compared 
to the level of serum ALT, which make ALT more sensitive in assessing hepatic damage in disease 
conditions (Ramaiah, 2007; Meyer and Harvey, 2004). Therefore, the unaffected serum AST level in our 







5.3.6 Conclusion  
Oral intervention of CAAF from whole fruit especially at the higher dose (300 mg/kg bw) have 
demonstrated anti-diabetic actions via improving bw gain, reducing food and fluid intake and 
hyperglycemia, improving glucose tolerance ability, insulin sensitivity, amelioration of pancreatic β-cell 
histology and β-cell functions and improving dyslipidemia in T2D. Hence, our findings suggest that acetone 
fraction of the whole C. annuum fruit ethanolic extract may provide an excellent anti-diabetic remedy with 
no considerable side effects. Further clinical study is required to confirm the effects in human subjects. The 
isolation and partial characterization of the active principle from CAAF is currently underway to find the 



























5.4 Anti-oxidant action of Capsicum annuum fruit acetone fraction in 
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5.4.1 Abstract 
Objectives: The present study evaluated the in vivo anti-oxidative actions of Capsicum annuum acetone 
fraction (CAAF) from fruit ethanolic extract in a type 2 diabetes (T2D) model of rats.  
Methods: T2D was induced in rats by feeding a 10% fructose solution ad libitum for two weeks followed 
by a single intraperitoneal injection of streptozotocin (40 mg/kg body weight (bw)) and the animals were 
orally treated with 150 or 300 mg/kg bw of the CAAF once daily for 4 weeks.  
Results: After four weeks of intervention, diabetic untreated animals showed significantly higher levels of 
thiobarbituric acid reactive substances (TBARS) and reductions of reduced glutathione (GSH) in the serum 
and organs (liver, kidney, heart and pancreas) compared to the normal animals. The activities of endogenous 
anti-oxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and reductase) were greatly 
impaired in in the serum and organs of diabetic untreated animals compared to the normal animals. These 
alterations were attenuated after the treatment of CAAF, especially at the dose of 300 mg/kg bw.  
Conclusion:  The results of our study suggest that CAAF treatment at 300 mg/kg bw showed potent anti-
oxidative potential in a T2D model of rats. 
 
Keywords: Acetone, Anti-oxidant, Capsicum annuum, Fruit ethanolic extract, Type 2 diabetes, Rats. 
 
5.4.2 Introduction 
Diabetes mellitus (DM) is a major threat to global public health that is rapidly escalating, and the 
highest impact on adults in most of the developing countries. The recent data indicate that more than 387 
million people have DM and this figure is likely to be doubled by 2035, with type 2 diabetes (T2D) been 




2014). T2D is a heterogeneous disorder characterized by insulin resistance and partially dysfunctional 
pancreatic β-cells which cannot properly secrete insulin in response to hyperglycemia (Hui et al. 2007).  
T2D is associated with severe chronic complications that are partly or solely depend on 
uncontrolled hyperglycemia (Monnier et al. 2006). The hyperglycemia in T2D induces generation of 
reactive oxygen species (ROS), which are responsible for oxidative stress induced pancreatic β-cell 
destruction (Ceriello and Testa, 2009). Oxidative stress is a condition due to the presence of ROS that 
usually arise either from an excess production of ROS or from the inactivation of the in vivo anti-oxidants 
defense system, thus shifting the ROS/anti-oxidant equilibrium towards stress (Ibrahim et al. 2012).  
In aerobic system, oxygen is required for energy production (in the form of ATP) via the 
metabolism of biomolecules such as fatty acids, glucose, lactate, ketones, and amino acids.  During this 
complex process, an unstable ROS, superoxide anion radical is produced, which is regarded as primary 
ROS and later generate the secondary ROS either directly or indirectly by a variety of enzyme or metal 
catalyzed processes (Sati et al. 2010). An enzyme, superoxide dismutase (SOD) catalyzes the conversion 
of superoxide to hydrogen peroxide, which subsequently cross the membranes and causes enzyme 
inactivation through oxidations of their thiol groups (Rajasekaran et al. 2005). The hydrogen peroxide is 
later converted to hydroxyl radicals in the presence of transition metals. This initiates a sequence for the 
generation of other ROS such as singlet oxygen and peroxyl (ROO•) radicals.  
Therefore, due to the shift in the ROS/anti-oxidant equilibrium balance in living organisms, the 
increased intake of anti-oxidants is necessary to prevent the oxidative damages due to oxidative stress. 
However, the use of synthetic anti-oxidants such as butylated hydroxy anisole (BHA), butylated hydroxy 
toluene (BHT), tertiary butylated hydroquinon and gallic acid esters in food protection and disease control 
have been associated with unwanted consequences. This has motivated researchers to look for options from 
plant-derived anti-oxidants. 
The fruit from Capsicum annuum L. has been a major component of various food preparations 
worldwide. In addition to this, C. annuum fruit has been reported to be an excellent source of important 
anti-oxidant biomolecules such as vitamins, polyphenols and other potentially active phytochemicals that 
may prevent the risk of T2D (Rahimi et al. 2005). More importantly, there is sufficient available data that 
support the anti-oxidative crude extracts of C. annuum in vitro (Azeez et al. 2012; Chen et al. 2012; Tundis 
et al. 2011; Perucka and Materska, 2007; Conforti et al. 2007; Kwon et. 2007), when no available study on 
the in vivo anti-oxidant action of any extracts, fractions or isolated compounds from C. annuum either in 
normal or diseased conditions.  
Therefore, the present study was designed to comprehensively investigate the in vivo anti-oxidant 





5.4.3 Materials and methods 
For sample collection, identification and preparation of the fraction, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.5.1 to 2.5.8.  
 
5.4.4 Results 
The results of thiobarbituric acid reactive substances (TBARS) expressed as malondialdehyde 
(MDA) concentration of the serum and organs (liver, kidney, heart and pancreas) of all the groups are 
presented in Figure 5.20. The TBARS concentrations were significantly (p < 0.05) elevated in the serum, 
liver, heart and pancreas of the DBC group compared to the NC group. The increase in kidney of the DBC 
group was not significantly (p < 0.05) different compared to NC group. However, treatment of CAAF to 
diabetic animals (DCAL and DCAH) significantly (p < 0.05) decreased the serum and pancreatic TBARS 
concentrations comparable to the DMF group (Figure 5.20). Moreover, the reductions of TBARS levels in 
the liver, kidney and heart of the DCAL and DCAH groups were not significantly (p < 0.05) different 
compared to the DBC group.  
    
 
Figure 5.20: Serum and organs thiobarbituric acid reactive substances of all animal groups at the end of the intervention period. 
Data are presented as the mean ± SD of 5-7 animals. a-dValues with different letter over the bars for a given sample are significantly 
different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, 
Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; 





The data of reduced glutathione (GSH) levels of serum and organs of all the groups are presented 
in Figure 5.21. According to the results, the concentration of GSH in the serum, liver and pancreas were 
significantly (p < 0.05) decreased in the DBC group compared to the NC group. Similarly, the decrease of 
GSH levels in the kidney and heart of the DBC group were not significantly (p < 0.05) different compared 
to the NC group. Oral administration of CAAF to diabetic animals significantly (p < 0.05) increased the 
levels of GSH in the liver, when that of the serum, kidney, heart and pancreas was not significantly (p < 
0.05) different compared to the DBC group (Figure 5.21). In addition, the effect was more pronounced in 
the DCAH compared to DCAL group. Furthermore, the GSH level in the NCAH was comparatively within 
normal range throughout the study period (Figure 5.21). 
 
Figure 5.21: Serum and organs reduced glutathione (GSH) content in all animal groups at the end of the study period. Data are 
presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are significantly different 
from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic 
Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; NCAH, Normal 
C. annuum high dose; GSH, Reduced glutathione. 
 
The results of the activity of superoxide dismutase (SOD) of serum and organs of all the groups are 
presented in Figure 5.22. It was observed from the data that induction of diabetes significantly (p < 0.05) 
decrease the activity of SOD in serum, liver, heart and pancreas of DBC group, whereas the reduction in 
kidney did not differ significantly (p < 0.05) compared to NC group. However, treatment of the fraction to 
diabetic animals, especially the DCAH group showed a significant (p < 0.05) increased in the SOD activity 
of the serum and organs, comparable to DMF group (Figure 5.22). Additionally, the SOD activity in the 





Figure 5.22: Superoxide dismutase (SOD) activities in the serum and organs of different animal groups at the end of the study 
period. Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are 
significantly different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; 
DBC, Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; 
NCAH, Normal C. annuum high dose. 
 
  The data of catalase activities in serum and organs of all the groups are presented in Figure 5.23. 
According the results, the activity of the catalase in the serum and organs was significantly (p < 0.05) 
decreased in the DBC group compared to the NC group. Treatment of CAAF to the diabetic animals 
increases the catalase activity, when the effect was more pronounced in the DCAH group than the DCAL 
group (Figure 5.23). Additionally, treatment of the fraction to the non-diabetic animals did not affect the 
serum or organ catalase activity throughout the study period (Figure 5.23).  
 
Figure 5.23: Catalase activities in the serum and different organs of different animal groups at the end of the study period. Data 
are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are significantly 
different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, 
Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; 




The activity of glutathione peroxidase (GPx) in serum and organs of all the groups are presented in 
Figure 5.24. The GPx activity of the serum and organs was significantly (p < 0.05) decreased in the DBC 
group compared to the NC group. Oral intervention of the CAAF, especially at the higher dose, significantly 
(p < 0.05) increased the GPx activity, which is comparable to the DMF group (Figure 5.24).  
 
Figure 5.24: Glutathione peroxidase activities in the serum and organs of different animal groups at the end of the study period. 
Data are presented as the mean ± SD of 5-7 animals. a-dValues with different letter over the bars for a given sample are significantly 
different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, 
Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; 
NCAH, Normal C. annuum high dose. 
 
The data of glutathione reductase (GR) activity in serum and organs of all the groups are presented 
in Figure 5.25. The activity of GR was not affected by the diabetes in kidney and heart, whereas greatly 
decreased in serum, liver and the pancreas of DBC group compared to the NC group. Treatment of the 
CAAF to diabetic animals improved the activity of the enzyme, when in DCAH group the activity was 
significantly (p < 0.05) increased in pancreas compared to the DBC group (Figure 5.25). In addition, the 





Figure 5.25: Glutathione reductase activities in the serum and organs of different animal groups at the end of the study period. 
Data are presented as the mean ± SD of 5-7 animals. a-cValues with different letter over the bars for a given sample are significantly 
different from each other group of animals (Tukey's-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, 
Diabetic Control; DCAL, Diabetic C. annuum low dose; DCAH, Diabetic C. annuum  high dose; DMF, Diabetic Metformin; 
NCAH, Normal C. annuum high dose. 
 
5.4.5 Discussion 
 Natural products such as plants are currently utilized as alternative in the treatment and control of 
several disorders including T2D. The prevention of diabetes has been associated with consumption of plants 
rich in natural anti-oxidants. This is because oxidative stress has been the major causal factor for most of 
the complications associated with diabetes (Ceriello, 2006). In our present study, we intent to 
comprehensively investigate the in vivo anti-oxidant effects of the acetone fraction derived from the fruit 
ethanolic extract of C. annuum in a T2D model of rats. This is the first study that explore the in vivo anti-
oxidant potentials of any parts, extracts or fractions derived from C. annuum despite several studies on the 
in vitro anti-oxidant activity (Azeez et al. 2012; Chen et al. 2012; Tundis et al. 2011; Perucka and Materska, 
2007; Conforti et al. 2007; Kwon et. 2007). 
 Diabetes has been associated with marked elevation of lipid peroxidation levels (thiobarbituric acid 
reactive substances (TBARS), which is an indication of increased ROS production (Maritim et al. 2003). 
This was clearly manifested in the DBC group, a direct evidence of increased cellular oxidative stress and 




this alteration, suggesting the protective role of CAAF in terminating the deleterious effect of ROS and 
oxidative stress as well (Figure 5.20).   
 In living system, there are some low molecular weight non-enzymatic molecules such as α-
tocopherol, ascorbic acid, bilirubin and glutathione (GSH) that support the anti-oxidant defense system and 
counteract the effects of oxidative stress (Rahimi et al. 2005). Moreover, diabetes has been associated with 
reduction of GSH levels, due to the depletion of in vivo anti-oxidant system in diabetic condition, which 
was observed in the DBC group in our present data (Figure 5.21). Treatment of the fraction to diabetic 
animals was found to increase the serum and organ GSH levels, which may be liked to either increased 
GSH biosynthesis or attenuated the oxidative processes leading to GSH reduction.  
  Superoxide anion radical has been considered as a primary ROS formed when molecular oxygen 
accept electron in the metabolism of complex macromolecules (Sati et al. 2010). The deleterious effect of 
this radical is prevented by an enzyme superoxide dismutase (SOD), which converts the superoxide radical 
to less toxic hydrogen peroxide. The activity of this enzyme was reported to be impaired in diabetic 
condition, due to increased ROS production that cannot be quenched by the enzyme action (Niki, 2010; 
Valko et al. 2007). In our present study, this was clearly observed in the DBC group compared to the NC 
group (Figure 5.22). However, the increased SOD activity observed in diabetic treated animals suggests 
that the fraction contributes to in vivo anti-oxidant system via increasing the SOD activity, which was 
further supported by the increased catalase activity (Figure 5.23). 
 Furthermore, the hydrogen peroxide released by the SOD is immediately converted to non-toxic 
molecules, water and oxygen by catalase (McCrod et al. 1976). In most of degenerative disorders, the 
activity of catalase is greatly altered; leading to increase in the conversion of hydrogen peroxide to hydroxyl 
radicals, which invariably increased the oxidative stress. Therefore, the decreased catalase activity in the 
DBC group observed in our present study may be attributed to increase conversion of hydrogen peroxide 
to hydroxyl radicals that overpowered and reduced the catalase activity. Interestingly, treatment of CAAF 
was found to improve the activity of catalase in the serum and organs, when is more pronounced in the 
DCAH than DCAL (Figure 5.23). This was again supported by the increased activities of glutathione 
peroxidase (GPx) and glutathione reductase (GR) (Figure 5.24 and 5.24). 
 According to our present data, the reduction of the activities of two glutathione dependent enzymes; 
GPx and GR in the serum and organs of the DBC group could be due to the oxidative damage initiated by 
increased ROS production. The moderate recovery of GPx and GR activities in the serum and organs of the 







5.4.6 Conclusion  
In conclusion, oral administration of the fraction especially at higher dose demonstrates strong anti-
oxidant activities via reduction of lipid peroxidation, improving glutathione levels and endogenous anti-
oxidants enzymes in serum and organs mostly affected by diabetic-complications. Therefore, CAAF is 
considered as excellent anti-oxidant agent with no considerable side effects. Further clinical study is 
required to confirm its effects in human subjects. The isolation and partial characterization of the active 































6.1 Anti-diabetic action of some African medicinal plants 
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6.1.1 Abstract 
Objective: The use of Aframomum melegueta K. Schum. (Zingiberaceae), Xylopia aethiopica (Dunal) A. 
Rich. (Annonaceae) and Capsicum annuum L. (Solanaceae) fruits for treatment of diabetes and related 
metabolic disorders have been reported. This has recently been established in vivo. However, compounds 
responsible for the anti-diabetic action have not been identified. The present study is aimed at carrying out 
the bioassay-guided isolation of possible compounds responsible for the anti-diabetic action of the selected 
plants.  
Methods: Plant parts were extracted in organic solvents and the secondary metabolites, isolated and 
purified before being identified by spectroscopic analysis.  Their α-glycosidase and α-amylase inhibitory 
activities were investigated. 
Results: Three arylalkanes, 6-paradol (1), 6-shagaol (2) and 6-gingerol (3) and a pentacyclic triterpene, 
oleanolic acid (4) were isolated from A. melegueta fruit. Compounds (3) and (4) were also isolated from 
the fruit of X. aethiopica. A mixture of aromatic compounds and a fatty acid (unable to be identified) was 
also isolated from the active subfraction of C. annuum and labeled as (5). All the compounds exhibited 
considerable inhibitory activity against α-amylase and α-glucosidase. Compounds (3) and (4) showed the 
best activity against α-amylase (IC50: (3): 156.96 ± 12.23 µM; (4): 91.72 ± 1.63 µM) and α-glucosidase 
(IC50: (3): 104.34 ± 3.99 µM; (4): 47.10 ± 0.42 µM) compared to the standard acarbose and the other isolated 
compounds.  The kinetics of the enzyme action shown by the compounds showed a non-competitive mode 




Conclusion: 6-Gingerol (3) oleanolic acid (4) present in the fruit of both A. melegueta and X. aethiopica 
are possibly responsible for the anti-diabetic action attributed to these plants. Both 3 and 4 could be potential 
anti-diabetic plants.  
 




 Type 2 diabetes (T2D) is a metabolic disorder characterized by chronic insulin resistance and loss 
of functional pancreatic β-cells due to relative (rather than absolute) deficiency of insulin (ADA, 2015). 
The inability of the pancreatic β-cell to secrete enough insulin disrupts the regulation of hepatic glucose 
synthesis, muscles glucose uptake and lipolysis in adipose tissue. The consequence is postprandial 
hyperglycemia which subsequently causes T2D (Gastaldelli, 2011). This postprandial hyperglycemia must 
be controlled in order to prevent diabetic complications (Rahati et al. 2014). One therapeutic approach to 
reducing postprandial hyperglycemia in T2D is delaying glucose absorption via inhibition of carbohydrate-
digesting enzymes, such as α-glucosidase and α-amylase located at the intestinal brush boarder (Holman et 
al. 1999). Acarbose and miglitol are the major available glucosidase inhibitors currently used in treatment 
of T2D. However these drugs have side-effects major drawback with the use of the existing drugs has been 
the adverse consequences such as diarrhea, bloating, flatulence, cramping and abdominal pain (Fujisawa et 
al. 2005). Thus anti-diabetic leads with similar or better activity are sought after with fewer side effects 
(Hung et al. 2012). The use of plant based approaches is emerging as alternatives to these nasty drugs and 
is currently receiving much attention. Plant-derived natural products are becoming popular as alternatives 
to synthetic drugs as they are considered to be safer with fewer side-effects (Taveira et al. 2010). 
 Aframomum melegueta K. Schum. (Zingiberaceae) commonly known as guinea or alligator pepper 
is abundantly found in the central and western part of Africa (Iwu, 2014). The fruit, leaf or seeds are 
consumed as flavoring agents in various traditional foods and are used locally to treat diseases including 
diabetes, microbial infections, diarrhea, abdominal pain, snakebite and wound healing in many parts of 
Africa (Iwu, 2014; Soladoye et al. 2012; Gbolade, 2009; Akendengue and Louis, 1994; Kokwaro, 1993). 
Previous studies have shown that A. melegueta possessed anti-microbial (Nneka and Jude, 2013; Doherty 
et al. 2010), hepato-protective (Nwozo and Oyinloye, 2011), anti-inflammatory (Ilic et al. 2014; Umukoro 
and Ashorobi, 2008), anti-oxidative and potent inhibitory effects against α-glucosidase activities 
(Mohammed et al. 2015; Onoja et al. 2014; Adefegha and Oboh, 2012a; Kazeem et al. 2012; Adefegha and 
Oboh, 2011; Etoundi et al. 2010). In a recent study, the diterpenoids isolated from the organic seed extract 




Staphylococcus aureus strains (Ngwoke et al. 2014). In another study, paradol (1), shogaol (2) and gingerol 
(3) isolated from the seed have showed anti-inflammatory activity in a rat paw edema model (Ilic et al. 
2014). El-Halawany et al. (2014) have also reported that diarylheptanoid, 8-dehydrogingerdione, 6-
dehydroparadol, dihydrogingerenone, 6-gingerol, dihydroparadol, paradol and 6-shogaol demonstrated 
hepato-protective and anti-oxidative actions in CCl4 induced acute liver injury in rats.  
 Xylopia aethiopica (Dunal) A. Rich. (Annonaceae) also known as Ethiopian pepper is an 
indigenous spice widely distributed in almost all parts of Africa. The fruit is popularly used as a condiment 
in many local dishes by different traditions in Africa and Asia (Kingsley, 2012). In addition, X. aethiopica 
fruit is widely used locally in the treatment of various ailments and as an excipient to many other medicines 
(Freiesleben et al. 2015). In Nigerian, Guinean, Togolese and Senegalese traditional medicines, the fruit 
decoction is widely used in the treatment of diabetes (Soladoye et al. 2012; Diallo et al. 2012; Karou et al. 
2011; Diéye et al. 2008). Moreover, previous studies have shown that various extracts from X. aethiopica 
fruit possessed anti-cancer (Kuete et al. 2013; 2011; Choumessi et al. 2012), anti-fertility (Nwangwa, 2012), 
anti-sickling (Uwakwe and Nwaoguikpe, 2008), anti-microbial (Esekhiagbe et al. 2009), anti-oxidative 
actions and inhibits the activities of carbohydrate hydrolyzing enzymes in vitro (Adefegha and Oboh, 
2012a,c; 2011; Etoundi et al. 2010; Odukoya et al. 2005; George and Osiama, 2011). Previously, diterpene 
kaurenoids isolated from X. aethiopica fruit exhibited hypotensive and diuretic effects in rats (Somova et 
al. 2001). 
 Capsicum annuum L. (Solanaceae) also known as red pepper is a spice that is readily available in 
almost all parts of the world. The fruit is widely consumed in vast quantities as a flavoring agent in various 
traditional foods (Khan et al. 2014). The fruit is locally used as a blood tonic, stimulant and in the treatment 
of nerve weakness or pain due to diabetes in some parts of Africa and Asia (Iwu 2014; Jayakumar et al. 
2010). Studies reported earlier indicated that C. annuum fruit extracts exhibited potent anti-microbial 
(Santos et al. 2012; Careaga et al. 2003), anti-diabetic (Monsereenusorn, 1980), anti-nociceptive and anti-
inflammatory (Hernández-Ortega et al. 2012), anti-oxidative and inhibitory effects against α-glucosidase 
activities (Tundis et al. 2011; 2013; Kwon et al. 2007; Materska and Perucka, 2005; Reddy and Lokesh, 
1992). In addition, consumption of the whole fruit extract or capsaicin was reported to attenuate 
dyslipidemia, improve satiety and have an impact on the thermogenic effect in hyperlipidemic animals 
(Kempaiah and Srinivasan 2006; Kawada et al. 1986; Sambaiah et al. 1978). Capsaicin and 
dihydrocapsaicin isolated from C. annuum fruit have demonstrated α-amylase and α-glucosidase inhibitory 
actions (Tundis et al. 2013). Moreover, the volatile oil derived from C. annuum fruit also exhibited excellent 
anti-parasitic effects against Anopheles gambiae (Dadji et al. 2011). 
 Our recent findings have shown that, A. melegueta ethyl acetate, X. aethiopica acetone and C. 




ameliorate β-cell dysfunction and other major diabetes-related parameters in a T2D model of rats (data not 
shown). However, the compounds responsible for the excellent anti-diabetic action of the above-mentioned 
fractions remain speculative.  
This study is therefore aimed at carry out the bioassay-guided isolation of possible compounds 
responsible for the anti-diabetic action of the selected plants. 
 
6.1.3 Materials and methods 
For sample collection, identification and preparation of the extracts, including the detail 
experimental protocols, please refer to chapter 2, sub-sections 2.3 and 2.4.  
 
6.1.4 Results 
The phytochemical investigation of the fruits A. melegueta, X. aethiopica  and C. annuum led to 
the isolation of compounds 1-4 and the mixture 5 (Figure 6.1) which were characterized by 1D (1H and 
13C) and 2D NMR and confirmed by comparison with data in the literature as 6-paradol (1) (Ma et al., 
2004), 6-shogoal (2) (Lee et al., 2011), 6-gingerol (3) (Lee et al., 2011), oleanolic acid (4) (Mahato and 
Kundo, 1994). The mixture 5 consisted of a fatty acid and aromatic compounds; however the structures 
could not be determined due to the mixture of compounds. Compounds 1-4 were isolated from A. 
melegueta, 3 and 4 were also obtained from X. aethiopica and the mixture 5 from C. annuum. 
 
                                    Figure 6.1: Structures of compounds 1-4 isolated from A. melegueta and X. aethiopica 
The data from the α-amylase inhibition of the compounds from the fruits of the three plants are 




melegueta and X. aethiopica exhibited the lowest IC50 value (156.96±12.23 µM), significantly lower 
(p<0.05) compared to 1, 2 and the mixture 5 from C. annuum (Table 6.1). However, the IC50 of oleanolic 
acid (4) (91.72 ± 1.63 µM) was significantly lower (p<0.05) than the 6-gingerol (3). The IC50 values of 
compounds 2-4 were significantly lower (p<0.05) than the standard acarbose (580.77 ± 20.71 µM), when 
the IC50 value (664.56 ± 11.58 µM) of 6-paradol (1) was higher compared to the acarbose (Table 6.1).  In 
addition, the IC50 value depicted by the mixture (5) was found to be 124.95±6.38 µg/ml. 
 
 
Figure 6.2: α-amylase Inhibition (%) of compounds isolated from A. melegueta, X. aethiopica and C. annuum fruits. Data are 
presented as mean ± SD of triplicate determinations. a-e Values with different letters presented for a given concentration for each 
extract are significantly different from each other. 
 





α-amylase inhibition α-glucosidase inhibition 
A. melegueta/X. aethiopica   
6-Paradol (1) 664.56 ± 11.58e 243.32 ± 6.65c 
6-Shagaol (2) 443.17 ± 1.38c 326.11 ± 5.60d 
6-Gingerol (3) 156.96 ± 12.23b 104.34 ± 3.99b 
Oleanolic acid (4) 91.72 ± 1.63a 47.10 ± 0.42a 
Acarbose 580.77 ± 20.71d 327.74 ± 9.88d 
Data are presented as mean ± SD values of triplicate determinations. a-d Different superscript letters presented within a column for 
























































The results of the α-glucosidase inhibition of the compounds from the fruits of A. melegueta, X. 
aethiopica and C. annuum are presented in Figure 6.3 and Table 6.1 (IC50 values). 6-Gingerol (3) and 
oleanolic acid (4) showed the lowest calculated IC50 values; 104.34 ± 3.99 µM for 3 and 47.10 ± 0.42 µM 
for 4, significantly lower (p<0.05) compared to 1, 2 and the mixture 5 as well as the standard, acarbose 
(Table 6.1). Following these two compounds (3 and 4), 6-paradol (1) (243.32 ± 6.65 µM) had a lower IC50 
than 6-shogoal (2) (326.11 ± 5.60 µM), and the acarbose (327.74 ± 9.88 µM) was the least active (Table 
6.1). It was also observed that the mixture (5) showed the IC50 value of 51.03 ± 2.73 µg/ml for the α-
glucosidase inhibition. 
 
Figure 6.3: α-glucosidase Inhibition (%) of compounds isolated from A. melegueta, X. aethiopica and C. annuum fruits. Data are 
presented as mean ± SD of triplicate determinations. a-e Values with different letters presented for a given concentration for each 
extract are significantly different from each other. 
 
 The kinetics data of the inhibitory mode of the α-amylase and α-glucosidase enzymes by the 
isolated compounds are presented in Figure 6.4, 6.5 and Table 6.2. Compounds 1, 3 and the mixture 5 
exhibited a non-competitive inhibition for α-amylase. The KM value remains unchanged (0.06%), and the 
Vmax was found to decrease from 35.67 µmol/min to 16.73 µmol/min (3), 24.10 µmol/min (1) and 15.60 
µmol/min (5). Oleanolic acid (4) and compound (2) showed a mixed inhibition type for α-amylase action 
were both the KM and Vmax values are altered (Figure 6.4 and Table 6.2). For the α-glucosidase action all 
the isolated bioactive compounds from A. melegueta, X. aethiopica and C. annuum demonstrated a non-
competitive inhibition mode. The KM value remains unchanged (1.10 mmol/L), and Vmax was found to 
decreases from 471.56 µmol/min to 123.10 µmol/min (3), 55.70 µmol/min (2), 81.20 µmol/min (1), 64.20 






















































inhibitor binding (Ki) of the compounds for α-glucosidase were lower compared to that of α-amylase (Table 
6.2). 
 
Table 6.2: Kinetic analysis of α-amylase and α-glucosidase inhibition by compounds isolated from the fruit 
of A. melegueta, C. annuum and X. aethiopica in anti-diabetic models. 
Compounds α-Amylase inhibition α-Glucosidase inhibition 
 KM (%) Vmax (µmol/min) Ki (µg/mL) KM (mM) Vmax (µmol/min) Ki (µg/mL) 
Control  0.06 35.65  1.10 471.56  
A. melegueta/ 
X. aethiopica 
      
6-Paradol (1) 0.06 15.60 23.29 1.10 81.20 6.24 
6-Shagaol (2) 0.09 24.10 62.33 1.10 55.70 4.02 
6-Gingerol (3) 0.06 16.73 26.46 1.10 123.10 7.83 
Oleanolic acid (4) 0.13 273.00 59.25 1.10 64.20 4.73 
C. annuum       













Figure 6.5. Lineweaver-Burke plot for α-glucosidase in the absence and presence of the inhibitors (bioactive compounds). 
 
6.1.5 Discussion  
 In our present study, three of the isolated compounds (1-3) from A. melegueta are arylalkanes 
common to the Zingeberaceae. These arylalkanes all have a common 4-hydroxy-3-methoxyphenyl moiety 
and differ  in the side chain due to the biosynthetic conversion of 6-paradol (1) to 6-gingerol (3) by 
hydroxylation and dehydration to 6-shogoal (2) (Figure 6.1). These compounds were previously isolated 
from A. melegueta seed and reported to possess a variety of interesting pharmacological properties 
including hepato-protective and anti-oxidant activity (El-Halawany et al. 2014), as well as insecticidal 
(Escoubas et al. 1995) and anti-inflammatory activity (Ilic et al. 2014; Dugasani et al. 2010; Young et al. 
2005). 6-Gingerol (3) was isolated from X. aethiopica for the first time and establishes a chemotaxonomic 
link between the two plants, A. melegueta and X. aethiopica. Oleanolic acid (4), a common phytocompound 
was isolated from X. aethiopica fruit previously (Bernhoft, 2008). Previous reports on the phytochemistry 




diterpenoids (Moreira et al. 2013; Tane et al. 2005). The isolation of oleanolic acid (4) a pentacyclic 
triterpene from A. melegueta fruit is not surprising since it is found quite commonly in the plant kingdom. 
Oleanolic acid is quite active pharmacologically, having anti-oxidant, anti-inflammatory and anti-diabetic 
activity (Pollier and Goossens, 2012).    
 The preferred method for screening anti-diabetic agents used recently involves the inhibition of 
carbohydrate hydrolyzing enzymes such as α-amylase and α-glucosidase with the aim of controlling 
postprandial hyperglycemia. Inhibitors of these enzymes decrease the breakdown of complex carbohydrates 
to absorbable monosaccharides such as glucose (Imam, 2015). The isolated arylalkanes have not been tested 
previously on α-amylase and α-glucosidase, however previous reports have shown that compound 6-
shogoal (2) and 6-gingerol (3) might play a crucial role in the treatment and control of T2D. Singh et al. 
(2009) reported that treatment of 6-gingerol (3) (100 mg/kg bw) to db/db mice for 12 days resulted in anti-
hyperglycemic, anti-hyperlipidemic and anti-oxidant action. In another study, 6-gingerol (3) (10 µM) was 
shown to attenuate β-amyloid-induced oxidative cell death in SH-SY5Y cell lines (Lee et al. 2011). 
Chakraborty et al. (2012) have shown that, 6-gingerol (3) (50 and 75 mg/kg bw) down-regulate the over-
expression of TNF-α and IL6 in sodium arsenate intoxicated mice via up-regulation of GLUT4, IRS-1, IRS-
2, PI3K, AKT, PPARα signaling molecules. 6-Shogoal (2) and 6-gingerol (3) (10 µM) were reported to 
inhibit the TNF-α mediated downregulation of adiponectin expression in 3T3-L1 adipocytes (Isa et al. 
2008). Interestingly, our present data support the studies mentioned above and further show the contribution 
of 1-3 to T2D treatment as they exhibited considerable inhibitory action on α-amylase and α-glucosidase 
(Table 6.1). The lowest calculated IC50 values of (3) (α-amylase: 156.96 ± 12.23 µM; α-glucosidase: 104.34 
± 3.99 µM) indicates that this is the most suitable candidate for an anti-diabetic drug compared to the other 
isolated compounds. 
 Oleanolic acid (4) was shown to have an inhibitory effect on α-amylase and α-glucosidase. Ali et 
al. (2002) reported an IC50 value of 11.16 ± 0.49 µM for 4 on α-glucosidase. Most recently, an IC50 value 
of 3.8 ± 0.2 µM on α-glucosidase was repoted by Guo et al. (2013). Komak et al. (2003) reported inhibitory 
activity of 4 against α-amylase with an IC50 of 154.89 µM. The IC50 values of oleanolic acid obtained in 
this study was 59.22 ± 1.05 µg/mL for α-amylase and 91.72 ± 1.63 µM for α-glucosidase. These values 
were lower than the standard acarbose (α-amylase: 580.77 ± 20.71 µM; α-glucosidase: 327.74 ± 9.88 µM) 
and that reported by Komak et al. (2003) for α-amylase action (154.89 µM). These results support previous 
findings, which have shown the ability of oleanolic acid (4) to improve blood glucose tolerance in mice fed 
a high-fat diet as well as enhance insulin secretion in pancreatic β-cells (Castellano et al. 2013; de Melo et 
al. 2010; Teodoro et al. 2008).     
The kinetic parameters derived from the double reciprocal plot revealed that the mode of α-amylase 




type (Figure 6.4, 6.5 and Table 6.2). It is therefore suggested that these compounds bind to other site(s), 
apart from the active site of the enzyme, which induces a conformational change in the three-dimensional 
structure of the enzymes and ultimately slows down its activity (Mahomoodally and Muthoora, 2014). The 
equilibrium constant for inhibitor binding (Ki) of the compounds were lower for α-glucosidase than α-
amylase, indicating greater stability of the enzyme-substrate complex for α-glucosidase compared to α-
amylase (Table 6.2).  
Structure-activity relationship reported in the literature for the arylalkanes state that the 4-hydroxy-
3-methoxyphenyl moiety and C-3 carbonyl group of the aliphatic side chain are crucial for the activity of 
these compounds (El-Halawany et al. 2014). It is also suggested that the presence of the β-OH at C-5 in 6-
gingerol (3) or α,β-unsaturated double bond in 6-shogoal (2) of the aliphatic side chain significantly 
increases the α-amylase and α-glucosidase inhibitory activity. In oleanolic acid (4), the hydroxyl at C-3 and 
the carboxyl group (C-28) are essential for its activity (Matsuda et al. 1998). 
 
6.1.6 Conclusion  
In conclusion, the results of the present study indicate that 6-gingerol (3) and oleanolic acid (4) 
isolated from the fruit of A. melegueta and X. aethiopica demonstrate better α-amylase and α-glucosidase 
inhibitory activity compared to the other isolated compounds and could be a good lead for an anti-diabetic 
drug. The anti-diabetic activity of the fruit of A. melegueta and X. aethiopica is attributed to these active 
ingredients. Further clinical and detailed toxicological studies are required to fully establish the potency of 



















7.0 General discussion, conclusion and recommendations  
7.1 General discussion  
Africa is among the regions endowed with the richest biodiversity in the world, with an abundance 
of many plants that could provide a new lead for treatment of several diseases including diabetes mellitus 
(DM).  In our present study, three (3) African medicinal plants [Aframomum melegueta K. Schum., 
Xylopia aethiopica (Dunal.) A. Rich. and Capsicum annuum L.] were selected based on their traditional 
uses in the treatment of DM.  
According to the literatures, several extraction methods of plant-derived products are available that 
include hot percolation, supercritical fluid extraction, soxhlet extraction and cold extraction among others 
(Brusotti et al. 2014; Harborne, 1998; Hostettmann et al. 1991). In our present study, the cold extraction 
technique was employed due to easeful extraction method and no heating is required. This allows most 
ingredients present in the plant samples to be extracted with low possibility of degradation (Heinrich et al. 
2012). This is of enormous interest as the bioactivity of plant-derived extracts depends entirely on the 
presence of compounds such terpenoids, alkaloids and polyphenols to mention a few. Additionally, the 
amount of the bioactive compounds depends on the polarity of the extracting solvents as well.  
In a number of previous studies, the most polar solvent extracts such as ethanolic (EtOH) and 
aqueous from the fruit of A. melegueta, X. aethiopica and C. annuum were reported to be rich in phenolic 
contents (Tundis et al. 2013; Adefegha and Oboh, 2012a, c; 2011; Etoundi et al. 2010; Deepa et al. 2007). 
This is in line with our present data (Tables 3.1, 4.1 and 5.1). In addition, the higher phenolic contents of 
the fruits than other parts (leaves, stems and roots) could be influenced by several factors including genetic 
and environmental factors (nature of the soil, high temperature and rain fall) (Mamphiswana et al. 2010; 
Pandey and Rizvi, 2009). Furthermore, it was observed from the results that higher phenolic content were 
available in the most polar solvent fractions (acetone and ethyl acetate (EtAOc)) after partitioning of the 
crude EtOH extracts (Tables 3.4, 4.4 and 5.4). This could be due to the greater polarity of these solvents 
than other less polar solvents (hexane and dichloromethane). While not discounting the contributions of 
other compounds, our interest in determining the phenolic contents was due to the fact that several 
therapeutic potentials of plant-derived products such as anti-oxidative action are attributed to their rich-
phenolic contents (Gülçin, 2012; Ferrazzano et al. 2011). Therefore, phenolics may play a significant role 




In the pathogenesis of T2D, increased generation of reactive oxygen species (ROS) due to 
hyperglycemia is considered as a major contributor for oxidative as well as associated complications 
(Pazdro and Burgess, 2010). A number of previous studies supported the contribution of anti-oxidants in 
attenuating the complications associated with diabetes (McCune and Johns, 2007; Rahimi et al. 2005; 
McCune and Johns, 2002). However, the increasing risk associated with the use of existing synthetic anti-
oxidants has been an issue of concern. This cause a shift to the use of plant-derived anti-oxidants in 
preventing oxidative damage either in disease condition or food preservation. Moreover, several methods 
are used to assess the anti-oxidative potential of plant-derived products due to the diverse nature of the 
ROS. In our present study, DPPH radical scavenging activity, ferric (Fe3+) reducing anti-oxidant power and 
inhibition of hemoglobin glycation were used to evaluate the anti-oxidative action of the extracts and/or 
fractions derived from the plants under this study. The anti-oxidative effectiveness of various solvent 
extracts was assessed base on the calculated IC50 values. 
In some previous studies, various extracts from these plants demonstrated anti-oxidative activity. 
The A. melegueta seed acetone and aqueous extracts (Adefegha and Oboh, 2012a, b; Kazeem et al. 2012), 
X. aethiopica fruit aqueous extract (Adefegha and Oboh, 2012a, c; 2011; Odukoya et al. 2005) and C. 
annuum fruit aqueous, methanolic and EtOH extracts (Azeez et al. 2012; Chen et al. 2012; Tundis et al. 
2012; Perucka and Materska, 2007; Conforti et al. 2007; Kwon et. 2007) were reported to demonstrate 
excellent anti-radical (IC50: 100-400 µg/mL) as well as anti-glycation (IC50 >100 µg/mL) activities in vitro. 
However, most of the above-mentioned studies did not evaluate the anti-oxidative activities of the extracts 
and fractions from the different parts of the plants which have been done in our study. The results of above-
mentioned studies are also in line with the results of our present data (Tables 3.5, 4.5, and 5.5). Therefore, 
the data of our study suggest that most active extracts or fractions contained active ingredients with high 
redox potentials that could reasonably quench the activities of ROS and other radicals released due to the 
disease condition.  
On the other hand, plant-derived products have been reported to demonstrate inhibitory effect 
against α-glucosidase and α-amylase activities (Xiao et al. 2013a,b; Elya  et al. 2012; Rastija et al. 2012; 
Sudha et al. 2011). These are key enzymes involved in the metabolism of complex carbohydrates to 
absorbable monosaccharides. Inhibition of the activities of these enzymes limit the release of dietary 
monosaccharide (glucose) and subsequent absorption via the intestinal brush border, thereby controlling 
postprandial hyperglycemia in T2D. Hence, this strategy is recently employed as a treatment option of T2D. 
According to the previous data, A. melegueta seed aqueous extract (Adefegha and Oboh, 2012a, b), X. 
aethiopica fruit aqueous extract (Adefegha and Oboh, 2012a; Etoundi et al. 2010) and C. annuum fruit 
EtOH extract (Tundis et al. 2013; 2012; Kwon et. 2007) exhibited inhibitory effect against α-glucosidase 




present study (Tables 3.2, 4.2, and 5.2). Interestingly, the inhibitory action against α-glucosidase (IC50: 40-
90 µg/mL) and α-amylase (IC50: 60-170 µg/mL) actions exhibited by the fractions in our present study were 
the least (Tables 3.5, 4.5, and 5.5) compared to the previously published studies (Tundis et al. 2013; 2012; 
Adefegha and Oboh, 2012a, b; Etoundi et al. 2010; Kwon et. 2007). This shows that fractionation of the 
crude extracts further increases the activities of the extracts. 
Moreover, analysis of the mode of inhibition exhibited by the most active fractions revealed that 
EtAOc fraction from A. melegueta and acetone fractions from X. aethiopica and C. annuum fruits 
demonstrated non-competitive or mixed inhibitions towards α-glucosidase and α-amylase actions (Figures 
3.13, 4.12, 5.14). This again is in accordance with the mode of inhibition exhibited by several phenolic 
compounds reported previously (Rastija et al. 2012). In these types of inhibition the inhibitor  binds to other 
site (s), apart from the active site of the enzyme, and causes some conformational changes in the three-
dimensional structure of the enzyme that slows down the activity of the enzyme (Mahomoodally and 
Muthoora, 2014).  
Based on the higher anti-oxidative and anti-diabetic effects of the most active extracts and fractions, 
they were subjected to GC-MS analysis. The objective of conducting GC-MS analysis was to identify the 
small organic secondary metabolites and possibly to find a link between these organic molecules and the in 
vitro anti-diabetic and anti-oxidative actions of the extracts and fractions. In addition, the data revealed the 
type of compounds present in the fractions under this study. Most small molecular weight compounds 
detected were volatile and identified by their fragmentation pattern based on the data from the NIST library 
(Tables 3.2, 3.5, 4.2, 4.5, 5.2, and 5.5). Interestingly, 4-hydroxy-3-methoxyphenyl derivatives including 
some terpenoids were observed to be available from the GC-MS analysis of the most active fractions, which 
confirmed the type of bioactive compounds present in these fractions. Finally, the fractions with higher in 
vitro anti-diabetic and anti-oxidative actions (A. melegueta EtAOc fraction (AMEF) and X. aethiopica 
acetone fractions (XAAF) and C. annuum acetone fractions (CAAF) from fruits) were selected for the in 
vivo studies to further confirm their potentials.  
The in vivo anti-diabetic and anti-oxidative actions were investigated in a fructose-fed 
streptozotocin (STZ)-induced T2D model of rats through 4 weeks oral intervention period. The high 
fructose feeding followed by low-dose STZ (40 mg/kg bw) injection was reported to induce the 2 major 
pathological features of T2D, insulin resistance and β-cell failure (Wilson and Islam, 2012). It is postulated 
that the fructose feeding stimulate lipolysis from the adipocytes, which promote the activity of HMG-CoA 
reductase and decrease lipoprotein lipase action (De Silva and Frayling, 2010; Hotamisligil, 2000). This 
leads to the elevation of TG and TC levels that induce insulin resistance. Furthermore, the selective affinity 




the DNA sugar residue and result in DNA strand breakage (KunduSen et al. 2011). This leads to pancreatic 
β-cell damage as well as hyperglycemia in T2D.  
It has been reported that polyphagia, polydipsia and weight loss are classical symptoms of T2D, 
possibly attributed to the increased energy expenditure, urinary excretion and catabolic processes in diabetic 
condition (ADA, 2015; Kamalakkannan and Prince, 2006). These effects were evidently observed in the 
diabetic group (DBC) compared to the normal control (NC) group. However, oral treatment of fractions at 
both dosages (150 and 300 mg/kg bw) significantly decreased these alterations which was comparable to 
diabetic metformin (DMF) treated group (Figures 3.15, 3.16, 4.14, 4.15, 5.16 and 5.17). This indicates a 
recovery from the diabetes-induced alterations in the feeding habit of the diabetic-treated animals, which 
was further supported by the significant decrease in hyperglycemia in diabetic treated groups. 
Persistent hyperglycemia and lack of glucose tolerance ability are the major contributors of most 
of the complications associated with T2D (Monnier et al. 2006). In some preliminary studies, it has been 
reported that the treatment of aqueous extracts from A. melegueta seed (200-400 mg/kg bw/2 weeks), X. 
aethiopica fruit (400 mg/kg bw/2 hours) and C. annuum fruit (500-700 mg/kg bw/2 hours) demonstrated 
blood glucose lowering effects in alloxan-induced diabetic, high sucrose-fed and normal rats, respectively 
(Etoundi et al. 2013; Adesokan et al. 2010; Monsereenusorn, 1980). However, the major limitations with 
above-mentioned previous studies include short treatment periods, lack of proper control groups and the 
type of animal models used, which have been considered in our present study. Our data showed better anti-
hyperglycemic action (Figures 3.17, 3.18 and 4.16) and glucose tolerance ability (Figures 5.18 and 5.19) 
in the diabetic treated groups compared to the previously reported studies (Etoundi et al. 2013; Adesokan 
et al. 2010; Monsereenusorn, 1980). Additionally, the better anti-hyperglycemic action of the fractions 
might be correlated to potent α-glucosidase and α-amylase inhibitory effects exhibited by these fractions 
that limit the absorption of dietary glucose in to the blood stream and thus, reduced hyperglycemia. Another 
assumption is that the active ingredients from the fractions might stimulate the regeneration of pancreatic 
β-cells in the diabetic animals due to their strong anti-oxidative nature. This speculation was supported by 
the increased serum insulin levels and improved pancreatic morphology and β-cell function in the diabetic 
treated animals.  
In prolong uncontrolled T2D, loss of pancreatic β-cell function and the insulin resistance lead to 
decrease in serum insulin level as well as damage to the pancreatic architecture (Bonner-Weir and O'Brien, 
2008; Nattrass and Bailey, 1999). These effects were prominent in the DBC group than the NC group 
(Figures 3.19 4.18 and 5.20; Tables 3.7, 4.7 and 5.7). The DBC group had a smaller islet and 
morphologically deformed β-cells with higher fatty infiltrations (Figures 3.19 4.18 and 5.20). However, 
oral administration of the fractions especially at the higher dose (300 mg/kg bw/day) significantly decreased 




the DMF group. This further display the anti-diabetic action of the plants used in our present study that was 
not yet previously reported. Therefore, the ability of AMEF, XAAF and CAAF to increase serum insulin 
levels might facilitate the passage of glucose across the membrane into the target cells and thereby attenuate 
hyperglycemia in diabetic treated animals. Furthermore, these effects might also be linked to the excellent 
in vitro anti-oxidative actions of the fractions, which is again supported by the potent reduced serum 
fructosamine levels in the diabetic treated groups (Tables 3.7, 4.7 and 5.7).  
On the other hand, long term pathological features of T2D may include elevation of hepatic 
glycogen content and increased liver weight (Paschos and Paletas, 2009). In our present study, these kind 
of alterations observed in the DBC group might be attributed to fructose feeding that triggers hepatic 
glycogenesis via stimulation of glucose-6-phosphatase activity and cause higher accumulation of glycogen 
in the liver despite low circulating serum insulin (Ciudad et al. 1988). However, AMEF and XAAF 
treatment to diabetic animals reverted these effects near to normal, when no significant alterations were 
observed in the treated non-diabetic animals (Tables 3.8, 4.8 and 5.8). The results were further supported 
by the excellent attenuation of dyslipidemia in the diabetic treated animals (Tables 3.9, 4.9 and 5.9). 
Previous data have strongly correlated insulin resistance in the etiology of dyslipidemia in T2D. 
Decrease in circulating serum insulin lead to lipoprotein lipase inactivation thereby causing lipid 
abnormalities (Verma et al. 2013). The most frequently observed diabetes-induced lipid alterations include 
elevation of serum TG and TC levels with concomitant reduction of HDL-cholesterol level. Furthermore, 
according to some previous studies, aqueous extracts from A. melegueta seed, X. aethiopica and C. annuum 
fruits showed lipid lowering potentials ethanol-induced hepatotoxic, hypercholesterolemic and normal rats, 
respectively (Nwozo and Oyinloye, 2011; Nwozo et al. 2011; Monsereenusorn, 1983), with no data on any 
diabetic-induced animal models. However according to our present data, the potent anti-hyperlipidemic 
effect in the diabetic treated groups further contribute to the anti-diabetic action of AMEF, XAAF and 
CAAF in diabetic-induced animal model. In addition, the reduction was more pronounced in groups treated 
with the higher dose of the fractions and comparable to the DMF group (Tables 3.9, 4.9 and 5.9). Moreover, 
the excellent decrease of the coronary risk index (CRI) and atherogenic index (AI) further support the 
effects of the fractions in ameliorating dyslipidemia in type 2 diabetic animals (Tables 3.9, 4.9 and 5.9). 
Therefore, it is suggested that the elevation of serum insulin level observed in the diabetic treated groups 
might be directly activated lipoprotein lipase activity, which promoted lipolysis and thus attenuated 
dyslipidemia. Our data are again supported by the reduction of serum indices of liver, heart and kidney in 
the diabetic treated groups compared to the DBC group (Tables 3.10, 4.10 and 5.10). 
It has been highlighted that in some disease conditions such as T2D, elevation of serum ALT, AST, 
ALP, creatinine, urea, LDH and CK-MB into blood circulation induces hepatic injuries, myocardial 




al. 2008). These effects were evidently observed in the DBC group of our study (Tables 3.10, 4.10 and 
5.10). However, oral administration of the AMEF, XAAF and CAAF (300 mg/kg bw) significantly 
ameliorated the serum elevations of ALT, ALP, creatinine, urea, LDH and CK-MB indicating their possible 
hepato-protective, cardio-protective and reno-protective effects (Tables 3.10, 4.10 and 5.10). It was 
observed from our data that serum AST level was not affected by the diabetes. In comparison with ALT, 
AST is less specific for the detection of hepatic injury (Center, 2007). This is partly due to the fact that the 
half-life of ALT is much longer compared to AST in experimental animals (Ramaiah, 2007; Meyer and 
Harvey, 2004). Therefore, in a condition of acute liver injury, there will be an increase in both serum ALT 
and AST levels. However, the serum AST level may likely return to normal more rapidly compared to the 
level of serum ALT, which makes ALT more sensitive in assessing hepatic damage in disease conditions 
(Ramaiah, 2007; Meyer and Harvey, 2004). The excellent hepato-protective, cardio-protective and reno-
protective effects observed might be also attributed to the potent anti-oxidative action in vitro as exhibited 
by the fractions. 
Moreover, in vivo anti-oxidative action of the various fractions was extended to further support the 
in vitro anti-oxidative effects. Our present data are the first to comprehensively reveal the anti-oxidative 
action of the extracts or fractions from A. melegueta seed, X. aethiopica and C. annuum in vivo. It has been 
highlighted that chronic uncontrolled hyperglycemia leads to increased production of ROS as well as 
declined of in vivo anti-oxidant defense system referred as oxidative stress. This results to increase lipid 
peroxidation that impaired cellular function by inducing osmotic stress and thereby alters the activity of 
membrane-bound enzymes and receptors (Verma et al. 2013). The observed elevation of lipid peroxidation 
(expressed as MDA equivalent) in DBC group were attenuated in the diabetic treated groups in the serum 
and organs (liver, kidney, heart and pancreas) in dose-depended manner (Figure 3.20, 4.19 and 5.21), 
attributed to the potent anti-oxidative action of the fractions in vitro. The data support the improved 
pancreatic β-cell morphology in the diabetic treated animals (Figures 3.19 4.18 and 5.20) that again 
correlated to the increase in both enzymatic and non-enzymatic in vivo anti-oxidants defense system in the 
diabetic treated groups. 
The α-tocopherol, ascorbic acid, bilirubin and reduced glutathione (GSH) are considered as non-
enzymatic in vivo anti-oxidant molecules. The GSH plays a crucial role in modulating the oxidative 
damages induced due to increased lipid peroxidation (Rahimi et al. 2005). According to our present data, 
the marked reduction of GSH levels in serum and organs of the DBC group were augmented in the diabetic 
treated groups (Figure 3.21, 4.20 and 5.22). Therefore, it is suggested that AMEF, XAAF and CAAF 
improve the anti-oxidant activity by stimulating the biosynthesis of GSH that prevented and terminated the 




The levels of the enzymatic anti-oxidants, superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (GPx) and glutathione reductase (GR) of the DBC group were observed to decrease 
in the serum and the organs as well. This might be due to the hyperglycemia-induced oxidative stress in the 
diabetic condition as reported earlier (Verma et al. 2013; Sreelatha and Inbavalli, 2012; Gokce and 
Haznedaroglu, 2008). However, the increased activities of these enzymes in the diabetic treated groups 
indicated the possible contribution of the constituents of the fractions in attenuating the deleterious action 
of the lipid peroxidation and consequently reduced the MDA levels (Figure 3.22-3.25, 4.21-4.24 and 5.23-
5.26). Therefore, as suggested earlier, the potent anti-diabetic and anti-oxidative activities observed in both 
in vitro and in vivo conditions in our present study are attributed to the bioactive compounds present in the 
AMEF, XAAF and CAAF.   
 In our present study, three of the isolated compounds (1-3) from A. melegueta are arylalkanes 
common to the Zingeberaceae. These arylalkanes all have a common 4-hydroxy-3-methoxyphenyl moiety 
and differ  in the side chain due to the biosynthetic conversion of 6-paradol (1) to 6-gingerol (3) by 
hydroxylation and dehydration to 6-shogoal (2) (Figure 6.1). These compounds were previously isolated 
from A. melegueta seed and reported to possess a variety of interesting pharmacological properties 
including hepato-protective and anti-oxidant activity (El-Halawany et al. 2014), as well as insecticidal 
(Escoubas et al. 1995) and anti-inflammatory activity (Ilic et al. 2014; Dugasani et al. 2010; Young et al. 
2005). 6-Gingerol (3) and oleanolic acid (4) were isolated from X. aethiopica for the first time and 
establishes a chemotaxonomic link between the two plants, A. melegueta and X. aethiopica (Bernhoft, 
2008). Previous reports on the phytochemistry of A. melegueta and X. aethiopica indicated these plants to 
contain monoterpenoids, sesquiterpenoids and diterpenoids (Moreira et al. 2013; Tane et al. 2005). The 
isolation of oleanolic acid (4) a pentacyclic triterpene from A. melegueta fruit is not surprising since it is 
found quite commonly in the plant kingdom. Oleanolic acid is quite active pharmacologically, having anti-
oxidant, anti-inflammatory and anti-diabetic activity (Pollier and Goossens, 2012).    
The isolated arylalkanes have not been tested previously on α-amylase and α-glucosidase, which 
have been done in our present study. However previous reports have shown that compound 6-shogoal (2) 
and 6-gingerol (3) might play a crucial role in the treatment and control of T2D (Chakraborty et al. 2012; 
Lee et al. 2011; Singh et al. 2009; Isa et al. 2008). Interestingly, our present data support the studies 
mentioned above and further show the contribution of 1-3 to T2D treatment as they exhibited considerable 
inhibitory action on α-amylase and α-glucosidase (Table 6.1). The lowest calculated IC50 values of (3) (α-
amylase: 156.96 ± 12.23 µM; α-glucosidase: 104.34 ± 3.99 µM) indicates that this is the most suitable 
candidate for an anti-diabetic drug compared to the other isolated compounds. 
According to some previous studies, oleanolic acid (4) was shown to have an inhibitory effect on 




oleanolic acid obtained in our present study for α-amylase (91.72 ± 1.63 µM) and α-glucosidase (47.10 ± 
0.42 µM) were significantly lower compared to the standard acarbose (α-amylase: 580.77 ± 20.71 µM; α-
glucosidase: 327.74 ± 9.88 µM). The results support previous findings, which have shown the ability of 
oleanolic acid (4) to improve blood glucose tolerance in mice fed a high-fat diet as well as enhance insulin 
secretion in pancreatic β-cells (Castellano et al. 2013; de Melo et al. 2010; Teodoro et al. 2008).     
The kinetic parameters derived from the double reciprocal plot revealed that the mode of α-amylase 
and α-glucosidase inhibitory activity exhibited by 1-5 is either non-competitive or of the mixed inhibition 
type (Figure 6.4, 6.5 and Table 6.2). It is therefore suggested that these compounds bind to other site(s), 
apart from the active site of the enzyme, which induces a conformational change in the three-dimensional 
structure of the enzymes and ultimately slows down its activity (Mahomoodally and Muthoora, 2014). The 
equilibrium constant for inhibitor binding (Ki) of the compounds were lower for α-glucosidase than α-
amylase, indicating greater stability of the enzyme-substrate complex for α-glucosidase compared to α-
amylase (Table 6.2).  
Structure-activity relationship reported in the literature for the arylalkanes state that the 4-hydroxy-
3-methoxyphenyl moiety and C-3 carbonyl group of the aliphatic side chain are crucial for the activity of 
these compounds (El-Halawany et al. 2014). It is also suggested that the presence of the β-OH at C-5 in 6-
gingerol (3) or α, β-unsaturated double bond in 6-shogoal (2) of the aliphatic side chain significantly 
increases the α-amylase and α-glucosidase inhibitory activity. In oleanolic acid (4), the hydroxyl at C-3 and 
the carboxyl group (C-28) are essential for its activity (Matsuda et al. 1998). 
 
7.2 Overall conclusion  
In conclusion, the results of our present study have shown that A. melegueta ethyl acetate fraction 
(AMEF), X. aethiopica acetone fraction (XAAF) and C. annuum acetone fraction (CAAF) from fruits 
demonstrated potent anti-diabetic and anti-oxidative actions in vitro and in vivo. The improved glucose 
tolerance ability, insulin sensitivity and in vivo anti-oxidants status as well as amelioration of pancreatic β-
cell histology and β-cell functions are mechanisms via which AMEF, XAAF and CAAF exhibited anti-
diabetic action that were not previously reported. Hence, our findings suggest that AMEF, XAAF and 
CAAF may provide an excellent anti-diabetic remedy with no considerable side effects. Moreover, our 
present study establish that 6-paradol (1), 6-shagaol (2), 6-gingerol (3) and oleanolic acid (4) isolated and 
purified from AMEF and XAAF are potential anti-diabetic drugs and the anti-diabetic action of A. 
melegueta and X. aethiopica fruits is attributed to the presence of these compounds. This study also 





7.3 Further research 
On the basis of the findings of this study, it is recommended that: 
i. Detail toxicological studies of the most active fractions (AMEF, XAAF and CAAF) and 
the isolated bioactive compounds (6-gingerol, 6-shagaol, 6-paradol and oleanolic acid) are 
required to further validate their safety  
ii. Mechanistic-based in vitro studies are required to evaluate the mode of action of the active 
fractions and the isolated compounds as well.   
iii. Clinical studies are necessary to further confirm the effects in human subjects.    
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